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Abstract 
Interval timing behaviour refers to the ability of animals and humans to adapt 
their behaviour to temporal regularities in their environments. Two important 
classes of interval timing behaviour are temporal discrimination (discriminating 
between the durations of external events) and temporal differentiation 
(behavioural adaptation during an ongoing interval). It has been known for 
many years that drugs that affect central dopaminergic function can alter both 
forms of timing behaviour. More recently, evidence has been accumulated 
which shows that manipulation of centra15-hydroxytryptaminergic (5-HTergic) 
function can also influence interval timing behaviour. The experiments 
described in this thesis examined the effects of drugs acting at some SUbtypes of 
5-HT receptors on temporal discrimination and temporal differentiation in the 
rat. 
Chapter 1 contains a review of the relevant literature. First, the anatomy, 
biochemistry and receptor pharmacology of the 5-HTergic system is outlined, 
and a selective review of the role of 5-HT in some behaviours relevant to this 
project is presented. This is followed by an overview of the behavioural 
methodology that has been used to study timing behaviour in animals, and an 
account of the major theories of timing behaviour. Finally, the behavioural 
pharmacology of timing behaviour is reviewed. 
Chapters 2-7 describe a series of experiments examining the effects of 
drugs acting at 5-HT1A, 5-HT2AJ2c, and 5-HT3 receptors on temporal 
discrimination and temporal differentiation. 
Experiment 1 examined the effect of the 5-HT3 receptor agonist m-
chlorophenylbiguanide (m-CPBG) and the non-selective agonist quipazine on 
V1l1 
temporal discrimination performance in the discrete-trials psychophysical 
procedure. Quipazine produced a dose-dependent disruption of temporal 
discrimination, consisting of a rightward displacement and flattening of the 
fitted psychometric function, reflected in a significant increase in the values of 
the indifference point T50 and the Weber fraction. m-CPBG had no significant 
effect on either T50 or the Weber fraction. The effects of quipazine were 
completely abolished by the 5-HT2A receptor antagonist ketanserin, but not by 
the 5-HT3 receptor antagonist topanyl 3,S-dichlorobenzoate (MDL-72222), 
indicating that the effect of quipazine was mediated by S-HT 2A, and not S-HT 3 
receptors. 
In experiment 2, the effects of quipazine and m-CPBG were examined 
on temporal differentiation performance in the free-operant psychophysical 
procedure. Quipazine dose-dependently displaced the psychometric function to 
the left, reducing the value of T50, and significantly increased the Weber 
fraction. m-CPBG had no effect on the parameters of the function. The effects 
of quipazine were reversed by co-administration of ketanserin, but not by co-
administration of MD L-72222. These results suggest that while 5 -HT 2A 
receptor stimulation has a robust influence on temporal differentiation, 5-HT3 
receptor stimulation does not. 
Experiment 3 further examined the effect of 5-HT2A receptor 
stimulation on temporal discrimination. The 5-HT 2AJ2C receptor agonist 2,5-
dimethoxy-4-iodoamphetamine (DOl) increased the Weber fraction and tended 
to increase T50. Ketanserin and the highly selective S-HT2A receptor antagonist 
(± )2,3-dimethoxyphenyl-l-(2-( 4-piperidine )-methanol) (MDL-I00907) fully 
IX 
antagonized the effects of DOL The results indicate that DOl disrupts temporal 
discrimination via stimulation of 5-HT2A receptors. 
Experiment 4 examined whether intra-striatal injection of 001 would 
affect temporal discrimination, and whether the effect of systemically 
administered DOl on temporal discrimination would be blocked either by 
MDL-I00907 or by 8-( 5 -(2, 4-dimethoxy-5 -( trifluoromethylphenyl-
sulphonamido )phenyl-5-oxopentyl)-1 ,3,8-triazaspiro( 4.5)decane-2,4-dione RS-
102221: a selective 5-HT 2C receptor antagonist), administered directly into the 
dorsal striatum. Intra-striatal injection of DOl did not affect temporal 
discrimination. Systemically administered DOl disrupted temporal 
discrimination; this effect was not attenuated by intra-striatal injection ofMDL-
100907 or RSI02221, suggesting that the 5-HT2 receptors that mediate DOl's 
effect on temporal discrimination are not located in the dorsal striatum. 
Experiments 5 and 6 examined the effects of intra-striatally 
administered DOl, MDL-I00907 and RS-I02221 on temporal differentiation. 
In experiment 5, systemic injection of DOl significantly reduced T50. This 
effect was antagonized by systemically administered MDL-I00907. In 
experiment 6, intra-striatally administered DOl had no significant effect on T50 
or the Weber fraction. Intra-striatal injections of MDL-l 00907 and RS-l 02221 
did not alter temporal differentiation, and failed to reverse the effects of 
systemically administered DOL The results suggest that the 5-HT2 receptor 
population responsible for DOl's effect on temporal differentiation is not 
located in the dorsal striatum. 
Experiment 7 examined the effect of a 5-HT1A and a 5-HT2A receptor 
agonist on another widely-used temporal differentiation schedule, the fixed-
x 
interval peak procedure. The 5-HT lA receptor agonist 8-hydroxy-2-( di-n-
propylamino)tetralin (8-0H-DPAT) and the 5-HT2A12C receptor agonist DOl 
had similar effects on performance: both agonists displaced the peak function to 
the left and reduced the peak time, {peak. The effect of 8-0H-DPAT was 
antagonized by the selective 5-HT1A receptor antagonist N-[2-( 4-[2-methoxy-
phenyl]-1-piperazinyl)ethyl]-N-2-pyridinylcyclohexane-carboxamide (WAY-
100635), and the effect of DOl by the 5-HT2A receptor antagonist ketanserin, 
respectively. These results, taken together with previous findings with the free-
operant psychophysical procedure, suggest that 5-HTIA and 5-HT2A receptors 
mediate similar effects on temporal differentiation. 
The final chapter (Chapter 8) summarizes the findings from the project, 
and discusses their implications for the putative role of 5-HT in interval timing 
and for current theoretical accounts of timing. It is argued that current models 
of timing behaviour that assume the existence of a unitary 'pacemaker-driven' 
internal clock may have difficulty accommodating the finding that the same 
drug can have qualitatively different effects on temporal discrimination and 
temporal differentiation. Some possible directions for future research in this 
area are also discussed. 
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CHAPTER 1 
INTRODUCTION 
1 
1.1. OVERVIEW OF THE PROJECT 
All behaviour happens in the continuous stream of time, and all 
behaviours that begin and end in a point of time have temporal properties. It 
has been argued that understanding time is the cornerstone for understanding 
learning, decision making, arid memory (Gibbon 1991). Two basic forms of 
timing are 'endogenous rhythms' (e.g. circadian oscillations) and interval 
timing (behaviour that comes under the control of temporal regularities in the 
environment as a result of learning) (Gibbon et aL 1997b). In cognitive terms, 
interval timing includes the perception, anticipation, and estimation of 
durations. According to Gibbon and his collaborators, appreciation of duration 
can be viewed as the core ofthe learning process (Galli stell and Gibbon 2000). 
There have been many attempts to devise theoretical accounts of timing 
behaviour. The dominant approach for well over half a century has been based 
on the analogy between the behaviour of an animal or human being performing 
a timing task and the operation of a man-made clock. Psychologists have 
noticed many points of similarity between interval timing behaviour and the 
action of clocks, and have proposed that timing behaviour may be viewed as 
the product of an 'internal clock'. 
The concept of an internal clock goes back to the first half of the 
twentieth century (Hoagland 1933). In subsequent decades, Treisman (1963), 
Wing and Kristofferson (1973), and finally Gibbon (1977), proposed more 
sophisticated formal mathematical models for the hypothetical internal clock. 
For some authors, the hypothetical internal clock is simply a useful concept 
that allows one to build mathematical models of interval timing (e.g. Killeen et 
-
2 
a1. 1997), whereas for others, the components of the internal clock are assumed 
to have biological reality that may be identified with specific neuroanatomical 
structures (Gibbon et a1. 1997a; MateH and Meck 2004). 
The present project is concerned with the psychopharmacology of 
interval timing behaviour. The project arose from previous work carried out on 
the role of 5-hydroxytryptaminergic (5-HTergic) pathways in interval timing 
behaviour (see Ho et a1. 2002). The overall aim of the project was to extend our 
understanding of 5-HT's putative role in interval timing by providing answers 
to specific questions raised by this previous research. Most of the experiments 
described in this thesis entailed systemic treatment with more or less selective 
agonists and antagonists of particular 5-HT receptors to rats that had been 
trained in various types of timing task. The aim of the project was to examine 
the effect of manipulating the 5-HTergic system on timing performance, and 
not to test any particular theory of interval timing. However, some of the 
results obtained in the project do have implications for internal clock models, 
and these implications will be discussed in the thesis. 
This introductory chapter starts with an overview of the structure and 
function of the 5-HTergic system of the brain. Many varied behavioural 
functions are believed to depend, at least in part, on the 5-HTergic system. No 
attempt will be made to provide an exhaustive review of these functions. 
However, a few of the functions that may have some relevance to the main 
topic of the thesis will be discussed. 
The overview of 5-HT is followed by a review of the methodology used 
to study interval timing in animals, and an account of the major current theories 
of interval timing. 
3 
The final section of the Introduction contains a review of the literature on 
the behavioural pharmacology of interval timing behaviour. Emphasis is given 
to previous studies of the putative role of the 5-HTergic system in timing 
behaviour, because these studies form the immediate background to the present 
project. 
1.2. THE 5-HYDROXYTRYPTAMINERGIC SYSTEM 
1.2.1. Anatomy of the 5-hydroxytryptaminergic pathways 
5-Hydroxytryptamine (5-HT, serotonin) was first isolated as a substance with 
vasoconstrictor properties that is present in the gastrointestinal tract by 
Erspamer and Asero (1953), who gave it the name "enteramine". The 
"enteramine" molecule was identified as 5-hydroxytryptamine by Twarog and 
Page (1953), who detected it in some brain areas. These authors gave the 
substance the name "serotonin" due to its vasoconstrictor effects (see Deakin 
1983). 
Dahlstrom and Fuxe (1964) were the first pioneers m direct 
visualization of serotonergic (5-HTergic) neurones using histochemical 
fluorescence, by treating brain sections with formaldehyde. Dahlstrom and 
Fuxe's work enabled the central 5-HTergic pathways to be mapped. It was 
discovered that the cell bodies of the central 5-HTergic neurones are located in 
the midline (raphe) nuclei of the brainstem. 5-HTergic neurons in the raphe 
nuclei are comprised of two distinct groups; the superior group is located at the 
boundary between midbrain and pons, and the inferior group extends from the 
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caudal pons to the cervical spinal cord. The dorsal raphe nucleus (DRN) and 
median raphe nucleus (MRN) have been classified as part of the superior raphe 
nuclear group; they are equivalent to groups B7 and B8 according to 
Dahlstrom and Fuxe's (1964) classification (see Deakin 1983; Harding et aL 
2004). 
The anatomical organization of the 5-HTergic pathways has been 
extensivel y studied in the cat and the rat (Leger et al. 2001; Harding et al. 
2004). There are at least five separate ascending pathways to the forebrain, and 
three pathways projecting to the spinal cord. In the rat, the main ascending 
projection pathways are contained within the medial forebrain bundle, which 
carries unmyelinated, slender fibres from both the MRN and DRN to many 
areas of the brain (see Azmitia et al 2002; Harding et al. 2004); a simplified 
diagram of these projections is shown in Figure 1.1. 
Neurones in the DRN and MRN differ somewhat in their topography; 
those in the DRN appear to be relatively condensed, while in the MRN they 
appear to be more loosely organized (Adell et al. 2002). Differences in axon 
morphology between fibres originating in the DRN and MRN have been 
reported by Murphy (1991), who found that the axons projecting from the 
DRN to the frontal cortex are very fine, having small varicosities, and are 
highly vulnerable to damage, while axons extending from the MRN to the 
hippocampus and lateral hypothalamus have large varicosities and are 
relatively resistant to the effects of selective neurotoxins (see below). 
The forebrain projection regions of the DRN and MRN show 
considerable overlap. Many areas, for example the amygdala and parts of the 
neocortex, receive equivalent inputs from both nuclei (Imai et al. 1986; 
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Figure 1.1. The ascending 5-HTergic pathways of the rat brain. 
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Neuman et al. 1992; Van Bockstaele et al. 1993). However, the dorsal striatum 
receives nearly all of its 5-HTergic innervation from the DRN, whereas the 
dorsal hippocampus is innervated almost exclusively by the MRN (Imai et al. ' 
1986). Consistent with these neuroanatomical findings, studies of 5-HT release 
have also indicated partial segregation of the 5-HTergic projection from the 
DRN and MRN. McQuade and Sharp (1997) measured extracellular 5-HT in 
brain regions, using microdialysis, following stimulation of the two nuclei. 
Stimulation of the DRN provoked 5-HT release in the frontal cortex, dorsal 
striatum and globus pallidus, while stimulation of the MRN provoked 5-HT 
release in the dorsal hippocampus. Stimulation of either nucleus resulted in 5-
HT release in the medial septum and ventral hippocampus. 
The raphe nuclei also project to other brainstem nuclei. There are 5-
HTergic projections to both the noradrenergic and the dopaminergic nuclei. 
Both the DRN and MRN contribute to these projections (Harding et al. 2004). 
Interestingly, both the DRN and MRN receive noradrenergic and dopaminergic 
input (Adell et al. 2002; Harding et al. 2004). The noradrenergic afferents to 
the raphe nuclei arise mainly from the locus coeruleus, although other. 
neighbouring noradrenergic nuclei also contribute (Peyron et al. 1996). 
Neurones in both the DRN· and MRN express ul-adrenoceptors and U2-
adrenoceptors. There is evidence that stimulation of U l-adrenoceptors can 
facilitate 5-HTergic transmission (Baraban and Aghajanian 1980), whereas Ur 
adrenoceptor stimulation suppresses the activity of 5-HTergic neurones (Adell 
and Artigas 1999). The dopaminergic input to the raphe nuclei arises from both 
the substantia nigra and the ventral tegmental area (Beckstead et al. 1979). The 
dopaminergic influence on neuronal activity in the raphe nuclei is mainly 
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facilitatory, and is mediated primarily by D2 dopamine receptors (Adell et al. 
2002). 
1.2.2. Synthesis and metabolism of 5-hydroxytryptamine 
The basic biochemical mechanisms involved in the synthesis and degradation 
of 5-HT have been known for many years (Costa and Meek 1974). Only a bnef 
summary is provided in this section. 
The synthesis of 5-HT begins from its precursor, the amino-acid 
tryptophan. Tryptophan is obtained from ingested food. However, normal diet 
generally contains lower amounts of tryptophan than of other large neutral 
amino-acids (e.g. tyrosine). The capillary endothelia that comprise the blood 
brain barrier contain a limited-capacity transport system for neutral amino-
acids; this is a 'passive' process (i.e. one that is not energy-dependent: 
Wurtman et al. 1981). Neutral amino-acids compete for passage through the 
blood-brain barrier via this transport process. Thus, a high dietary loading of 
other neutral amino-acids results in a reduction of brain tryptophan levels. This 
is the basis of the 'acute tryptophan depletion' procedure that has been widely 
used in studies of 5-HTergic function in man (Delgado et al. 1990). There is a 
diurnal variation in tryptophan levels in the plasma (lower at midday, and 
higher in the evening), which is mainly due to the consumption of meals. 
Insulin secretion following the ingestion of a carbohydrate-rich meal results in 
lowering of the plasma levels of most neutral amino-acids; however tryptophan 
levels are not significantly affected, due to the binding of tryptophan to 
albumin in the plasma. The net result of this is that the plasma tryptophan ratio 
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(i.e. the ratio of tryptophan to other amino-acids) is increased, and this results 
in increased penetration of tryptophan into the brain (Wurtman et al. 1981). 
Tryptophan is taken into 5-HTergic neurones by an energy-dependent 
process. The specific intracellular enzyme tryptophan hydroxylase converts 
tryptophan to 5-hydroxytryptophan. This is the rate-limiting step in 5-HT 
synthesis; inhibition of the enzyme by para-chlorophenylalanine (PCP A) 
results in long-lasting 5-HT depletion in the brain (Costa and Meek 1974). 
5-Hydroxytryptophan is converted to 5-HT by the non-specific enzyme 
L-aromatic amino-acid decarboxylase. 5-HT, like other neurotransmitters, is 
retained in vesicles within the nerve terminals, which protect it from enzymatic 
degradation (see below). 
Like many other transmitters, the release of 5-HT into the synaptic cleft 
is accomplished by a calcium-dependent process following depolarization of 
the membrane of the presynaptic terminal. 5-HT's action at post-synaptic 
receptors is considered in the following section. 
Following release, 5-HT is taken back into the 5-HTergic neurone by 
an energy-dependent transport process. The serotonin transporter (SERT) 
molecule which is responsible for this process has been found in all areas of 
the brain that receive a 5-HTergic projection (Gainetdinov and Caron 2003). 
The uptake process can be inhibited by tricyclic antidepressants (which also 
inhibit noradrenaline uptake), and by 'selective serotonin reuptake inhibitors' 
(SSRls) (see Szabadi and Bradshaw 2004). 
After reuptake, 5-HT is degraded by the mitochondrial enzyme 
monoamine oxidase (MAO), which deaminates 5-HT and other monoamines. 
In the case of 5-HT, the resulting metabolite is 5-hydroxyindoleacetic acid (5-
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HIAA). There are two forms of MAO; MAO-A and MAO-B. Although 5-HT 
is a better substrate for MAO-A than MAO-B, 5-HT cell bodies in the brain 
contain greater amounts of MAO-B than MAO-A (Azmitia et al. 2002). 
Monoamine oxidase inhibitors (MAO I) can block the destruction of 5-HT, 
thereby increasing the synaptic availability of 5-HT (see Szabadi and 
Bradshaw 2004). 
1.2.3. 5-hydroxytryptamine receptors 
1.2.3.1. Historical background 
5-HT mediates a wide range of physiological functions in both the central 
nervous system (eNS) and in the periphery. These functions are mediated by 
multiple types of receptor. Early attempts to define and classify these receptors, 
starting in the 1950s, necessarily relied on the functional pharmacological 
methods that were available at that time. The introduction of radioligand 
binding techniques, second messenger assays, and, more recently, cloning 
techniques, have resulted in the discovery of an increasing number of receptor 
sUbtypes. 
Peripheral 5-HT receptors were classified into two major subtypes by 
Gaddum and Picarelli (1957). These authors demonstrated that 5-HT-induced 
contractions of the guinea-pig ileum could be blocked partly by morphine and 
partly by dibenzyline. This led them to conclude that the contractile response 
might be mediated by two different receptor populations, which they named M-
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and D-receptors, respectively (see Hoyer et al. 2002; Lanfumey and Hamon 
2004). 
In 1979, Perutka and Snyder, using radio ligand binding techniques, 
identified two distinct 5-HT binding sites in brain tissue, which they designated 
5HT1 and 5-HT2 receptors. 5-HT1 receptors were found to have high affinity 
for 5-HT, and 5HT2 receptors to have lower affinity for 5-HT, but higher 
affinity for 5-HT antagonists. The peripheral M-receptors were thought to be 
distinct from 5-HT 1 receptors, but the D-receptors were thought to be 
pharmacologically similar to 5-HT2 receptors (Lanfumey & Hamon 2004; 
Hoyer et al 2002). It soon became apparent that 5-HT, receptors are 
heterogeneous and can be divided into several subgroups (see below). 
Interest in the M-receptor increased with the discovery of selective 
antagonists for this site (Fozard and Gittos 1983). The receptor was formally 
re-named the 5-HT3 receptor in an internationally agreed taxonomy of 5-HT 
receptors (Bradley et al. 1986). 
To date, at least seven different types of 5-HT receptor have been 
identified, several of them have been described with mUltiple subtypes 
(Glennon et al. 2002). Except for the 5HT3 receptor, which belongs to the 
'superfamily' of ligand-gated ion channels, all other 5-HT receptor types 
belong to the G protein-coupled receptor 'superfamily'. The widespread use of 
binding and cloning techniques has led to the identification of a large number 
of binding sites, and it is not clear how many of them may eventually be 
attributed to the 5-HT receptor family. Therefore, an international committee 
has proposed a new system of classification, in which the term 5-HT receptor 
can be applied only when three classes of operational criteria - structural, 
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transductional and functional information - are available for that receptor 
(Hoyer et al. 1994). Some of the newly discovered recognition sites for 5-HT, 
which are not coupled to any known physiological mechanism, have been 
named with lower case designations (e.g.5-htIF and 5-htsA). 
The aim of this section is to provide a synopsis of the principal 
subtypes of 5-HT receptors, including their neuroanatomical distribution and 
pharmacological features. The behavioural roles of the receptors are mainly 
discussed in the following section. As well as the original papers cited below, 
this synopsis draws heavily on recent major reviews of 5-HT receptors, 
including Barnes and Sharp (1999), Glennon et al. (2002), and Hannon and 
Hoyer (2002), and Hoyer et al. (2002). The chemical names of compounds 
identified by pharmaceutical company codes are only provided in the case of 
drugs that have relevance to later chapters of the thesis; a comprehensive list of 
chemical names is given in the Appendix (see also Hoyer et al. 2002). 
1.2.3.2. The 5-HT1 receptor family 
This group of receptors was first subdivided into six subtypes, designated 5-
HTIA, 5-HTIB, 5-HTIC, 5-HTlO, 5-HTIE, and 5-HT lF. Subsequently, the 5-HT lc 
receptor was re-assigned to the 5-HT 2 receptor family and re-named 5-HT 2C, 
because it was found to have close homology with other 5-HT2 receptors both 
in terms of DNA coding and second messenger coupling (Lanfumey and 
Hamon 2000, 2004). Little is known about 5-HTlE and 5-HTIF receptors, and 
therefore many authors still prefer the lower-case designation 5-htlE and 5-htlF 
(Pauwels 2003). 
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5-HT1 receptors are the largest class of 5-HT receptors, and they have 
high affinity for 5-HT. Like all other 5-HT receptors except the 5-HT 3 receptor, 
they belong to the G-protein-coupled superfamily. 5-HT I receptors inhibit 
adenylyl cyclase when they are stimulated. 
1.2.3.2.1. 5-HT lA receptors 
These receptors can be found in many parts of the CNS. They occur in large 
numbers in the median and dorsal raphe nuclei. The great majority of these 
receptors are located on the somata and dendrites of 5-HTergic neurones, 
although a significant minority are expressed by non-5-HTergic cells (Kirby et 
al. 2003). The 5-HT1A receptors on 5-HTergic neurones are believed to 
function as inhibitory autoreceptors. Stimulation of these receptors inhibits cell 
firing in the raphe nuclei. 
5-HT1A receptors are also abundant in many other parts of the CNS, 
especially the limbic system, where they function as postsynaptic receptors. 
They are expressed most densely in the hippocampus, and are also found in the 
septum and amygdala. Somewhat lower. concentrations are found in the 
prefrontal and entorhinal cortex, and some nuclei of the thalamus and 
hypothalamus. They are barely detectable in the basal ganglia and cerebellum 
(see Barnes and Sharp 1999). 
5-HT1A receptors are negatively coupled to the adenylyl cyclase second 
messenger system (Glennon et al. 2002; Hoyer et aL 2002). The most widely 
used full agonist of 5-HT1A receptors is 8-hydroxy-(di-n-propylamino)tetralin 
(8-0H-DPAT). The anxiolytic buspirone, and its close relatives ipsapirone and 
l3 
gepirone, are rather selective partial agonists at these receptors. N-[2-( 4-[2-
methoxyphenyl]-1-piperazinyl)ethyl]-N-2-pyridinylcyclohexane-carboxamide 
(WAY-I00635) is a highly selective antagonist with high affinity for 5-HT 1A 
receptors (Pauwels 2003). 
1.2.3.2.2. 5-HTIB receptors 
5-HTIB receptors can be found in many areas of the eNS. In the globus 
pallidus, substantia nigra and parts of the frontal cortex, they act as terminal 
autoreceptors on 5-HTergic neurones, controlling the release of 5-HT. 5-HTm 
receptors are also thought to act as terminal heteroreceptors on non-5-HTergic 
neurones, controlling the release of acetylcholine, glutamate, dopamine, 
noradrenaline, and y-aminobutyric acid (GAB A) (Barnes and Sharp 1999: 
Hoyer et al. 2002; Boothman et al. 2003; Pauwels 2003). These receptors have 
also been found in arteries of the cerebral circulation, where they mediate the 
vasoconstrictor effect of 5-HT (Hoyer et a12002; Lanfumey and Hamon 2004). 
5-HT IB receptors are negatively coupled to adenylate cyclase. The first 
reported full agonist at 5-HTm receptor was RU-24969. The anti-migraine drug 
sumatriptan, and the closely rell;lted compounds rizatriptan and zolmitriptan, 
are partial agonists at these receptors. These compounds have more or less 
equal affinity for 5-HTIB and 5-HTID receptors (see below). Other 5-HTIB 
receptor agonists include the 'serenics' (e.g. eltoprazine), which were 
developed as potential anti-aggressive agents, but were found to be inetfecti ve 
in controlling aggression in clinical trials (de Koning et al. 1994). There are no 
entirely satisfactory 5-HT IB receptor antagonists available at present. The ~ ~
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adrenoceptor antagonists pindolol and cyanopindolol are effective antagonists 
at these receptors, as is the non-selective 5-HT1 receptor antagonist 
methiothepin (see Barnes and Sharp 1999; Hoyer et al. 2002). SB-216641 and 
SB-224289 are among the few compounds which discriminate between 5-HT1B 
and 5-HTID receptors (Price et al. 1997); they are inverse agonists at 5-HT1B 
receptors (Roberts et al. 2000). 
1.2.3.2.3. 5-HTID receptors 
The receptor originally designated as 5-HT ID is almost completely absent in the 
rat brain, but has a distribution in the human and guinea-pig brain that closely 
resembles the distribution of 5-HTlB receptors in the rodent brain. The situation 
is complicated by the fact that there are two distinct forms of the 5-HTID 
receptor, originally designated 5-HTIDa. and S - H T I D ~ ' ' which display about 77% 
sequence homology (see Glennon et al. 2002). The 5-HT IDa. is, in fact, present 
both in rodents and in humans, whereas the 5 - H T I D ~ ~ receptor (which is one and 
the same as the original5-HTID receptor) is absent in rodents. The taxonomy of 
these receptors has now been simplified by identifying the 5-HT lB and 5-HT I D ~ ~
receptors as species variants of a single receptor SUbtype. According to the 
current nomenclature, these species variants are collectively known as the 5-
HTlB receptor, and the name '5-HTID' is now reserved for the 5-HTIDa. receptor 
(Barnes and Sharp 1999; Pauwels 2003). 
5-HT ID receptors have been identified predominantly in the caudate-
putamen, and to lower degrees in other parts of eNS, especially the olfactory 
tubercle, entorhinal cortex, dorsal raphe nucleus, and cerebellum (see Pauwels 
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2003; Lanfumey and Hamon 2004). These receptors are G protein-linked, and 
are coupled to inhibition of adenylyl cyclase. They are believed to contribute 
(together with 5-HTJB receptors) to the inhibitory regulation of 5-HT release, 
and also to mediate the inhibitory effect of 5-HT on glutamate and somatostatin 
release (Maura et al1998; see Lanfumey and Hamon 2004). 
As indicated above, sumatriptan is an agonist at 5-HT 10 receptors, but 
also binds to 5-HTJB, and to some extent to 5-HT1A receptors. PNU 109291 
shows greater selectivity for the 5-HTlO receptor (Pauwels 2003). 5-HTlO 
receptor antagonists include GR127935 and GR55562, although these do not 
show good selectivity for 5-HTlO over 5-HTIB receptors (Glennon et a1. 2002). 
1.2.3.2.4. 5-htlE receptors 
Since it is not confirmed that these receptors have a true physiological role, 
they retain their lower case appellation. Like other members of 5-HT I family 
subtypes, this receptor is coupled negatively to adenylyl cyclase. In terms of 
their structure, there is considerable sequence homology between 5-htlE and 5-
HT 10 receptors, leading to the suggestion that the two receptor subtypes belong 
to the same group (Glennon et al. 2002). However they differ in their affinity 
for ligands; 5-carboxytryptamine has very low affinity for the 5-htlE binding 
site, in contrast to its high affinity for the 5-HTlO site (Lanfumey and Hamon 
2004). There is evidence for slight differences between the human and rodent 
5-htlE receptors, which have been labelled 5-htlEa and 5 - h t I E ~ ' ' respectively 
(Glennon et al. 2002). 
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The 5-htlE receptor has been found in the frontal cortex, but a 
comprehensive mapping of its distribution in the brain has not yet been 
undertaken. Selective agonists and antagonists for this receptor are not yet 
available (see Pauwels 2003; Lanfumey and Hamon 2004). 
1.2.3.2.5. 5-htlF receptors 
This receptor is thought to be closely related to 5-htlE receptor, because the two 
subtypes exhibit considerable sequence homology (>70%; see Hoyer et al. 
2002). Antimigraine drugs, for example sumatriptan, label5-htlF receptors with 
high affinity, and this property distinguishes the 5-htlF receptor from the 5-htlE 
receptor (Barnes and Sharp 1999). It has been suggested that the 5-htlF 
receptor, rather than the 5-HTID receptor, may be the mediator of the 
therapeutic effects of these drugs (Hamon and Bourgoin 2000). 5-htlF receptor 
mRNA has been found in the dorsal raphe nucleus, hippocampus, cerebral 
cortex, striatum, thalamus and hypothalamus (see Lanfumey and Hamon 2004). 
5-htlF receptors are negatively coupled to adenylyl cyclase. Two 
putative selective agonists have been described: L Y -344864 and L Y -334370 
(see Pauwels 2003). 
1.2.3.3. The 5-HT2 receptor family 
This class of 5-HT receptors consists of three SUbtypes: 5-HT2A, 5-HT2B, and 5-
HT2C. The last of these was formerly termed 5-HT1C (see above). Like the 5-
HT l family, this class belongs to the metabotropic receptor 'superfamily'. All 
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three subtypes of 5-HT2 receptor are coupled to the phosphoinositide system, 
receptor stimulation resulting in an increase in inositol phosphate hydrolysis 
(see Hoyer et al. 2002). The three receptors in this class show a high sequence 
similarity; the homology within the transmembrane domains has been reported 
as more than 70% (Hoyer and Martin 1997; Glennon et al. 2002; Leysen 2004). 
1.2.3.3.1. 5-HT2A receptors 
The 5-HT 2A receptor has been identified with the classical D receptor of 
Gaddum and Picarelli (1957), which was later defined by Peroutka and Snyder 
(1979) as the 5-HT 2 receptor. These receptors have been found in almost all 
parts of the brain. They are especially abundant in the telencephalon (including 
the olfactory system, cerebral cortex, hippocampus, amygdala and corpus 
striatum), but are also present in considerable numbers in the diencephalon 
(dorsal thalamus and hypothalamus), mesencephalon (substantia nigra and 
ventral tegmental area), metencephalon (latero-dorsal tegmental nucleus), and 
on spinal cord motoneurons; they have also been found on sympathetic and 
sensory ganglion neurones (Barnes and Sharp 1999; Hoyer et al. 2002). The 
distribution of 5-HT 2A receptors indicates that they are postsynaptically located 
in structures innervated by the 5-HTergic projection (Blue et al. 1988). They 
have been localized on GABAergic interneurones and on the apical dendrites 
of glutamatergic projection neurones of the cerebral cortex (see Barnes and 
Sharp 1999). It has been proposed that 5-HT2A receptors have a 'balancing' 
role in the regulation of inhibitory and excitatory signalling in the cortex; for 
example their activation may promote GABA-mediated inhibition of 
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glutamatergic pyramidal neurones and may simultaneously produce a direct 
excitatory effect on the pyramidal cells (see Leysen 2004). 
There are no known selective agonists for the 5-HT2A receptor. DOl 
(2,5-dimethoxy-4-iodoamphetamine) has been widely used as a 5-HT2A 
receptor agonist; however this agent also has a high affmity for 5-HT2C 
receptors. Amongst the antagonists, ketanserin has an 80-fold selectivity for 5-
HT2A over 5-HT2C receptors (with little affinity for 5-HT28 receptors) (Baxter 
et al. 1995). MDL 100907 (2,3-dimethoxyphenyl-l-[2-( 4-piperidine)-
methanol]) is even more selective, having an affinity for the 5-HT2A receptor 
that is almost two-and-a-half orders of magnitude greater than its affinity for 
the 5-HT 2C receptor (Kehne et al. 1996; see Barnes and Sharp 1999; Glennon et 
al. 2002; Hoyer et al. 2002; Leysen 2004). 
1.2.3.3.2. 5-HT 2B receptors 
5-HT 2B receptors were first described in the rat stomach fundus, and then were 
identified in human gastrointestinal tract, particularly in the colon, and in the 
myenteric plexus where they mediate contractile functions. They have also 
been found on endothelial cells of the cerebral arteries where they cause 
vascular relaxation by releasing nitric oxide. Their presence in the. brain 
appears to be restricted to the cerebellum, lateral septum, hypothalamus and 
medial amygdala (Hamon and Hoyer 2002; Leysen 2004). 5-HT2B receptors in 
the brain are coupled to phosphoinositol hydrolysis (Barnes and Sharp 1999). 
Interestingly there is a high homology (>90%) between rat and human 5-HT 28 
receptors (Hoyer and Martin 1997; Leysen 2004). 
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Selective agonists (e.g. BW-723C86) and antagonists (SB-200464) are 
available for the 5-HT2B receptor (see Pauwels 2003; Leysen 2004). 
1.2.3.3.3. 5-HT2c receptors 
This subtype was the first of 5-HT 2 receptor family to be cloned, and was once 
referred to as the 5-HT1c receptor. This receptor was identified in the choroid 
plexus of various species, suggesting that it may have a role in the regulation of 
cerebrospinal fluid (Kaufman et al. 1995). 5-HT2C receptors have also been 
found in the pyriform and cingulate cortices, parts of the limbic system 
(nucleus accumbens, amygdala and hippocampus) and basal ganglia (caudate 
nucleus, substantia nigra) (Palacios et al. 1991; Barnes and Sharp 1999). Their 
presence on GABAergic neurones in the basal ganglia has led to the suggestion 
that they may exert an indirect influence on dopaminergic transmission 
(Eberle-Wang et al. 1996, 1997). In keeping with this suggestion, 5-HT2c 
receptor antagonists have been reported to increase extracellular dopamine 
levels in the basal ganglia (Pozzi et al. 2002). 
5-HT2C receptors are coupled to phosphoinositol hydrolysis. No highly 
selective agonists have been described. As indicated above, DOl has similar 
affinity for 5-HT2A and. 5-HT2C receptors; mCPP (2-(2-methyl-4-
chlorophenoxy)propanoic acid) has affinity for 5-HT 2B as well as 5-HT 2C 
receptors. Among its antagonists, SB-242084 and RS-I02221 are the most 
selective (Pauwels 2003; Leysen 2004). 
1.2.3.4. 5-HT3 receptors 
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The 5-HT3 receptor is the same as Gaddum and Picarelli's (1957) "Moo 
receptor. It is unique among the families of 5-HT receptors in belonging to the 
ligand-gated ion channel (ionotropic) receptor superfamily. 5-HT3 receptor 
stimulation produces a depolarising response, due to non-selective cation 
channel opening. 5-HT3 receptors are found both in the CNS (area postrema, 
enthorinal cortex, frontal cortex, and hippocampus) and in the periphery 
(gastrointestinal tract, cardiovascular system). Three subunits of the 5-HT3 
receptor have been identified, designated 5-HT3A, 5-HT3B and 5-HT3C (see 
Costall and Naylor 2004). 
5-HT3 receptors have been localized on GABAergic neurones in the 
basal ganglia, and 5-HT3 receptor stimulation has been reported to promote 
GAB A release (Morales and Bloom 1997). 5-HT3 receptor agonists also 
promote dopamine release in the nucleus accumbens; the location of the 5-HT3 
receptors responsible for this effect is not known (DeDeurwaerdere et a1. 
1998). 
Selective 5-HT3 receptor agonists include 2-methyl-5-HT, 
phenylbiguanide, and m-chlorophenylbiguanide (mCPBG), mCPBG having the 
highest affinity (within the nanomolar range) (Kilpatrick et al. 1990). 
Quipazine, which has nanomolar affinity for 5-HT 3 receptors, also has 
relatively high affinity (micromolar range) for 5-HT2A receptors (Hoyer 1988; 
Glennon et al. 1989; Sharif et al. 1991). MDL-72222 (tropanyl 3,5-
dichlorobenzoate) was the first potent and selective 5-HT3 receptor antagonist 
to be described (Fozard and Gittos 1983). Other selective antagonists for 5-HT3 
receptors include ondansetron, tropisetron and granisetron; these compounds 
are efficacious in suppressing nausea and vomiting induced by cytotoxic 
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agents, this effect being mediated by blockade of 5-HT 3 in the area postrema 
and possibly also on vagal afferents in the gut (Andrews 1994; Costal! and 
Naylor 2004). 
1.2.3.5. The 5-HT4 receptor family 
The 5-HT4 receptor was first identified in cultured neurones from the mouse 
colliculi (Bockaert et al. 1990). The application of cloning technology revealed 
that there are numerous variants (eight, according to a recent review: Bockaert 
et al. 2004), labelled 5-HT4a, 5-HT4b, etc. These variants show subtle 
differences in binding affinities for agonists and antagonists, and subtly 
different regional distribution in the brain. However, the degree of 
pharmacological specificity shown by currently available ligands has proved 
insufficient to identify clearly distinct functional profiles (see Bockaert et al. 
2004). Therefore for the purposes of this brief synopsis, they will be treated as 
though they constituted a unitary receptor population. 
5-HT4 receptors are metabotropic receptors that are positively coupled 
to adenylyl cyclase. They occur in the periphery and in the CNS. In the 
periphery, they are located mainly in the gastrointestinal tract, where they 
increase gut motility, apparently via acetycholine release (Buchheit et al. 
1995). They are widely distributed in the eNS, high concentrations being 
found in limbic structures (nucleus accumbens, amygdala), olfactory tubercle, 
hippocampus, basal ganglia (striatum, globus pallidus), substantia nigra and 
hypothalamus (Bockaert et al. 2004). 5-HT4 receptors in the striatum have been 
localized on the somata and dendrites of GABAergic neurones, including those 
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that project to the substantia nigra and globus pallidus (Compan et aL 1996). 
5-HT4 receptors in the hippocampus and prefrontal cortex have been localized 
on both cholinergic and glutamatergic neurones (Matsumoto et al. 2001). 5-
HT 4 receptor agonists promote dopamine release in the dorsal striatum (Lucas 
et al. 2001), and acetylcholine release in the frontal cortex (Consolo et al. 
1994). An interesting feature of 5-HT4 receptors is that they show varying 
degrees of 'constitutive' activity, that is, they can be functionally active in the 
absence of any agonist stimulation. An implication of this property is that 
antagonists may act as inverse agonists, depending on the level of constitutive 
activity (see Bockaert et al. 2004). 
No full agonists have yet been described. High-affinity partial agonists 
include RS-67333 and RS-67506; GRI13808 and GR125487 are selective 
antagonists (Bockaert 2004). 
1.2.3.6. The 5-ht5 receptor family 
The 5-hts receptor has been classified as an 'orphan' receptor (Hoyer et al. 
2002), due to lack of evidence for any physiological role for this binding site. 
Two subtypes have been cloned, 5-htsA and 5-hts8, which have been found in 
the mouse and rat respectively, and share 70% overall sequence identity (see 
Pauwels 2003). The 5-hts8 receptor is not expressed in humans (Nelson 2004; 
Hannon and Hoyer 2002). Some authors reported that, in the rat, 5-htsA 
receptor may be negatively coupled to adenylyl cyclase; however, it has also 
been reported that this receptor may couple positively to cyclic AMP 
production (see Hoyer et al. 2002). 5-hts receptors have been found in the 
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olfactory bulb, caudate-putamen, neocortex, hippocampus, hypothalamus, and 
cerebral ventricles (Nelson 2004; Hannon and Hoyer 2002). At present there 
are no selective agonists or antagonists for these receptors (Pauwels 2003). 
1.2.3.7. The 5-ht6 receptor family 
The 5-h4; receptor in the rat is positively coupled to adenylyl cyclase, and 
shares <40% sequence homology with all other 5-HT receptors that couple to 
G-proteins (Wooley et aL 2004). It is expressed almost exclusively in the brain. 
The richest area for 5-ht6 receptors is the nucleus accumbens, and the poorest 
area is cerebellum; 5-ht6 receptors are also found in the hippocampus, olfactory 
tubercle, striatum and cortex (Wooley et al. 2004; Hoyer et al. 2002). The 5-ht6 
receptor has a high affinity for both typical and atypical antipsychotics; 
Wooley et al. (2004) suggested that the preponderant location of this receptor 
in the ventral striatum (nucleus accumbens) is consistent with a potential role 
in the mode of action of antipsychotics. The receptors are apparently located on 
postsynaptic structures, because destruction of the 5-HTergic pathways does 
not reduce the receptor population in the forebrain (Gerald et al. 1996). SB-
271046 and Ro 04-6790 are reported to be selective and potent antagonists at 
5-ht6 sites; no highly selective agonists are available as yet (Hoyer et al. 2002; 
Wooley et al. 2004). 
1.2.3.8. The 5-HT7 receptor family 
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5-HT 7 receptors are coupled positively to adenylyl cyclase via G-proteins. 
They have been found in eNS, and also in the peripheral tissue. To date a 
number of subtypes have been reported for 5-HT7 receptors: 5-HT7(a), 5-HT7(b)' 
and 5-HT 7(c) in the rat, and 5-HT 7(a), 5-HT 7(b), and 5-HT 7(d) in the human brain 
(Thomas and Hagan 2004). These receptors are expressed in thalamus, 
hypothalamus, cerebral cortex and amygdala. The receptors are believed to be 
postsynaptic. The hypothalamic receptor population is particularly dense in the 
suprachiasmatic nucleus, which has been implicated in the control of the 
circadian rhythm and hormone release (Hedlund and Sutcliffe 2004). 
No selective 5-HT7 agonists exist at present. The 5-HT 1A receptor 
agonist 8-0H-DPAT has a high affinity for the 5-HT7 receptor; however, the 5-
HTlA receptor antagonist WA Y-I00635 has very little affinity for the 5-HT7 
receptor. Selective antagonists for the 5-HT7 receptor include SB 258719, and 
DR 4004 (Hedlund and Sutcliffe 2004; Thomas and Hagan 2004). 
1.2.4. Behavioural role of the S-hydroxytryptaminergic system 
The behavioural role of the 5-HTergic system includes a very broad range of 
behaviours, from sleep, locomotor activity, feeding, sexual behaviour, 
aggression and anxiety, to complex learned behaviours such as inter-temporal 
choice, memory and timing. Dysfunction of the 5-HTergic system has been 
implicated in a range of psychiatric disorders, including generalized anxiety 
disorder, obsessive-compulsive disorder, depression, schizophrenia and 
pathological impUlsiveness. In this section, some behavioural roles of 5-HT 
that have potential relevance to the experimental work described in this thesis 
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will be outlined. Previous studies of the role of 5-HT in timing behaviour will 
be reviewed separately in section 1.5. (Behavioural pharmacology of timin?;). 
1.2.4.1. 5-HT and sleep/arousal 
The possible role of the 5-HTergic pathways in sleep and arousal was first 
suggested by Bradley's (1958) observation that intraventricularly administered 
5-HT to cats induced a brief increase in arousal followed by prolonged 
somnolence. Subsequently it was shown that central 5-HT depletion by p-
chlorophenylalanine suppressed sleep in cats (Koella et al. 1968). JOLlve( 
(1972) showed that loss of 5-HTergic function had an especially marked effect 
on 'paradoxical' or rapid-eye-movement (REM) sleep. Jouvet (1972) proposed 
that 5-HT might serve to induce sleep. However, this theory was contradicted 
by the finding that 5-HTergic neurones of the dorsal raphe nucleus were most 
active during wakefulness, less active during slow-wave sleep, and quiescent 
during REM sleep (e.g. Lydic et al. 1987). Consistent with this finding, 
microdialysis studies have shown that extracellular 5-HT in the raphe nuclei is 
at its highest level during wakefulness, lower during REM sleep and minimal 
during slow wave sleep (Portas et al. 1998, 2000). Suppression of 5-HTergic 
activity by intra-raphe injection of the 5-HT1A receptor agonist 8-0H-DPAT 
(thus stimulating 5-HT release-inhibiting autoreceptors: see above) induces 
REM sleep (Portas et al. 1996; Bjorvatn et al. 1997). 
The targets for the 5-HTergic neurones involved in the suppression of 
REM sleep have been proposed to be the pedunculopontine and laterodorsal 
tegmental nuclei, both of which have been implicated in the genesis of REM 
sleep (see Portas et al. 2000). Studies of the effects of intracerebrally injected 
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agonists and antagonists indicate that the postsynaptic 5-HT receptors 
mediating this effect include 5-HT1A (Monti et al. 1994; Monti and Monti 
2000) and 5-HT2A (Amici et al. 2004) receptors. In addition, studies of the 
sleep patterns of 5-HTlB receptor knockout mice, and the ability of 5-HT lB 
receptor antagonists to induce REM sleep, indicate that this receptor subtype 
may also be involved in the regulation of REM sleep (Boutrel et al. 1999). 
The 5-HTergic projection to the suprachiasmatic nucleus has also been 
implicated in the circadian sleep-wakefulness cycle, in which that nucleus is 
prominently involved. 5-HT's action in the suprachiasmatic nucleus appears to 
be mediated by 5-HT 7 receptors (Hagan et aL 2000). 
The recent discovery of the important role played by histaminergic and 
orexinergic neurones in sleep and arousal mechanisms has tended to relegate 
the 5-HTergic system to a subsidiary role in current models of sleep 
mechanisms (see Pace-Schott and Hobson 2002; Mignot et al. 2002). For 
example, according to one model, 5-HTergic neurones of the raphe nuclei 
contribute to the inhibition of y-aminobutyric acid (GABA)- and galanin-
producing neurones of the ventrolateral preoptic nucleus, which in turn inhibit 
the raphe nuclei, locus coeruleus and cholinergic neurones of the 
pedunculopontine tegmental nucleus and laterodorsal tegmental nucleus. All 
these regions receive excitatory influences from orexinergic neurones of the 
lateral hypothalamus (see Pace-Schott and Hobson 2002). The complexities of 
this system are beyond the scope of this review; however it is clear that there 
are many questions about the contribution of 5-HTergic mechanisms to sleep 
and arousal that remain unresolved (see Jouvet 1999). 
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1.2.4.2. 5-HT and locomotor behaviour 
Central 5-HT depletion results in enhancement of spontaneous locomotor 
behaviour and locomotor behaviour conditioned to food presentation (e.g. 
Winstanley et al. 2004). In two-lever operant tasks, 5-HT depleted rats 
consistently switch between levers at a higher rate than normal rats (AI-Zahrani 
et al. 1996; see AI-Ruwaitea et al. 1997). Although this effect of 5-HT 
depletion may reflect locomotor activation, this is not necessarily the case, 
because other interventions that facilitate spontaneous locomotion (e.g. 
systemic treatment with d-amphetamine) do not promote switching (Chiang et 
al. 2000a). 
Systemic treatment with 5-HT receptor agonists and antagonists 
generally has rather weak effects on spontaneous locomotor behaviour. The 5-
HTlA receptor agonist 8-0H-DPAT has been found to suppress locomotion 
(De la Garza and Cunningham 2000). 5-HT2A receptor agonists and antagonists 
have been found to have no significant effect on spontaneous locomotion 
. (Koskinen et al. 2000), whereas 5-HT2C receptor stimulation has been found to 
induce hypolocomotion (Kennett and Curzon 1988). The role of 5-HT3 
receptors is unclear. For example, Mazzola-Pomietto et al. (1995) reported that 
the 5-HT3 receptor agonist m-CPBG had no significant effect on spontaneous 
locomotion, whereas the antagonist MDL-72222 dose-dependently reduced 
locomotion. 
In contrast to their relatively weak effects on spontaneous locomotion, 
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agonists and antagonists of several types of 5-HT receptor have profound 
effects on the hyperiocomotion induced by psychostimulant drugs. Thus, 5-
HT2A receptor antagonists attenuated cocaine-induced hyperlocomotion (Filip 
et aI, 2001; McMahon and Cunningham 2001; Fletcher et a1. 2002). In contrast, 
5-HT 2C receptor antagonists potentiated cocaine-induced hyperlocomotion 
(Fletcher et a1. 2002; Filip et a1. 2004). 5-HT1A receptors may also mediate 
attenuation of cocaine-induced locomotor stimulation. Thus, 8-0H-DPAT was 
found to reduce the effect of cocaine on locomotion, and the selective 5-HT 1A 
receptor antagonist blocked the effect of 8-0H-DPAT without altering the 
'baseline' effect of cocaine (Przegalinski and Filip 1997). 
The anatomical location of the 5-HT receptor populations mediating 
these effects is not clear. There is evidence that post-synaptic 5-HT2C receptors 
exist in the nucleus accumbens and prefrontal cortex, two target regions for the 
meso limbic dopaminergic projection. 5-HT 2C receptors in these two regions 
may exert opposing effects. Thus Filip and Cunningham (2002, 2003) found 
that injection of 5-HT 2C receptor agonists into the accumbens enhanced 
cocaine-induced locomotion, whereas injection of the same agonists into the 
prefrontal cortex had the oppisite effect. 
1.2.4.3. 5-HT and feeding 
It has been known for many years that manipulation of the 5-HTergic system 
has marked effects on ingestive behaviour. Destruction of the ascending 5-
HTergic projection results in an increase of food intake (Hoebel et a1. 1978), 
whereas the 5-HT-releasing agent fenfluramine (Grignaschi et al. 1992) and 5-
29 
HT reuptake inhibitors (Lucki et al. 1988; Fletcher et al. 1993) suppress 
feeding behaviour. Such observations suggest that 5-HT plays a predominantly 
inhibitory role in the control of feeding. 
Several types of 5-HT receptor have been implicated in S-HT's role in 
feeding, including 5-HT1A, 5-HT IB and 5-HT2c receptors (see De Vry and 
Schreiber 2000). 
The 5-HT lA receptor agonist 8-0H -DP AT promotes feeding behaviour 
(Dourish et al. 1985); this effect can be blocked by the selective 5-HT 1A 
receptor antagonist WAY-100635 (Hartley and Fletcher 1994). The effect is 
seen following direct injection of the agonist into the raphe nuclei, and is 
absent after destruction of the 5-HTergic pathways with 5,7-
dihydroxytryptamine, indicating that the effect is mediated by stimulation of 
the somatodendritic release-inhibiting autoreceptor population of 5-HT 1A 
receptors (Bendotti and Samanin 1986). 8-0H-DPAT's facilitatory effect on 
feeding is seen in freely feeding rats, but not in food-deprived rats, suggesting 
that 8-0H-DPAT may dis inhibit feeding following satiety (Dourish et al. 
1985). Consistent with this interpretation, Voigt et al. (2000) showed that 5-
HT release in the lateral hypothalamus (an area that plays a prominent role in 
ingestive behaviour) was enhanced by 8-0H-DPAT in freely feeding rats, but 
not in food-deprived rats. 
There is good evidence for an important role of 5-HT IB receptors in 
feeding. The non-selective 5-HT1B12C receptor agonist l-(m-chlorophenyl)-
piperazine (mCPP) and the selective 5-HT IB receptor agonist CP-94,253 
suppress food intake (e.g. Hewitt et al. 2002; Clifton et al. 2003). Analysis of 
the pattern of ingestive behaviour suggests that CP-94,253 inhibits feeding by 
30 
advancing the 'behavioural satiety sequence' (progression from ingestion, 
through locomotor activity and grooming, to quiescence) (Lee et al. 2004). The 
effect of CP-94,253 can be reversed by the selective 5-HTIB receptor 
antagonist SB-224289 (Lee et al. 2004). These effects are absent in 5-HT IB 
receptor knockout mice (Lee et al. 2004). These mice are characterized by 
increased food intake and body weight compared to wild-type mice, further 
supporting a role of 5-HT IB receptors in the inhibitory regulation of feeding 
(Bouwknecht et al. 2001). 5-HTlB receptors occur on 5-HTergic terminals 
(terminal autoreceptors) and on postsynaptic membranes. The effects on 
feeding are likely to be mediated by postsynaptic receptors, as indicated by the 
increase in Fos immunoreactivity in the hypothalamus and amygdala following 
CP-94,253 administration; an action on nerve terminal activity is considered 
unlikely to result in a change in this index of neuronal activation (Lee et al. 
2004). 
Although the suppression of feeding by fenfluramine is partly mediated 
by 5-HT IB receptors (see above), there is also evidence for a role of 5-HT2C 
receptors in this effect. 5-HT2C receptor knockout mice show reduced 
sensitivity to fenfluramine (Vickers et al. 1999). Moreover, in intact rats, the 
hypophagic effect of fenfluramine can be mimicked by the selective 5-HT)( 
receptor agonist Ro-60-0175, and attenuated by the selective 5-HT2C receptor 
antagonist SB-242084 (Clifton et al. 2000). Further evidence for a role of 5-
HT 2C receptors in feeding is provided by the finding that hypophagia induced 
by 3,4-methylenedioxy-N-methamphetamine (MDMA, 'ecstasy') can be 
blocked by the selective 5-HT 2C receptor antagonist RS-l 02221 (Conductier et 
al. 2005). 
31 
1.2.4.4. 5-HT and reinforcement 
The putative role of 5-HT in feeding behaviour suggests that behaviour 
controlled by positive reinforcement might be sensitive to manipulation of the 
5-HTergic system, possibly by altering the 'palatability' of food reinforcers 
(Cooper and Neill 1987). 
Wogar et al. (1991) used a quantitative operant paradigm based on 
Herrnstein's (1970) response strength equation to examine the effect of central 
5-HT depletion on reinforcer efficacy. S-HT depletion reduced the rate of 
reinforcement needed to maintain response rates at the half-maximum rate, 
consistent with an enhancement of reinforcer efficacy. 
Harrison and Markou (2001) found that systemic treatment with the 5-
HTlA receptor agonist 8-0H-DPAT enhanced the reinforcing efficacy or 
hypothalamic stimulation. This effect was mimicked by direct injection of 8-
OH-DPAT into the median (but not the dorsal) raphe nucleus, suggesting that 
the effect was mediated by 'switching off the 5-HTergic projection via 
. somatodendritic autoreceptors. 
Fletcher et al. (1999) found that 5-HT depletion enhanced responding 
for a conditioned reinforcer. This suggests that the effect of 5-HT depletion on 
positive reinforcement is not simply due to an alteration of food palatability. 
1.2.4.5. 5-HT and learning and memory 
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Central 5-HT depletion has been found to have complex effects on learning 
and memory. Spatial learning in the Morris water maze has been found to be 
impaired following 5,7-dihydroxytryptamine-induced 5-HT depletion (Lehman 
et al. 2000). However, 5-HT depletion has no effect on working memory in 
delayed non-matching-to-sample tasks (Ruotsalainen et al. 1998). 
Graham et al. (1994) found that 5-HT depletion facilitated the learning 
of a difficult temporal discrimination (discrimination between 200-ms and 800-
ms light presentations). It was suggested that this effect might have been due to 
a reduction of proactive interference between trials. However, a detailed 
analysis of the effect of 5-HT depletion on performance in delayed matching-
to-sample tasks using stimuli of different durations failed to find any effect on 
proactive interference (Al-Ruwaitea et al. 1997). In contrast to its facilitatory 
effect on acquisition in temporal discrimination tasks, 5-HT depletion impedes 
learning in tasks requiring delayed responding (Wogar et al. 1992; AI-
Ruwaitea et al. 1997). 
The roles of different 5-HT receptor SUbtypes in learning and memory 
are complex and, in some cases, controversial. Stimulation of postsynaptic 5-
HT1A receptors in the hippocampus by 8-0H-DPAT results in impairment of 
. spatial memory in the water maze, an effect that can be reversed by WAY-
100635 (Carli et al. 1995). 8-0H-DP AT injected into the raphe nuclei, thereby 
presumably suppressing ongoing 5-HTergic activity, has been reported to 
Improve spatial memory (Warburton et al. 1997), an observation that is 
difficult to reconcile with the deleterious effect of 5-HT depletion on 
performance in the water maze (see above). 
5-HT lB receptor stimulation in the hippocampus induced by 
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intrahippocampal injection of the selective agonist CP-93,129 has been 
reported to impair spatial memory (Buhot et al. 1995). Another 5-HT 1B 
receptor agonist, GR-466 11 , has been reported to impair learning in an 
autoshaping task, an effect that could be reversed by the selective antagonist 
GR-127935 (Meneses et al. 1997). 
There has been considerable interest in the possible role of 5-HT4 
receptors in learning and memory (see Bockaert et al. 2004). For example, the 
5-HT4 receptor partial agonist RS-67333 has been reported to facilitate object 
recognition and spatial memory (Lamirault and Simon 2001), whereas 
olfactory memory may be impaired by the 5-HT4 receptor antagonist RS-67532 
(Marchietti et al. 2000). 
Finally, there is increasing evidence for a role of 5-HT 6 receptors in 
some aspects of learning and memory. For example, 5-HT6 receptor 
antagonists have been found to enhance acquisition in an autoshaping task, and 
to reverse the impairment of learning induced by the cholinoceptor antagonist 
scopolamine (Meneses 2001). It has been suggested that 5-HT6 receptors may 
regulate cholinergic transmission in some areas of the brain such as the 
hippocampus, that are believed to be important for learning and memory 
. (Branchek and Blackburn 2000). 
1.2.4.6. 5-HT and 'impulsiveness' 
It has long been suspected that dysfunction of 5-HTergic mechanisms is a 
contributory factor in human "impulsiveness" (Linnoila et al. 1983; Coccaro et 
al. 1989; Linnoila and Virkkunen 1992; Coscina 1997). A major problem in 
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this area is the definition of impulsiveness. Clinical definitions generally 
emphasise "action without due thought", and often fail to distinguish between 
aggressive or violent behaviour and other forms of "impulsiveness" (see Ho et 
a1. 1998, 1999; Evenden 1999; Hollander and Rosen 2000). Definitions based 
on behavioural principles have been proposed by Evenden (1999) and Ho et al. 
(1999). According to Ho et a1. (1999), it is useful to distinguish between two 
quite different forms of "impulsiveness": impulsive action and impulsive 
choice. The former refers to premature responding in situations where delayed 
responding is advantageous; the latter refers to selection of small short-term 
gains in preference to larger delayed gains, and corresponds to the definition of 
impulsiveness championed by Ainslie (1974). Both forms of impulsiveness are 
relevant to the topic of this thesis, because both generally entail timing; 
impulsive action may be revealed by tasks which require the subject to withold 
a response for a specified duration (differential-reinforcement-of-low-rates 
[DRL] schedule: Ferster and Skinner 1957), whereas impulsive choice may be 
revealed in inter-temporal choice schedules (see below, Section 1.3). 
The putative role of 5-HT in timing performance will be reviewed in 
greater detail in a subsequent section. However, it may be noted at this point 
. that destruction of the 5-HTergic pathways appears to promote both forms of 
impUlsive responding. Thus, central 5-HT depletion impairs performance in 
delayed response schedules (Wogar et a1. 1992; Carli and Samanin 2000; 
Winstanley et a1. 2004), and promotes the selection of smaller immediate 
rewards in preference to larger delayed rewards (Wogar et a1. 1993; Al-
Ruwaitea et a1. 1999b; Mobini et a1. 2000; however, see Winstanley et a1. 2004 
for contrary results). These results suggest that the 5-HTergic pathways 
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normally place some form of restraint on impulsive responding. Consistent 
with this suggestion, the 5-HT releasing agent dexfenfluramine (Poulos ci aL 
1996) and the 5-HT reuptake inhibitors fluoxetine, citalopram and paroxetine 
(Wolff and Leander 2002) promoted rats' selection of the larger delayed 
reward in an inter-temporal choice schedule (,self-controlled choice'). Cherek 
and Lane (1999) obtained similar results with fenfluramine in a group of 
human subjects with histories of conduct disorder. 
Little is known about the 5-HT receptors involved in impulsiveness. 
The 5-HT1A receptor agonist 8-0H-DPAT enhanced "impulsive action" in a 
serial reaction time task (Carli and Samanin 2000), and promoted "impulsive 
choice" in a delay-discounting task (Winstanley et al. 2005). The highly 
selective 5-HT 2A receptor antagonist MDL-100907 reversed the impairment of 
DRL performance induced by the N-methyl-D-aspartate (NMDA) antagonist 
dizocilpine, whereas the 5-HT2c receptor antagonist S8-242084 tended to 
exacerbate the effect (Higgins et al. 2003). 
1.3. TIMING PARADIGMS 
, 1.3.1. Introduction: timing paradigms and schedules of reinforcement 
A reinforcement schedule is a rule that describes how some readily measured 
behaviour (such as pressing the lever, for a rat, or pecking at a coloured light, 
for a pigeon) affects the delivery of food or some other positively or negatively 
valued event (Ferster and Skinner 1957; Staddon et al. 1991). The principal 
schedules of positive reinforcement first defined by Skinner (1938), and 
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subsequently studied in great detail by Ferster and Skinner (1957), are fixed 
and variable interval (FI and VI), and fixed and variable ratio (FR and VR) 
schedules. In each case, a response is required for the delivery of a reinforcer 
(usually a small amount of food). On afixed-interval schedule, the response is 
effective only after a fixed time period, I, has elapsed since the preceding 
reinforcer delivery. On a fixed-ratio schedule, only the Nth response after 
reinforcer delivery is effective. On variable-interval and variable-ratio 
schedules, I and N vary unpredictably from one reinforcer delivery to the next. 
After an initial learning period these four schedules produce characteristic, 
regular patterns of behaviour in almost all mammals and birds exposed to them 
(Staddon et a1. 1991). Of these four basic types of schedule, only fixed-interval 
schedules specify a regular and predicatable temporal relation between 
successive reinforcer deliveries. Nevertheless, there is evidence that the 
temporal distribution of reinforcer deliveries is an important determinant of 
performance even in the case of schedules where no explicit temporal 
contingency is specified (Neuringer and Schneider 1969). 
Humans and animals can readily learn to anticipate the time when a 
reinforcing event will occur. This process is termed interval timing. It is 
. typically studied in well-trained animals under steady-state conditions. A large 
number of reinforcement schedules have been devised to study interval timing 
behaviour in animals. Killeen and Fetterman (1988) and Killeen et al. (1997) 
developed a taxonomy of timing schedules based on the relationship between 
the animal's timing response and the interval being timed. According to this 
taxonomy, the three main classes of timing schedule are (i) retrospective 
timing schedules, in which the subject is trained to emit discriminative 
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responses depending upon the duration of an interval which has already 
elapsed when the response is made; (ii) immediate timing schedules, in which 
the subject's behaviour comes under the control of time during an ongoing 
interval and (iii) prospective timing schedules, in which the animal is trained to 
emit discriminative responses on the basis of intervals which follow the 
responses. The aim of this section is to offer a relatively detailed description of 
each of these three paradigms. 
1.3.2. Retrospective timing schedules 
1.3.2.1. Conditional temporal discrimination tasks 
In this type of task, the subject is trained to emit one of two mutually exclusive 
responses following the offset of a signal, the two responses being 
differentially reinforced depending upon the duration of the signal (see Killeen 
and Fetterman 1988; Killeen et al. 1997). The conventional performance 
measure is the percentage of correct responses (i.e. the percentage of trials in 
which a reinforcer is earned). 
1.3.2.2. Interval bisection task 
In this task (Catania 1970; Church and Deluty 1977), the subject is first trained 
to discriminate two durations ("short" and "long") in a discrete-trials 
conditional discrimination schedule. When accurate performance has been 
attained, probe trials, in which stimuli of intermediate duration are presented, 
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are introduced into each session. In the case of each duration, the percentage of 
occasions on which the subject responds on the lever appropriate to the long 
stimulus (%L) is recorded. %L increases as function of stimulus duration; this 
function approximates closely to a sigmoid logistic curve: 
where t is stimulus duration, Tso is a location parameter, and £ a slope 
parameter (Killeen et al. 1997; Ho et al. 2002). The logistic relation between 
%L and stimulus duration provides the basis for the estimation of two basic 
indices of interval timing behaviour (Killeen et al. 1997). (i) The measure of 
central tendency is the bisection point (Tso: the duration corresponding to %L = 
50), which occurs at about the geometric mean of the two standard durations. 
(ii) The Weber fraction, a measure of the precision of temporal discrimination, 
may be computed from the ratio of the limen (half the difference between the 
durations corresponding to %L = 25 and %L = 75) to the bisection point 
(Church and Deluty 1977; Ho et al. 2002). 
1.3.2.3. Discrete-trials psychophysical procedure 
In this task (Body et al. 2002a), each session consists of a number of trials, 
successive trials being initiated at regular intervals. Each trial starts with the 
illumination of a lamp above the central reinforcer recess. After a 
predetermined interval has elapsed, two levers are inserted into the operant 
chamber. A single response on either lever results in withdrawal of both levers 
and extinguishing of the light; the chamber remains in darkness until the start 
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of the next trial. A response on one lever (A) is reinforced if the light has been 
presented for a shorter time than some specified duration, whereas a response 
on the other lever (B) is reinforced if the light has been presented for longer 
than the specified duration. In Body et al. 's (2002a) schedule, the trials were 50 
s in duration and in each trial the levers were inserted into the chamber at one 
of the following "entry points" following the start of the trial: 2.5, 7.5, 12.5, 
17.5,22.5,27.5,32.5,37.5,42.5, or 47.S-sec. A response on A was reinforced 
if insertion took place at any of the first five entry points (i.e., less than 25 s 
after trial onset), whereas a response on B was reinforced if lever insertion took 
place at any of the last five entry points (i.e., more than 25 s after trial onset). 
Performance on this schedule can be characterized by the same logistic 
psychometric function as that which describes interval bisection performance 
(Bodyet al. 2002a). 
1.3.2.4 Temporal generalization 
In a temporal generalization procedure, a stimulus of some duration is 
presented; if it is of one particular duration, a response is reinforced (Church 
. and Gibbon 1982). The performance measure is the relationship between 
probability of responding and stimulus duration. Typically a bell-shaped 
generalization curve is generated, in which response probability is greatest near 
the reinforced duration, with approximately symmetrically decreasing 
probabilities at shorter and longer durations (Church and Gibbon 1982; 
Wearden 1992; Wearden and Grindrod 2003). 
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1.3.3. Immediate timing schedules 
1.3.3.1. Fixed-interval peak procedure 
The peak procedure was devised by Catania (1970) to study temporal control 
under fixed-interval schedules. In a fixed-interval schedule food delivery 
follows the first response emitted after a specified and constant time period has 
elapsed since the previous reinforcer (Ferster and Skinner 1957; see above). In 
the peak procedure, the interval is timed from the onset of a trial, usually 
signalled by insertion of the lever into the chamber, and successive trials are 
separated by an inter-trial interval. The schedule consists of two types of trial. 
In "standard" trials, reinforcement is provided for the first response after the 
fixed interval has elapsed; in "empty" or "probe" trials, the reinforcer is 
omitted, and the lever remains in the chamber for a long period (usually three 
or four times longer than the fixed-interval duration) (see Staddon and Cerutti 
2003). Behaviour in the probe trials consists of progressively increasing 
, response rate up to the end of the criterion interval, followed by a declining 
response rate (see Hinton and Meck 1997). The bell-shaped function obtained 
form this procedure may be used to derive several behavioural indices. The 
peak rate is the highest response rate achieved during the trial, and the peak 
time is the elapsed time within the trial at which the peak rate occurs; the 
spread time may be defined as the interval between the point in time when 
response rate reaches 70% of the peak rate, until it first falls below that level, 
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and the Weber fraction may be calculated as the ratio of the spread time to the 
peak time (Church et al. 1991). Numerous studies have shown that the peak 
time occurs close to the time at which reinforcement occurs in the standard 
trials, and that the Weber fraction remains roughly constant across a broad 
range of criterion intervals (see Hinton and Meck 1997; Lejeune et al. 1998). 
1.3.3.2. Mixed fixed-interval schedules 
Another immediate timing schedule devised by Catania (1970) is a mixed 
schedule consisting of two fixed-interval components. In this schedule, the 
subject is trained in discrete trials in which a reinforcer is available either I 
seconds or txn seconds after the onset of the trial. Typical performance 
consists of an initial rise in response rate which achieves a peak approximately 
t seconds after trial onset, followed by a decline in response rate, and then a 
secondary rise in response rate that reaches its peak about txn seconds after 
trial onset. Leake and Gibbon (1995) and Whitaker et al. (2003) examined the 
performance of rats under this schedule using a range of values of t and n. In 
general, clear separation of the two peaks can only be discerned when n > 3; 
. this appears to be the case irrespective of the value of t (Whitaker et al. 2003). 
1.3.3.3. 'Tri-peak' procedure 
Another recently developed variant of the fixed-interval peak procedure is the 
"tri-peak" procedure (Paule et al. 1999). This schedule requires subjects to 
track three target durations presented sequentially within a single trial. This is 
42 
accomplished by pairing a different response lever with each target duration 
(e.g., 10,30 and 90-s). Rats tend to produce uneven response rates on the three 
operanda during the course of the trials, with peaks corresponding to the 
scheduled times of reinforcer delivery on each lever. An advantage of this 
method is that it allows measurement of the "start time", "stop time", "peak 
time" and "spread time" for each of the three durations, as well as correlations 
among these measures within a single session (Church et al. 1994). 
1.3.3.4. 'Gap' procedure 
This is a variant of the peak procedure designed to examine the effect of 
interrupting an ongoing timing task (Roberts 1981). Animals are first trained 
under a fixed-interval procedure. Then, in probe trials interspersed among the 
standard peak interval trials, a "gap" is introduced; for example, if the trials are 
signalled by a continuously present tone, the tone may be discontinued for a 
brief period, and the duration of this interruption is added to the duration of the 
interval. It has been found that the effect of the gap depends on its location 
within the trial. If the gap is presented early in the trial, it has little effect on the 
time of peak responding; however gaps presented later in the interval tend to 
induce a delay of the peak time. These effects have been interpreted as 
indicating a "stopping and re-starting" of an internal timing process in the 
former case, and the "resetting" of the process in the latter (MateH and Meck 
1999; Buhusi and Meck 2000). 
1.3.3.5. Free-operant psychophysical procedure 
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The free-operant psychophysical procedure was devised by Stubbs (1976, 
1980). In this schedule, each experimental session consist of a series of trials in 
which reinforcement is provided, under a variable-interval schedule, for 
responding on one of two continuously available operanda. Reinforcement 
availability is allocated to operandum A during the first half, and to operandum 
B during the second half of each trial. The typical pattern of responding on this 
schedule consists of an increasing response rate on operandum B and a 
concomitantly declining response rate on operandum A during the course of 
the trial. This is reflected in an increasing relative response rate on operandum 
B (i.e. response rate on operandum B divided by the combined response rate on 
both operanda), which passes the "indifference point" Tso (50% responding on 
operandum B) approximately midway through the trial, when reinforcer 
availability is transferred from operandum A to operandum B. The relationship 
between relative response rate and time, measured from the onset of the trial, is 
well described by the same logistic function that has been found to define the 
psychometric curve in retrospective timing tasks (Stubbs 1979, 1980; Bizo and 
White 1994; Killeen et al. 1997; Chiang et al. 1998). 
Chiang et al. (1998, 1999, 2000a, 2000b) introduced a modification to 
the free-operant psychophysical procedure. In Stubbs' (1976) original 
schedule, the subject is able to switch back and forth between the two operanda 
throughout the trial ("unconstrained switching"). In contrast, in Chiang et al.' s 
(1998) modified schedule, the first response to occur on lever B results in 
withdrawal of lever A. This has the effect of restricting switching to one switch 
per trial ("constrained switching"). The resulting psychometric curves tend to 
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be steeper than those obtained in the conventional "unconstrained-switching" 
task, although the locus of T50 is not greatly affected by the imposition of the 
constraint (Chiang et al. 1998, 1999, 2000a, 2000b). 
1.3.3.6. Differential-reinforcement-of-low-response rate (DRL) 
In this schedule, also known as the "inter-response-time-greater-than-t 
(IRT>t)" schedule, reinforcer delivery follows every response that is separated 
from the previous response by an interval of at least t s (Ferster and Skinner 
1957; Zeiler 1977). Steady-state behaviour on this schedule consists of low 
overall responses rates, with long interresponse times interspersed by brief 
bursts of responding. The long interresponse times have a mode that 
approximates to the criterion interresponse time (t); there is, however, a 
tendency for short criterion interresponse times to be overestimated and long 
ones to be underestimated, resulting in a linear relation between criterion and 
actual interresponse times that has a slope considerably less than one. The 
variation of interresponse times about the modal value is approximately normal 
in form, and the ratio of the standard deviation to the modal interresponse time 
. has often been used as an expression of the Weber fraction (Platt 1979) 
1.3.4. Prospective timing schedules 
Prospective timing schedules entail the control of behaviour by events that 
follow the response by a specified time interval. In most instances the 
controlling event is reinforcement, and thus tasks of this type frequently take 
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the form of intertemporal choice schedules, in which the subject chooses 
between reinforcers differing in magnitude and delay (see Ho et al. 2002). 
1.3.4.1. Adjusting delay schedule 
In this schedule (Mazur 1987), the subject undergoes a series of discrete trials 
in which it chooses between a smaller reinforcer, A, delivered after a short 
delay, dA, and a larger reinforcer, B, delivered after a variable delay, dB. 
Sessions are divided into blocks of trials, and the value of dB is varied in 
successive blocks as a function of the subject's choices in the previous block. 
If the subject displays a preference for A, dB is reduced in the following block; 
conversely, if the subject shows a preference for B, dB is increased in the 
following block. Mazur (1987) showed that behaviour on this schedule is 
characterized by fluctuations in the obtained value of dB, which eventually 
stabilize; the stable value of dB, which is taken as a measure of the 
"indifference point", is sensitive to the relative sizes of the reinforcers and the 
delay imposed on the smaller reinforcer (dA) (Mazur 1987; Ho et al. 1999). 
1.3.4.2. Time-left procedure 
This is a two-link concurrent chain schedule (Autor 1960), in which 
reinforcement is provided for responding on two operanda, A and B, in a series 
of trials each lasting T sec. At the start of the trial, both operanda are available 
(initial link). At a randomly determined time point, t seconds after the start of 
the trial, the next response on either operandum results in entry into one of the 
two mutually exclusive terminal links, each of which terminates in reinforcer 
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delivery. A response on operandum A initiates a fixed delay (dA) followed by 
reinforcement, whereas a response on operandum B initiates a variable delay 
(dB) followed by reinforcement at the end of the trial. The length of dB is thus 
determined by the value of t, i.e., by the time, elapsed since the start of trial 
(Gibbon and Church 1981; Gibbon and Fairhurst 1994). Performance on this 
schedule consists of increasing preference for B as a function of time from the 
start of the trial (e.g. Al-Ruwaitea et aL 1999a). Preference can generally be 
described by a sigmoid (approximately logistic) psychometric function, and the 
Weber fracton is approximately constant across a range of values of T (Gibbon 
and Fairhurst 1994). 
1.3.4.3. Progressive delay schedule 
Evenden and Ryan (1996) described a procedure in which rats were trained to 
make repeated choices between a small immediate reinforcer, A, and a larger 
delayed reinforcer, B, the delay to the larger reinforcer being increased 
progressively in successive blocks of trials within a session. This method was 
modified by Kheramin et al. (2002). In Kheramin et al.' s schedule, a short 
delay, dA, was imposed on the smaller reinforcer; the delay to the larger 
reinforcer (dB) was the same as dA at the start of the session, and was 
incremented in successive blocks of trials according to the formula dB = 
dA x(1.75t-t, where n is the ordinal position of the block of trials within the 
session. Kheramin et al. (2002) found that percent choice of the larger 
reinforcer decreased asymptotically towards zero as a function of dB. When the 
'indifference delay to B' (the value of dB corresponding to 50% choice of B) 
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was plotted against the delay imposed on A (dA), a linear relation was revealed, 
consistent with the model of intertemporal choice proposed by Ho et al. (1999). 
104. THEORIES OF INTERVAL TIMING 
A number of theoretical models of interval timing behaviour have been 
proposed. In this section, only those models that have been applied to the 
behaviour of animals in the timing paradigms described above will be 
reviewed. The oldest and most widely studied of these models is Scalar 
Expectancy Theory (SET); accordingly, this theory will receive greater 
attention in the following review than other, newer theories that have not yet 
been subjected to extensive experimental examination. 
1.4.1. Scalar Expectancy Theory (SET) 
The Scalar Expectancy Theory (SET) was conceived and developed by John 
Gibbon (Gibbon 1977, 1981; Gibbon et al. 1984; Malapani and Fairhurst 2002) 
and remains today the most prominent of the theoretical accounts of timing in 
animals and humans. It consists of a mechanistic interpretation of timing 
behaviour based on information processing principles, which account for the 
principal phenomena of timing behaviour outlined in the previous section. 
The central principle of SET is that interval timing behaviour is scalar. 
This means that the accuracy (or rather its converse, the variability) of timing is 
deemed to be proportional to the target interval being timed, in accordance to 
Weber's law. This implies that the relative accuracy of timing, expressed as the 
Weber fraction, should be constant. For example, if a subject trained under an 
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inter-response time schedule to emit responses at 15-s intervals, generates an 
interresponse time distribution with a standard deviation of 5 s (Weber fraction, 
expressed as the coefficient of variation, = 5/15 = 0.33), then the same subject 
trained to emit responses at 30-s intervals should display a standard deviation 
of 10 s (Weber fraction = 10/30 = 0.33). 
An extension of this principle is the notion of superposability of 
psychometric functions. For example, if the logistic psychometric functions 
derived from performance on two interval bisection schedules are re-scaled in 
such a way that time (t) is expressed as a fraction of the indifference point 
(T50), the two sigmoid curves should become identical (Gibbon 1977, 1991). 
According to SET, organisms possess an endogenous 'internal clock' 
that enables them to perform interval timing tasks. This clock is composed of 
several components, each of which generates a certain amount of variance in 
the organism's timing behaviour. These various sources of variance are 
random, and are not in themselves scalar. However, the overall variability of 
timing which, according to the theory, is derived from a multiplicative 
combination of the various sources of variance, is scalar (see Gibbon 1991). 
The structure of the hypothetical internal clock posited by SET IS 
shown in Figure 1.2. The operation of the clock is divided into three stages, 
which are usually considered sequentially. The first stage involves a pacemaker 
connected to an accumulator or counter, which receives the pacemaker pulses 
via a switch. The switch controls when the flow of pulses into the accumulator 
is started and stopped. The accumulator stores the total number of pulses which 
represent the amount of time passed. The contents of the accumulator can be 
copied to a short term memory (STM) or working memory. In some versions of 
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SET, the accumulator and STM are regarded as one entity (Wearden et al. 
1999). Information is transferred to another memory store, long term memory 
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Figure 1.2. Model of the hypothetical internal clock proposed by Scalar 
Expectancy Theory. According to the theory, an endogenous pacemaker 
generates pulses at a constant mean rate, and the accumulator counts the pulses. 
In timing an interval, the organism is supposed to compare the current number 
of pulses (in its working memory) to a sample of previously recorded numbers 
of pulses (in its reference memory). If the current number is approximately 
equal to the sample from reference memory, the organism emits the appropriate 
timing response. 
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(LTM) or reference memory. LTM is able to retain a record of many instances 
of the expected time of some relevant event (e.g. reinforcement time). Finally, 
there is a comparator, or decision-maker, which assesses the similarity between 
the contents of STM and L TM, and if the values are sufficiently similar a 
response is made. 
In Gibbon's (1977,1991) original version of SET, there was no attempt 
to identify the components of the hypothetical internal clock with actual 
anatomical structures or physiological processes. The model was conceived as 
a 'black box' whose performance closely approximated the behaviour of real 
organisms. However, the discovery that the effects of drugs on interval timing 
behaviour could be characterized as changes in the functioning of the various 
components of the hypothetical clock (Meek 1986; 1996) led some proponents 
of SET to identify these components with particular pathways or nuclei in the 
brain (e.g. Gibbon et al. 1997a; Hinton and Meck 1997, 2004; MateH and Meck 
2000,2004; see below). 
1.4.2. Behavioural Theory of Timing (BeT) 
The Behavioural Theory of Timing (BeT: Killeen and Fetterman 1988; Killeen 
et al. 1997) is another pacemaker-based theory. Like SET, BeT assumes an 
endogenous pacemaker that emits pulses at more-or-Iess constant rate. 
However, unlike the essentially cognitive mechanisms proposed by SET, BeT 
assumes that pacemaker's role is to drive the organism through a series of 
behavioural states (Ho et al. 2002). Each state is associated with a different 
class of behaviour, and these behaviours serve as discriminative stimuli that set 
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the occasion for appropriate operant responses. 
BeT is based on the following premises (Killeen and Fetterman 1988): 
(i) Stimuli that signal reward engender responses. These responses are 
called adjunctive, because they can be elicited or emitted (Killeen & 
Fetterman 1988; Morgan et al. 1993). 
(ii) Transitions between adjunctive behaviours are caused by pulses from 
the pacemaker. The pacemaker in this model is started at the onset of 
the interval being timed, and it drives the animal into different 
behavioural states with each pulse. 
(iii) During the learning of a timing task, operant responses come to be 
associated with adjunctive 'behavioural states' by Pavlovian 
conditioning. Thus, after extensive training, the animal learns that when 
a particular state in the sequence has been reached, an operant response 
will result in reinforcement. 
(iv) Pacemaker speed is proportional to reinforcement density. This IS a 
unique feature of BeT (Morgan et al. 1993; see below). 
Killeen and Fetterman (1988) argue that cognitive processes such as memory 
and decision processes, which playa central role in SET, are not really 
necessary to account for interval timing behaviour. Instead of the complex 
cognitive apparatus posited by SET, BeT posit only one hypothetical construct, 
the endogenous pacemaker. In order to account for the scalar property of 
timing, BeT assumes that the accuracy of timing is determined by the rate of 
the pacemaker, which is in turn determined by the rate of reinforcement. In 
other words, timing an interval is likely to be more accurate if the inter-pulse 
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interval is short (analogous to the ticking of a wrist-watch) than if it is long 
(analogous to the ticking of a grandfather clock). The significance of the 
postulated relation between reinforcement rate and pacemaker speed can be 
appreciated from the example of fixed-interval peak performance. In a peak 
fixed-interval 30-s schedule the reinforcement rate is twice as high as in a peak 
fixed-interval 60-s schedule; accuracy should therefore be greater in the former 
case than in the latter, leading to approximately equivalent relative accuracy in 
the two cases (Le. conformity to Weber's law). 
It follows from this argument that if reinforcement rate is altered 
without changing the length of the interval being timed, a reduction of the 
Weber fraction should be observed. This prediction was confirmed by Bizo and 
White (1994) in the case of the free-operant psychophysical procedure; 
doubling the rate of 'background' reinforcement provided throughout the trials 
by a variable-interval schedule did not alter T50 but substantially reduced the 
Weber fraction. 
1.4.3. Learning to Time (LeT) theory 
This theory is a refinement of BeT, designed to account not only for steady-
state timing behaviour, but also for the acquisition and extinction of interval 
timing (Machado 1997; Machado and Guilhardi 2000). Like BeT, each time 
marker (e.g. reinforcer delivery) is assumed to activate a series of behavioural 
states. These states include elicited, interim and terminal classes of behaviour 
(Staddon and Simmelhag 1971; Staddon 1977; Killeen and Fetterman 1988). 
Elicited behaviours, for example retrieving and consuming food in the food 
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hopper by a rat, may occur immediately after reinforcer delivery. Interim 
behaviours, for example grooming or exploration, may occur in the middle of 
interval, when getting food is not probable. Terminal behaviours, for example 
approach to the food hopper, can be seen in the final segment of the interval. 
At the onset of the interval only the first state is active, but as time goes on the 
other states become activated sequentially. Like BeT, LeT assumes that the 
operant response becomes coupled to the behavioural states by a process of 
Pavlovian conditioning, the associative strength depending on the proximity of 
the state to reinforcer delivery. If a state is active during extinction, it loses its 
coupling and eventually may not support the operant response. If a state is 
active during reinforcement, its coupling will be increased and may therefore 
sustain the response. 
The mathematical aspects of the model are beyond the scope of.this 
overview. In essence, however, it is assumed that by adding the activation 
strength of the behavioural states, the strength of each operant response can be 
obtained (Machado 1997; Machado & Guilhardi 2000). A crucial difference 
between BeT and LeT is that in BeT, discrete behavioural states occur in 
sequence, only one of which becomes coupled to the operant response; LeT, in 
contrast, proposes a graded strength of association of the operant response with 
all the behavioural states that make up the sequence (Machado 1997). 
LeT is able to account for all the principal phenomena of interval 
timing behaviour, including its scalar property. However, Machado (1997) has 
drawn attention to some quantitative discrepancies between predicted and 
actual behaviour. These include modest discrepancies between the theoretical 
and empirical peak times in the fixed-interval peak procedure, and indifference 
55 
points (T50) in the interval bisection procedure. Machado (1997) acknowledged 
that these discrepancies can only be accounted for by arbitrary post hoc 
assumptions of delayed onset of timing. It should be noted, however, that other 
timing models, including SET, are forced to make similar arbitrary 
assumptions (e.g. 'attentionallatency'; see Hinton and Meck 1997). 
Machado and Guilhardi (2000) have pointed out that a crucial 
difference between SET on the one hand, and BeT and LeT on the other, is the 
essential role of reinforcement rate in determining pacemaker rate in the 
behavioural theories. In contrast, reinforcement plays no role in the cognitive 
mechanisms of SET, other than in sustaining the index response and providing 
markers for timing. SET therefore has difficulty explaining the findings of Bizo 
and White (1995) and Machado and Guilhardi (2000), that the value of T50 in 
the free-operant psychophysical procedure can be manipulated by providing 
different 'background' variable-interval schedules in the first and second 
halves of the trials. Thus, if the schedule provided for responding on lever A in 
the first half of the trial offers a higher rate of reinforcement than the schedule 
provided for responding on lever B in the latter half of the trial, T50 is reduced 
(i.e. the psychometric curve is displaced to the left); conversely, if the schedule 
operating in the second half is richer than the one operating in the first half, T50 
is increased (i.e. the psychometric curve is displaced to the right) (Bizo and 
White 1995; Machado and Guilhardi 2000). 
1.4.4. MUltiple Time Scales Theory 
Multiple Time Scales Theory (MTS: Staddon and Riga 1996; Staddon et al. 
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1999; 2002) is the only major timing theory at the present time that does not 
posit a pacemaker-based internal clock. Like the theories outlined above, MTS 
assumes that interval timing behaviour is derived from a unitary endogenous 
timing process; however, unlike pacemaker-based theories, MTS does not 
assume that this process consists of repetitive emission of discrete pulses. 
Rather, the 'clock' proposed by MTS is based on the phenomenon of 
habituation (Staddon and Higa 1996). 
Staddon and Higa (1996) summarize habituation as the waning of a 
response to a stimulus, as the stimulus is repeatedly presented. Two important 
characteristics of habituation are stimulus specificity and rate sensitivity. 
Stimulus specificity means that when habituation has occurred for one 
stimulus, it does not extend to others. Rate sensitivity can be seen when the 
time between successive presentations of the stimulus (inter-stimulus interval 
[lSI]) is varied. Habituation is more rapid when ISIs are short than when they 
are long; moreover, recovery from habituation occurs more rapidly following 
short ISIs than following long ISIs (Staddon and Higa 1996). 
According to MTS, habituation arises from a cascade of 'habituation 
units', each of which entails an exponential time-dependent decay of the 
memory trace for the stimulus. This is illustrated in Figure 1.3. During 
successive presentations of a stimulus, the response to each presentation is 
determined by a simple subtractive relation: 
Response = (direct effect of the stimulus) - (remembered effect) 
Because the remembered effect decays exponentially, this simple relation can 
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Figure 1.3. 'Cascade' of multiple habituation units proposed by the Multiple 
Time Scales theory of interval timing. Each integrator (represented by the 
boxes) receives an input (X), and generates an output (V) according to an 
exponential decay (habituation) function.The stimulus (S) activates the first 
integrator, whose output (V \) provides the input (X2) for the second integrator, 
and so on. The output from each integrator also provides a weighted 
connection to an 'output node', which generates the overall timing output (Vo) 
(after Riga and Staddon 1997). 
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account for the rate-sensitivity phenomenon: the 'remembered effect' is greater 
with short ISIs than with long ISIs, and therefore the response tends to become 
smaller (i.e. there is greater habituation) with short ISIs (Staddon and Higa 
1996). 
Staddon et al. (1999) proposed that MTS can account for interval 
timing behaviour. In brief, it is proposed that the memory-trace constitutes the 
'clock' for steady-state interval timing (Staddon et al. 2002). As in SET, the 
reinforcer serves as a time-marker, the memory-trace of which decays 
according to the principles of habituation (see above). In fact, in MTS the clock 
is just the memory for the time-marker, because in this theory the process of 
starting and stopping the clock (timing function) and the clock arc not 
separable (Staddon et al. 2002). Operant responses become conditioned to 
particular strengths of the memory trace. For example, in the case of the fixed-
interval peak procedure, the animal learns that responding is most likely to 
result in reinforcement when the memory-trace of the previous reinforcer has 
decayed to a particular level. 
MTS has been applied mainly to fixed-interval schedules and response-
initiated delay schedules (in which the fixed interval preceding each reinforcer 
is initiated by the first response after the previous reinforcer: Higa and Staddon 
1997; Staddon et al. 1999). Proponents of SET have criticized MTS because it 
fails to address questions about the variability of timing, and in particular it 
fails to predict the constancy of relative variability (Weber's law) (Gallistel 
1999; Gibbon 1999). In response to these criticisms Staddon et al. (1999) 
argued that scalar invariance is at best only approximately true (see also 
Grondin 2001), and that MTS is able to accommodate approximate conformity 
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to Weber's law. 
1.4.5. Coincidence Detection Theory (Striatal Beat Frequency Model) 
The theories reviewed above attempt to provide 'working models' of interval 
timing performance, without making specific assumptions about the brain 
mechanisms underlying timing behaviour. Meck (1986, 1996) and Hinton and 
Meck (1997) attempted to relate the components of SET to particular brain 
structures. According to these authors, the nigrostriatal dopaminergic pathway 
is the neural substrate of the internal clock, the substantia nigra representing 
the pacemaker, and the corpus striatum the accumulator. Evidence cited in 
support of this proposal included the leftward displacement of the peak interval 
function by the dopamine-releasing agent amphetamine (attributed to a 
reduction of the period of the pacemaker) and the rightward shift of the 
function produced by D2 dopamine receptor antagonists (attributed to slowing 
of the pacemaker). According to Hinton and Meck (1997) 5-
hydroxytryptaminergic (5-HTergic) input to the striatum may serve to oppose 
the dopaminergic influence on 'clock speed'. The memory component of SET 
has been identified with cholinergic mechanisms in the hippocampus and 
neocortex (Olton et al. 1987, 1988). 
A weakness of this view of the brain mechanisms underlying interval 
timing was pointed out by MateH and Meck (2000). Interval timing typically 
entails adaptation of behaviour to events taking place in the range of seconds, 
minutes, or even hours (Gibbon et al. 1997a), whereas there are no known 
neural events within the basal ganglia that occur on such a long time scale. 
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MateH and Meck (2000) proposed that a solution to this problem might be 
found in the idea of 'coincidence detection'; the simultaneous occurrence of 
neural signals that occur regularly but with different frequencies could have a 
period that is very much longer than the period of anyone of the individual 
signals (Miall 1989, 1996). Adapting this principle to interval timing, MateH 
and Meck (2000) suggested that striatal neurones receive mUltiple oscillatory· 
inputs from the cortex, discharging in response to the coincidence of a finite 
number of inputs. These events were proposed to constitute the neural bases of 
SET's pacemaker. This proposal has been greatly elaborated by MateH and 
Meck (2004); their revised model is illustrated in Figure 104. 
The revised Striatal Beat Frequency (SBF) model (MateH and Meck 
2004) is based on the striatum's position within a cortico-striato-thalamo-
cortical loop. Spiny neurones of the striatum are assumed to function as 
coincidence detectors of cortical and thalamic input. The cortical and thalamic 
oscillations constitute the pacemaker pulses, while the spiny neurones function 
as the accumulator. Memory storage is supposed to be achieved by setting the 
activity of an ensemble of cortical neurones in such a way that the striatal spiny 
neurones fire at a designated time. Dopaminergic input to the striatum is no 
longer assumed to playa central role in the generation of pacemaker pulses, 
although it is assumed to contribute to modulating pacemaker speed. The SBF 
model has been tested in computer simulations of timing behaviour, and has 
proved capable of generating an output that resembles peak fixed-interval 
schedule performance with criterion intervals within the range of seconds or 
minutes (MateH and Meck 2004). However, as yet, there is no direct 
evidence that the neural events postulated by the SBF model actually occur 
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Fig. 1.4. Neural circuitry proposed to account for interval timing by the 
modified Striatal Beat Frequency theory (MateH and Meck 2000, 2004). It is 
proposed that during interval timing, activity in the cortex is synchronized by 
the onset of a stimulus, after which the cortical activity continues with a variety 
of oscillatory periods. The coincident activity of a subset of these neuroncs is 
detected by striatal spiny neurones. The output of these neurones is integrated 
by the basal ganglia output nuclei (entopeduncular nucleus and substantia nigra 
pars reticulata), and relayed to the thalamus for behavioural expression. 
Dopaminergic input from the substantia nigra pars compacta and 5-HTergic 
input from the dorsal raphe nucleus (not shown) provide 'tuning' to the system, 
and the thalamus provides feedback via its inputs to the cortex and the striatum 
(after MateH and Meck 2000). 
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during interval timing behaviour. 
Like all the other models of timing behaviour discussed in this section, 
the SBF model assumes a unitary timing mechanism that underlies all forms of 
interval timing behaviour. This leads to the prediction, which will be addressed 
by the experiments described in later chapters, that pharmacological 
manipulation of the putative neural substrate of timing should give risc to 
equivalent effects on timing performance in different types of timing schedule. 
1.5. BEHAVIOURAL PHARMACOLOGY OF TIMING 
Behavioural pharmacology has been described as the synthesis of the 
experimental analysis of behaviour and pharmacology (Odum 2002), and is 
focused on investigating the behavioural effects of drugs by manipulating the 
environment and pharmacology in different ways. One of the most important 
variables in the experimental analysis of behaviour is time. Different drugs 
have been used in different categories of temporally-based schedules; and 
different authors in recent years have been trying to investigate 
pharmacological and environmental underpinnings of timing. The aim of this 
section is to summarize research in this area. In recent years increasing 
attention has been paid to the neural mechanisms underlying interval timing 
behaviour. Three neurotransmitter systems have been mainly implicated in 
these mechanisms: the dopaminergic, cholinergic and 5-HTergic systems. 
These are reviewed in the following three sections. 
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1.5.1. Dopaminergic mechanisms and timing 
The prototypical timing schedule is the fixed-interval schedule, in which 
reinforcement is provided following the first response to be emitted after a 
designated interval since the previous reinforcer delivery (Ferster and Skinner 
1957; see above). Skinner (1938) was the flrst to report the sensitivity of fixed--
interval schedule performance to the catecholamine releasing agent 
amphetamine. Dews (1958) carried out the first quantitative analysis of 
amphetamine's effect on fixed-interval performance, and formulated the 
descriptive principle of 'rate-dependency'. According to the rate-dependency 
principle, the effect of a drug on response rate depends on the baseline 
response rates; low response rates tend to be increased, and high rates to be 
suppressed. This principle is consistent with amphetamine's tendency to 
facilitate responding in the early part of a fixed interval (when baseline 
response rate is low), and to suppress responding later in the interval (when 
baseline response rate is high). Although Dews' (1958) early observations 
were"· based on fixed-interval schedule performance, the rate-dependency 
principle does not attribute the effects of drugs to an interaction with timing 
processes; indeed Sanger and Blackman (1976) Dews and Wenger (1977) 
reviewed a body of evidence suggesting that amphetamine has similar rate-
dependent effects in schedules that are not based on explicit timing (see Odum 
2002, for a recent review). It is also noteworthy that the rate-dependency 
principle does not only apply to amphetamine; drugs belonging to quite diverse 
pharmacological classes have been found to exert rate-dependent effects on 
operant behaviour (see Sanger and Blackman 1976; Dews and Wenger 1977). 
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Although rate-dependency is a robust finding, subsequent studies 
indicated that amphetamine may interact more directly with timing processes. 
Maricq et al. (1981) and Maricq and Church (1983) found that 
methamphetamine altered performance on the interval bisection task, 
displacing the psychometric function to the left (i.e. reducing the indifference 
point, T50), without reducing overall discriminative accuracy. Similarly, in a 
series of experiments using the fixed-interval peak procedure, Meck (1983; 
1986) reported that methamphetamine displaced the response rate function to 
the left (i.e. reducing the peak time). Interestingly, the reduction of peak time 
induced by methamphetamine diminished with repeated daily treatment; 
however, when treatment was subsequently witheld, the peak time increased 
above its baseline value, before gradually returning again to the baseline. 
Meck (1986, 1996; Hinton and Meck 1997) interpreted these results in 
terms of Scalar Expectancy Theory. He suggested that dopamine release 
induced by amphetamine-like drugs increases the rate of pulse generation by 
the hypothetical pacemaker, thereby causing the subject to 'overestimate' the 
durations of stimuli. Meck further proposed that when the drug is present 
during repeated training sessions, the animal learns to 'recali brate' the 
accumulator, allowing the peak time to resume its optimal location. When the 
drug is withdrawn, peak time is initially increased due to temporal 
underestimation, but this is followed by a return to the baseline location as the 
accumulator is again recalibrated (see Hinton and Meck 1997). 
The effects of d-amphetamine and methamphetamine on interval timing 
have been attributed to dopamine release in the striatum (Meck 1986, 1996; 
Hinton and Meck 1997). However, as well as promoting dopamine release, 
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amphetamine-like drugs also promote noradrenaline release and, to a lesser 
extent, 5-HT release, and have some catecholamine uptake blocking action (for 
review, see Rothman and Baumann 2003). More direct evidence for the 
involvement of dopaminergic transmission comes from experiments with 
selective dopamine receptor antagonists. Meck (1986, 1996) reported that 
several D2 dopamine receptor antagonists affected peak fixed-interval schedule 
performance in the opposite direction to amphetamine-like drugs; however, 0 I 
receptor antagonists were ineffective in this respect. It was therefore proposed 
that dopaminergic transmission, operating via D2 dopamine receptors, exerts a 
facilitatory effect on the hypothetical pacemaker (Meek 1986). 
More recently, Meek and his colleagues have developed a revised 
pacemaker-based model based on the functioning of a cortico-striato-thalamo-
cortical circuit (Meck and Benson 2002; Matell and Meek 2000, 2004). The 
model assumes that neurones in the striatum detect the coincidence of 
oscillating inputs from the neocortex and thalamus. These oscillating inputs are 
regarded as constituting the neural basis of the hypothetical pacemaker. 
Computer simulation studies have shown that a mechanism of this type could 
g ~ n e r a t e e an output with temporal properties consistent with interval timing 
behaviour (Matell and Meek 2004), and a recent single unit recording study has 
identified striatal neurones whose oscillating firing patterns coincide with the 
duration of a stimulus in a temporal differentiation task (Matell et al. 2003). 
According to Matell and Meck's (2000, 2004) 'striatal beat frequency model', 
(see above, 1.4.5), dopaminergic mechanisms contribute to the temporal 
control of behaviour in two ways: firstly, by adjusting or 'tuning' the 
pacemaker inputs to the striatum, and secondly by controlling 'attention-
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sharing' between temporal processing and other, simultaneous tasks. It is 
proposed that these two roles of dopamine in timing are mediated by D2 and D\ 
receptors, respectively (Meck and Benson 2002; Buhusi 2003). 
This revised pacemaker-based model of timing lS the most 
comprehensive account of the neural substrate of interval timing available at 
the present time. However, as discussed by Chiang et al. (2000a) and Odum 
(2002), the principal source of biological evidence supporting all pacemaker 
models derives from the behavioural effects of amphetamine-like drugs and 
dopamine receptor antagonists, and this evidence is not entirely consistent. For 
example, while early studies with the interval bisection task showed that 
amphetamine-like drugs reduced T50 (Maricq et al. 1981; Maricq and Church 
1983), other experiments indicated that these drugs produced a general 
breakdown of temporal discrimination. Thus, an early study by Stubbs and 
Thomas (1974) showed that d-amphetamine dose-dependently reduced 
pigeons' ability to discriminate two different durations. Similar results were 
obtained by Rapp and Robbins (1976), and by Santi et al. (1995) using a 
delayed matching to sample task. More recently, Chiang et al. (2000a) found 
that d-amphetamine produced a dose-dependent increase in the Weber fraction 
in the interval bisection task (i.e. it reduced discriminative accuracy) without 
altering T50. Similar findings were reported by Odum et al. (2002) using a free-
operant retrospective timing schedule. 
The evidence from immediate timing schedules is also ambiguous. 
Thus, the finding that methamphetamine displaced the peak function to the left 
(Meck 1983, 1986) has been confirmed by Kraemer et al. (1997) and B uhusi 
and Meck (2002), but not by Bayley et al. (1998). Chiang et al. (2000a) found 
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that d-amphetamine dose-dependently reduced T50 III the free-operant 
psychophysical procedure, although it also increased the Weber fraction, 
suggesting that it may also have produced a more general disruption of 
temporal differentiation. 
Chiang et al. (2000a) suggested that amphetamine-like drugs may have 
different effects on performance in retrospective and immediate timing 
schedules; in the former case, effects on discriminative accuracy predominate, 
whereas in the latter case, changes in the locus of the timing function (i.e. peak 
time or T50) may be more apparent. 
Cevik (2003) suggested that other methodological factors may be 
responsible for the discrepant results. Using an interval bisection task, Cevik 
(2003) showed that a low dose of d-amphetamine (0.5 mg kg-I) shifted the 
psychometric curve to the left 100 minutes after drug treatment, whereas no 
such shift was seen at shorter post-injection times (20-100 min). 
In conclusion, the evidence reviewed above indicates that performance 
on timing schedules is sensitive to amphetamine-like drugs and to D2 receptor 
antagonists, in accordance with the view that dopaminergic mechanisms 
contribute to the regulation of timing behaviour. However, at the present time 
the data are insufficiently consistent to allow a precise definition of dopamine's 
role in interval timing. 
1.5.2. Cholinergic mechanisms and timing 
Cholinergic mechanisms are purported to be involved in memory and 
attentional processes, and disorders of cholinergic function may be associated 
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with cognitive impairments (see Meck and Church 1987; Sarter and Bruno 
1997; Ragozzino 2000). Meck and Church (1987) and Hinton and Meck (1997) 
proposed a specific role for central cholinergic mechanisms in interval timing: 
regulation of the transfer of temporal information to and from reference 
memory. 
Unfortunately, there have been relatively few attempts to delineate the 
effects of manipulating cholinergic function on interval timing performance. 
Meck and Church (1987) reported that the anticholinesterase physostigmine 
and the acetylcholine precursor choline 'sharpened' the peak of the response 
rate function in the fixed-interval peak procedure and displaced the function to 
the left (i.e. reducing the peak time), whereas the muscarinic cholinoceptor 
antagonist atropine broadened the peak and displaced it to the right. These 
effects were interpreted as reflecting reductions and increases, respectively, of 
remembered durations (Meck and Church 1987). 
Meck et al. (1986) reported that systemic treatment with argmme 
vasopressm, which increased high-affinity choline uptake in the cortex, 
attenuated the age-related rightward shift of the response rate function, an 
effect that Meck et al. (1986) interpreted in terms of an improvement of 
cholinergic transmission-dependent memory function. More recently, Meck 
and Williams (1997) reported that a dietary choline supplement reversed the 
effect of choline-deficient diet on peak fixed-interval performance. Meck and 
Williams (1997) interpreted the effect of the dietary deficiency in terms of an 
attentional deficit rather than a direct effect on temporal memory. 
Odum (2002) examined the effects of atropine and physostigmine on 
performance on a retrospective timing schedule similar to the interval bisection 
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task. Physostigmine produced a reduction of T50, consistent with the findings of 
Meck and Church (1987) with the peak procedure. However, Odum (2002) 
found that atropine produced an even more marked reduction of T50, the 
opposite result to that obtained by Meck and Church (1987). 
In conclusion, the study of the role of central cholinergic mechanisms 
in interval timing is insufficiently well developed for any definite conclusions 
to be drawn. In view of the theoretical importance of cholinergic functions for 
pacemaker-based timing theories (Hinton and Meck 1997), it would seem that 
this topic deserves further investigation. 
1.5.3. 5-HTergic mechanisms and timing 
There is increasing evidence that the ascending 5-HTergic pathways contribute 
to the regulation of timing behaviour. However, the precise nature of this 
contribution remains unclear. Manipulation of 5-HTergic function has been 
found to have qualitatively different effects on performance in different types 
oftiming schedules (see AI-Ruwaitea et al. 1997; Ho et al. 2002). 
Wogar et al. (1992) examined the effect of destruction of the ascending 
5-HTergic projection by injection of 5,7-dihydroxytryptamine (5,7-DHT) into 
the dorsal and median raphe nuclei on performance on an inter-response time 
schedule (IRT> 15-s, or differential-reinforcement-of-Iow-response-rate [DRL] 
15-s). The lesion retarded the acquisition of accurate performance, reduced the 
mean IRT and increased the Weber fraction. Morrissey et al. (1994) examined 
the effect of the same lesion on performance on the fixed-interval peak 
procedure. The peak time was not affected by the lesion, although acquisition 
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was slowed down and the Weber fraction was increased (see also AI-Ruwaitea 
et a1. 1997). AI-Ruwaitea et a1. (1997) speculated that in both these 
experiments the lesion may have facilitated the rats' propensity to switch 
between the behavioural states represented by lever pressing and 'other 
behaviour'. However, this suggestion could not be tested, since both schedules 
entail the use of a single operandum. 
AI-Zahrani et a1. (1996) used the free-operant psychophysical 
procedure to provide direct evidence for an effect of 5-HT depletion on 
switching between behaviours. The lesion did not prevent the animals from 
acquiring accurate performance on this schedule, nor did it affect the steady-
state values of the indifference point (T50) or the Weber fraction. However, the 
lesion consistently increased the rate of switching between the two levers. 
Chiang et al. (1999) predicted that if switching were restricted to one 
switch per trial in the 'constrained switching' version of the free-operant 
psychophysical procedure (Chiang et a1. 1998; see above, 1.3.3.5), 5-HT 
depletion would result in a reduction of T50, due to facilitation of the switch to 
lever B early in the trial. However, this did not occur (Chiang et al. 1999), 
suggesting that 5-HT depleted rats are able to learn to withold switching in 
immediate timing tasks. 
The facilitation of switching induced by 5-HT depletion apparently 
does not reflect an interaction with timing processes, because AI-Ruwaitea et 
al. (1999b) found that the lesion markedly enhanced switching between 
concurrent schedules of reinforcement which did not entail temporal 
differentiation of behaviour (variable-interval and variable-time schedules). 
Several experiments have shown that central 5-HT depletion disrupts 
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behaviour in prospective timing schedules. Wogar et al. (1993) and Mobini et 
al. (2000) found that 5-HT depleted rats were less tolerant of delay of 
reinforcement than sham-Iesioned control rats in an adjusting delay schedule 
(see above, 1.3.4.1.). Similar results were obtained by AI-Ruwaitea et al 
(1999a) using the 'time-left' procedure (see above, 1.3.4.2). 
The experiments reviewed above have shown that total ablation of the 
5-HTergic pathways can alter performance on different timing schedules in 
different ways. However, in no case does 5-HT depletion prevent animals from 
displaying relatively accurate timing behaviour. More detailed information 
about the possible role of 5-HTergic neurotransmission in interval timing can 
be provided by studies of the effects of acute treatment with drugs that interact 
with specific 5-HT receptors. 
Chiang et al. (2000b) examined the effect of acute treatment with the 5-
HTIA receptor agonist 8-0H-DPAT on performance on the free-operant 
psychophysical procedure. The drug produced a dose-dependent leftward shift 
of the psychometric function, reflected in a reduction of T50. Chiang et al. 
(2000b) suggested that this effect of 8-0H-DPAT might have been due to 
stimulation of the somatodendritic autoreceptor population of 5-HT1A 
receptors. However, Body et al. (2001) found that this was not the case, 
because the effect of 8-0H-DPAT was not altered by destruction of the 5-
HTergic pathways by 5,7-DHT. The effect of 8-0H-DPAT on performance on 
the free-operant psychophysical procedure could be blocked by the selective 5-
HTIA receptor antagonist WA Y-I00635, indicating that the effect was 
mediated by 5-HTIA receptors, rather than by 5-HT7 receptors, for which 8-
OH-DPAT also has some affinity (Body et al., 2002b). 
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Chiang et al. (2000b) found that 8-0H-DPAT also affected 
perfonnance on the interval bisection task. However, unlike its effect on 
perfonnance in the free-operant psychophysical procedure, 8-0H-DPAT did 
not affect Tso, but did increase the Weber fraction in this schedule. Body et al. 
(2002a) obtained similar findings with another retrospective timing schedule, 
the discrete-trials psychophysical procedure (see above, 1.3.2.3). These 
findings emphasize the importance of examining the effects of drugs on more 
than one type of timing schedule. Moreover, according to Chiang et al. 
(2000a,b), the finding of qualitatively different effects of the same intervention 
on different timing tasks argues against the possibility that the effects are 
mediated by an interaction with a 'unitary' internal clock (see also Ho et al. 
2002). 
Body et al. (2003), examined the effect of the mixed 5-HT2A12C receptor 
agonist, 2,5-dimethoxy-4-iodoamphetamine (001), and antagonist, ketanserin, 
on temporal differentiation in the free-operant psychophysical procedure. Body 
et al. (2003) speculated that 5-HT IA receptors might be subordinate to a 
prepotent, and functionally opposite, population of 5-HT 2 receptors. This 
speculation, however, was not confinned by their finding that DOl had a 
qualitatively similar effect on temporal differentiation to that produced by 8-
OH-DPAT (i.e. DOl dose-dependently reduced Tso). The reduction of Tso by 
DOl was reversed by ketanserin; since ketanserin has an approximately 80-fold 
higher affinity for 5-HT2A receptors than for 5-HT2c receptors (Barnes and 
Sharp 1999; Hoyer et al. 2002), this finding implicates 5-HT2A receptors in 
DOl's effect. It is not known whether 5-HT2A receptor stimulation affects 
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temporal discrimination performance in the same way that it alters temporal 
differentiation. 
The results discussed above indicate that temporal differentiation in the 
free-operant psychophysical procedure is sensitive to stimulation of both 5-
HTIA and 5-HT2A receptors; in both cases, the receptor population appears to 
be postsynaptic. Body et al. (2004) investigated whether either or both these 
receptor populations can be stimulated by endogenously released 5-HT. These 
authors found that the 5-HT releasing agent fenfluramine, like 8-0H-DPAT 
and DOl, displaced the psychometric curve to the left, reducing T50. This effect 
offenfluramine was absent in rats whose 5-HTergic pathways had been ablated 
by intra-raphe injection of 5,7-DHT, confirming that the effect depended on the 
existence of intact 5-HTergic neurones, and suggesting that it was mediated by 
the release of endogenous 5-HT. The effects of both 8-0H-DPAT and DOl 
were unaffected by the lesion, confirming that these agonists' effects· were 
mediated by post-synaptic receptor populations. Interestingly, fenfluramine's 
effect could be antagonized by ketanserin but not by WAY -100635, suggesting 
that endogenous 5-HT influenced temporal differentiation principally via an 
interaction with 5-HT 2A rather than 5-HT lA receptors. 
In conclusion, the experiments reviewed in this section indicate that, 
while the integrity of the 5-HTergic pathways is not essential for the accurate 
performance of timing tasks, acute stimulation of at least two subtypes of 5-HT 
receptor, 5-HTIA and 5-HT2A receptors, can have marked effects on timing 
behaviour. In the case of 5-HT1A receptor stimulation, there is an interesting 
disjunction between the effects on temporal differentiation and temporal 
discrimination: in the former case, the psychometric function is displaced to the 
74 
left (i.e. Tso is reduced), whereas in the latter case the main effect is a flattening 
of the function (i.e. the Weber fraction is increased). The implications of these 
findings for the neural mechanisms underlying interval timing behaviour have 
not yet been fully worked out. However, Ho et al. (2002) have argued that the 
qualitatively different effects of the same drug treatment on different timing 
tasks are difficult to reconcile with the notion of a unitary internal clock, such 
as that proposed by SET and BET, which is assumed to subserve timing 
behaviour in all types of timing schedule. 
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CHAPTER 2 
Experiment 1: 
EFFECTS OF QUIPAZINE AND 
m-CHLOROPHENYLBIGUANIDE (m-CPBG) 
ON TEMPORAL DISCRIMINATION 
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2.1. INTRODUCTION 
Two major classes of timing schedule are immediate and retrospective timing 
schedules (Killeen and Fetterman 1988; Killeen et al. 1997; see above, section 
1.3). Immediate timing schedules require the organism to regulate its own 
behaviour in time (temporal differentiation), whereas retrospective timing tasks 
entail discrimination of the durations of exteroceptive stimuli (temporal 
discrimination). Examples of immediate timing schedule are the free-operant 
psychophysical procedure and fixed-interval peak procedure (see section 
1.3.3). An example of a retrospective timing schedule is the discrete-trials 
psychophysical procedure (Body et al. 2002a; see section 1.2.3.3). In this 
schedule, a light is presented for a variable time, t < 50 s, following which two 
levers are offered; a response on A is reinforced if t < 25 s, whereas a response 
on B is reinforced if t > 25 s. Temporal discrimination is measured 
quantitatively from a sigmoid psychometric curve derived from the 
proportional choice of B as a function of t. In both types of schedule, the 
psychometric curve conforms to a two-parameter logistic function from which 
indices of timing are derived which reflect its central tendency (the 
indifference point, T50, or 'point of subjective equality', PSE: see Killeen et al. 
1997) and its variability (the Weber fraction) (see Killeen et al. 1997; Ho et al. 
2002). 
Despite the superficial similarity of the timing indices derived from 
immediate and retrospective timing tasks, they differ in their sensitivities to 
pharmacological challenge (see section 1.5.3.). For example, the 5-HT 1A 
receptor agonist 8-hydroxy-2-( di-n-propylamino )tetralin (8-0H -DP AT) has 
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been found to reduce T50 without altering the Weber fraction in an immediate 
timing schedule, but to increase the Weber fraction without altering T50 in 
retrospective timing schedules (Chiang et al. 2000, Body et al. 2001, 2002a, 
2002b, 2004). Both these effects are apparently mediated by postsynaptic 
receptor populations, since they are impervious to destruction of the ascending 
5-HTergic pathways (Body et al. 2001, 2002a, 2002b, 2004). 
It is not known whether 5-HT3 receptor stimulation has any systematic 
effect on temporal discrimination. The present experiment examined the effects 
of m-chlorophenylbiguanide (m-CPBG) and quipazine on performance in the 
discrete-trials psychophysical procedure. m-CPBG is a selective 5-HT3 
receptor agonist (Kilpatrick et al. 1990); quipazine has nanomolar affinity for 
5-HT3 receptors and micromolar affinity for 5-HT2A receptors (Hoyer 1988; 
Glennon et al. 1989; Sharif et al. 1991). The sensitivity of quipazine' s effects 
to antagonism by the 5-HT3 receptor antagonist MDL-72222 (Fozard 1984) 
and the 5-HT2A receptor antagonist ketanserin (Barnes and Sharp 1999; Hoyer 
et al. 2002) was also examined. 
2.2. METHODS 
2.2.1. Subjects 
Twenty-four female Wistar rats, aged approximately 4 months and weighing 
250-290 g at the start of the experiment, where housed individually under a 
constant cycle of 12 h light and 12 h darkness (lights on 07.00-19.00 hours), 
and were maintained at 80% of their initial free-feeding body weights by 
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providing a limited amount of standard rodent diet after each experimental 
session. Tap water was freely available in the home cages. 
2.2.2. Apparatus 
The rats were trained in operant conditioning chambers (Campden Instrument 
Limited, Sileby, UK) of internal dimensions 20 cm x 23 cm x 22.5 cm. One 
wall of the chamber contained a recess into which a motor-operated dipper 
could deliver 50 I.d of a liquid reinforcer. Apertures were situated 5 cm above 
and 2.5 cm on either side of the recess; a motor-driven retractable lever could 
be inserted into the chamber through each aperture. Each lever could be 
depressed by a force of approximately 0.2 N. The chamber was enclosed in a 
sound-attenuating chest; masking noise was provided by a rotary fan. Twelve 
chambers were used; each rat was always tested in the same chamber. An 
Acorn microcomputer programmed in Arachnid BASIC (CeNeS I,teL 
Cambridge, UK), located in an adjoining room controlled the schedules and 
recorded the behavioural data. 
2.2.3. Behavioural training 
At the start of the experiment, the food-deprivation regimen was started and the 
rats were gradually reduced to 80% of their free-feeding body weights. They 
were then trained to press the levers, and were exposed to a discrete-trials 
continuous reinforcement schedule, in which the two levers were presented in 
random sequence, for three sessions. Thereafter, the rats underwent 50-minute 
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training sessions under the discrete-trials psychophysical procedure, 7 days a 
week, at the same time each day during the light phase of the daily cycle 
(between 8.00 and 13.00 hours). The reinforcer, a 0.6 M solution of sucrose in 
distilled water, was prepared daily before each session. 
The discrete-trials psychophysical procedure was identical to that 
described by Body et al. (2002). Each session consisted of fifty trials, 
successive trials being initiated at 60-s intervals. Each trial started with the 
illumination of a lamp above the central reinforcer recess. After a 
predetermined interval had elapsed (see below), the levers were inserted into 
the chamber. A single response on either lever resulted in withdrawal of both 
levers and extinguishing of the light; the chamber remained in darkness until 
the start of the next trial. Lever insertion took place once in each trial, at one of 
the following "entry points" following the start of the trial: 2.5, 7.5,12.5,17.5, 
22.5, 27.5, 32.5, 37.5, 42.5, 47.5 s. If lever insertion took place at any of the 
first five entry points (i.e., less than 25 s after trial onset), a response on lever A 
resulted in reinforcer delivery, whereas a response on lever B did not; 
conversely, iflever insertion took place at any of the last five entry points (i.e., 
more than 25 s after trial onset), a response on lever B resulted in reinforcer 
delivery, whereas a response on lever A did not. If no response occurred within 
5 s of lever insertion, the levers were withdrawn and the light was extinguished 
(this seldom occurred after the first few sessions of training). The positions of 
levers A and B (left versus right) were counterbalanced across subjects. In each 
session, there were 40 trials in which both levers were presented (four trials 
with each entry point, in pseudo-random sequence). The remaining trials were 
forced-choice trials in which only one lever was presented (lever A in five 
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trials and lever B in the other five), the entry points occurring in a pseudo-
random sequence. 
2.2.4. Drug treatment 
The drug treatment regimen started after 90 sessions of preliminary trai ning 
under the discrete-trials psychophysical procedure. Injections of drugs were 
given on Tuesdays and Fridays, and injections of the vehicle alone (O.9(Yo 
sodium chloride solution) on Mondays and Thursdays; no injections were 
given on Wednesdays, Saturdays or Sundays. Each dose of each drug was 
administered five times, in order to accrue a sufficient number of trials for 
function fitting (see below). The order of treatments within each series was 
balanced within and between animals according to a Latin square. 
Subcutaneous injections were given using a 26-gauge needle at a volume of 1.0 
ml kg-I; intraperitoneal injections were given using a 25-gauge needle at a 
volume of 2.5 ml kg-I. The doses of the drugs tested were as follows (doses 
were selected on the basis of previous behavioural studies with rats: see 
Discussion for references). 
Agonists: quipazine dimaleate, 0.5, 1, 2 mg kg-I; m-chlorophenyl-
biguanide hydrochloride (m-CPBG), 2.5, 5, 10 mg kg-I. Both drugs were 
dissolved in 0.9% sodium chloride solution; quipazine was administered 
subcutaneously 15 min before the start of the experimental session. and m-
CPBG intraperitoneally 30 min before the start of the session. 
Antagonists: topanyl 3,5-dichlorobenzoate (MDL-72222), 0.25, 0.5, I 
mg kg-I was dissolved in glacial acetic acid, buffered to pH 5.5, and diluted 
81 
with 0.9% sodium chloride to give the desired concentration; it was i ~ e c t e d d
intraperitoneally 30 min before the start of the session. Ketanserin tartrate, 0.5, 
1, 2 mg kg- I was dissolved in 0.9% sodium chloride; it was injected 
subcutaneously 15 min before the start of the session. 
Agonist/antagonist interaction: Quipazine 2 mg kg- I was administered 
alone and in combination with either MDL-72222 1 mg kg-lor ketanserin 2 mg 
k -I g . 
2.2.5. Data analysis 
Separate analyses were carried out on the effects of quipazine, m-CPBG, 
MDL-72222 and ketanserin, and the interaction between quipazine, MDL-
72222 and ketanserin. 
For each treatment condition, the percentages of responses emitted on 
lever B (%B) at each time-point were analysed by two-factor analyses of 
variance (treatment x time) with repeated measures on both factors. In the 
event of a significant main effect of treatment or a significant treatment x time 
interaction, analyses of the simple main effect at each time-point were carried 
out, followed by comparisons between each active treatment with the vehicle-
alone condition using Dunnett's test. 
For the quantitative analysis of the psychometric functions (%B plotted 
against stimulus duration, t), two-parameter logistic functions were fitted to the 
data obtained under each treatment condition: %B = 1001(1 +[tIT5or'), where T)() 
(indifference point) is the stimulus duration corresponding to %B = 50%, and £ 
is the slope of the function (AI-Zahrani et aI. 1996). The curve-fitting 
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procedure yields estimates (± SE est.) of the values of T50 and s, from which 
the Weber fraction was determined as follows. The limen was defined as half 
the difference between T75 and T 25 (T75 and T 25 being the values of t 
corresponding to %B=75% and %B=25%), and the Weber fraction was 
calculated as the ratio of the limen to T50. Goodness of fit of the logistic 
functions was expressed as the index of determination, /. The values of T50, s, 
and the Weber fraction were analysed by one-factor analyses of variance 
(treatments) with repeated measures. In the case of a significant effect of 
treatment, comparisons were made between each active treatment and the 
control (vehicle alone) condition using Dunnett's test (significance criterion, 
P<0.05). In the case of data from the quipazine-ketanserinlMDL-72222 
interaction, multiple comparisons were made between treatment with quipazine 
alone and the combined quipazine + antagonist treatments, using Neuman-
Keul's test (significance criterion, P<0.05). 
2.3. RESULTS 
Under each treatment condition, the proportion of responding allocated to lever 
B (%B) increased progressively as a function of stimulus duration, t. Under the 
vehicle-alone condition and all active treatment conditions, the number of 
'missed' trials (i.e. trials in which no response was emitted on either lever A or 
lever B) was <0.5%. 
2.3 .1. Effects of the agonists 
Quipazine. The effect of quipazine on proportional choice of lever B 
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(%B) is shown in Fig. 2.l.A. Analysis of variance of these data revealed 
significant main effects of treatment [F(3,69) = 12.0, P<O.OOI] and time 
[F(9,207) = 556.6, P<O.OOl], and a significant treatment x time interaction 
[F(27,621) = 8.2, P<O.OOl]. Analysis of the simple main effects revealed 
significant treatment effects 7.5 s after trial onset, and at all time points >25 s 
after trial onset. Multiple comparisons with the vehicle-alone condition showed 
that quipazine 2 mg kg-1 produced a significant increase in %B 7.5 s after trial 
onset and significant decreases in %B at all time points> 25 s after trial onset. 
Quipazine 1 mg kg-1 produced decreases in %B 27.5,32.5,37.5 and 47.5 s after 
trial onset. 
Logistic functions were fitted to the data from each rat under each 
treatment condition; the group mean values of parameters of these functions (± 
SEM) are shown in Table 2.1. Quipazine flattened the psychometric function 
and displaced it rightwards; these effects are reflected in the parameter values. 
There was a dose-dependent increase in the value of T50; analysis of variance 
showed a significant effect of treatment [F(3,69) = 10.9, P<O.OOI], and 
multiple comparisons with the vehicle-alone condition indicated that quipazine 
1 and 2 mg kg-1 significantly increased T50. There was also a significant effect 
on the slope of the function, E [F(3,69) = 16.5, P<O.OOI], the effects of 1 and 2 
mg kg-1 being statistically significant. The Weber fraction was increased by 
quipazine [F(3,69) = 4.1, P<O.Ol], the effect of2 mg kg-I being significant. 
m-CPBG. The %B data are shown in Fig. 2.1.B. Analysis of variance of 
these data revealed a significant main effect of time [F(9,207) = 1085.3, 
P<O.OOI], but no significant main effect of treatment [F(3,69) = 1.1, P>O.1] 
and no significant treatment x time interaction [F(27,621) = 1.5, P>O.l]. 
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Figure 2.1. A. Effect of quipazine on relationship between proportional choice 
of lever B (%B) and stimulus duration (t, seconds) in the discrete-trials 
psychophysical procedure. Points indicate group mean data under each 
treatment condition (see inset). Significance of difference from vehicle-alone 
treatment: * P < 0.05. B Effect of m-CPBG on relationship between 
proportional choice of lever B and stimulus duration; conventions as in A. 
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Table 2.1. Effects of the agonists on measures of performance on the discrete-trials 
psychophysical procedure: group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment T50, s slope, 8 i Weber fraction 
Vehicle 24.0 ± 0.7 -3.8 ± 0.2 0.94 ± 0.04 0.31 ± 0.02 
quipazine 0.5 mg kg-I 24.4 ± 0.7 -3.6 ± 0.3 0.95 ± 0.01 0.37 ± 0.04 
quipazine 1 mg ki l 26.1 ± 0.7 * -3.1 ± 0.2 * 0.93 ± 0.02 0.43 ± 0.02 * 
00 quipazine 2 mg kg-I 30.2 ± 1.5* -2.3 ± 0.2 * 0.89 ± 0.02 0.84 ± 0.25 * 
0\ 
Vehicle 24.1 ± 0.4 -5.7 ± 0.4 0.99 ± 0.00 0.21 ± 0.01 
m-CPBG 2.5 mg kg-I 24.4 ± 0.5 -6.8 ± 0.7 0.97 ± 0.00 0.20 ± 0.02 
m-CPBG 5 mg ki 1 23.6 ± 0.5 -5.5 ± 0.4 0.98 ± 0.00 0.22 ± 0.01 
m-CPBG 10 mg kil 24.0 ± 0.6 -5.4 ± 0.5 0.97 ± 0.01 0.24 ± 0.02 
Significance of difference from vehicle condition, * P < 0.05 
The parameters of the logistic functions are shown in Table 2.1. m-CPBG had 
no significant effect on the values of Tso [F(3,69) = l.5, P>0.05], I:: [F(3.69) = 
2.4, P>0.05] or the Weber fraction [F(3,69) = 2.4, P>0.05]. 
2.3.2. Effects of the antagonists 
MDL-72222. The %B data are shown in Fig. 2.2.A. Analysis of 
variance of these data revealed a significant main effect of time [F(9,207) "'-= 
967.0, P<O.OOl], but no significant main effect of treatment [F(3,69) = 1.7, 
P>O.I] and no significant treatment x time interaction [F<l]. 
The parameters of the logistic functions are shown in Table 2.2. MDL-
72222 had no significant effect on the values of Tso [F(3,69) = 2.3, P>0.05] or 
E [F(3,69) = 2.2, P>0.05]. There was a significant treatment effect in the case 
of the Weber fraction [F(3,69) = 4.3, P<O.Ol]; however this did not appear to 
be dose-related, and none of the individual doses of m-CPBG differed 
significantly from the vehicle-alone condition. 
Ketanserin. The %B data are shown in Fig. 2.2.A. Analysis of variance 
of these data revealed a significant main effect of time [F(9,207) = 1050.3, 
P<O.OOI], but no significant main effect of treatment [F(3,69) = 1.6, P>O.I] 
and no significant treatment x time interaction [F<I]. 
The parameters of the logistic functions are shown in Table 2.2. 
Ketanserin had no significant effect on the values of T50 [F(3,69) = 2.1, 
P>0.05] or E [F(3,69) = 1.5, P>0.05] or the Weber fraction [F(3,69) = 0.6, 
P>0.05]. 
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Table 2.2. Effects of the antagonists on measures of performance in the discrete-trials psychophysical procedure: 
group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment T50, s slope, c p"2 Weber fraction 
Vehicle 23.9 ± 0.4 -5.0 ± 0.3 0.98 ± 0.00 0.24 ± 0.02 
MDL-72222 0.25 mg kg'l 24.7 ± 0.5 -5.8 ± 0.4 0.97 ± 0.01 0.21 ± 0.02 
MDL-72222 0.5 mg kg'l 23.7 ± 0.4 -6.2 ± 0.8 0.97 ± 0.00 0.23 ± 0.02 
MDL-72222 1 mg kg'! 23.8 ± 0.6 -4.7 ± 0.4 0.97 ± 0.01 0.27 ± 0.02 
00 
1..0 
Vehicle 23.6 ± 0.5 -5.4 ± 0.4 0.99 ± 0.00 0.22 ± 0.01 
ketanserin 0.5 mg kg"! 24.5 ± 0.5 -5.5 ± 0.4 0.97 ± 0.00 0.22 ± 0.02 
ketanserin 1 mg kg"! 24.1 ± 0.5 -6.3 ± 0.7 0.97 ± 0.00 0.20 ± 0.02 
ketanserin 2 mg kg"l 23.6 ± 0.6 -5.9 ± 0.4 0.97 ± 0.00 0.21 ± 0.01 
2.3.3. Agonist-antagonist interaction 
The %Bdata are shown in Fig. 2.3. Analysis of variance of these data revealed 
significant main effects of treatment [F(3,69) = 16.9, P<O.OOI] and time 
[F(9,207) = 585.5, P<O.OOI], and a significant treatment x time interaction 
[F(27,621) = 16.8, P<O.OOI]. Analysis of the simple main effects revealed 
significant treatment effects 7.5 and 12.5 s after trial onset, and at all time 
points >25 s after trial onset. Multiple comparisons with the vehicle-alone 
condition showed that quipazine and quipazine + MDL-72222 produced 
significant increases in %B 7.5 and 12.5 s after trial onset and significant 
decreases in %B at all time points >25 s after trial onset. In no case did 
quipazine + ketanserin differ significantly from vehicle-alone treatment, and 
there were no significant differences between the quipazine and quipazine + 
MDL-72222 treatment conditions. 
The parameters of the logistic functions are shown in Table 2.3. There 
was a significant effect of treatment on T50 [F(3,69) = 7.9, P<O.OOI]. Multiple 
comparisons with the vehicle condition (Dunnett's test) showed that T50 was 
significantly increased by quipazine and by quipazine + MDL-72222, but not 
significantly changed by quipazine + ketanserin. Multiple comparisons with the 
quipazine condition (Newman-Keul's test) showed that the increase in T50 
produced by quipazine was significantly reversed by combined treatment with 
ketanserin but not by combined treatment with MDL-72222. 
There was a significant effect of treatment on £ [F(3,69) = 42.7, 
P<O.OOI]. Multiple comparisons with the vehicle alone condition showed that 
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Figure 2.3. Interaction between quipazine (QUIP), MDL-72222 (MDL) and 
ketanserin (KET) on relationship between proportional choice of lever Band 
stimulus duration in the discrete-trials psychophysical procedure. Conventions 
as in Fig.2.1. The psychometric function was flattened and displaced to the 
right by quipazine; this effect was reversed by co-administration of ketanserin, 
but not by co-administration of MDL-72222. Significance of difference from 
vehicle-alone treatment: * P < 0.05; note that asterisks refer to both the 
quipazine and quipazine + MDL-72222 treatments. 
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Table 2.3. Interaction between quipazine and the antagonists on measures of performance in the discrete-trials 
psychophysical procedure: group mean values (± SEM) 
Treatment 
Vehicle 
quipazine 2 mg kg-! 
quipazine 2 mg kg-! + 
MDL-72222 1 mg kg-! 
quipazine 2 mg kg"! + 
ketanserin 2 mg kg-! 
T50, S 
23.4 ± 0.4 
25.9 ± 0.8 * 
28.1 ± 1.5 * 
23.9 ± 0.6 # 
Parameters of logistic psychometric function 
slope, I> p2 Weber fraction 
-5.1 ± 0.3 0.94 ± 0.04 0.21 ± 0.01 
-2.8 ± 0.2 * 0.90 ± 0.02 0.60 ± 0.13 * 
-2.6 ± 0.3 * 0.97 ± 0.01 0.70 ± 0.18 * 
-5.3 ± 0.3 # 0.89 ± 0.03 0.22 ± 0.01 # 
Significance of difference from vehicle condition, * P < 0.05; significance of difference from quipazine 2 mg kg- l 
condition, # P < 0.05 
the value of £ was increased both by quipazine and by quipazine + MDL-
72222, but not by quipazine + ketanserin. Multiple comparisons with the 
quipazine condition showed that quipazine's effect on the parameter was 
reversed by ketanserin but not by MDL-72222. 
There was a significant effect of treatment on the Weber fraction 
[F(3,69) = 7.1, P<O.OOl]. Multiple comparisons with the vehicle alone 
condition showed that quipazine and quipazine + MDL-72222 increased the 
Weber fraction. Multiple comparisons with the quipazine condition showed 
that the increase in the Weber fraction produced by quipazine was significantly 
reversed by ketanserin but not by MDL-72222. 
2.4. DISCUSSION 
Temporal discrimination in the discrete-trials psychophysical procedure seen in 
these experiments was similar to that reported previously: proportional choice 
of lever B increased as a sigmoid function of stimulus duration, this being well 
described by a two-parameter logistic equation (Body et al. 2002). 
Quipazine (0.5-2.0 mg kg-I) produced a dose-dependent disruption of 
temporal discrimination, which was most readily apparent in the case of longer 
stimulus durations. This resulted in rightward displacement and flattening of 
the fitted psychometric function, reflected in a significant increase in the value 
of T50, combined with significant increases in £ and the Weber fraction. The 
increase in the Weber fraction produced by quipazine indicates an impairment 
of the precision with which the rats discriminated the durations of the light 
stimulus (see Killeen et al. 1997). The origin of the increase in Tso induced by 
quipazine remains unclear. Acute changes in T50 are often ascribed to changes 
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in the period of the hypothetical internal pacemaker, the putative substrate of 
interval timing behaviour (see Gibbon et al. 1997a; see below). However, other 
explanations for quipazine's effect on T50 may be possible. For example, the 
increases in T50 and the Weber fraction may both be explained in terms of a 
general breakdown of stimulus control induced by the drug, if it is assumed 
that stimulus control is weaker, and therefore more vulnerable to disruption, 
during the longer stimulus durations. Further experiments will be needed to 
address this issue; one obvious question to ask is whether quipazine's effects 
on discrimination performance are specific to the temporal dimension, or 
whether discriminative control exerted by other stimulus dimensions may be 
equally sensitive to this drug. 
The effect of quipazine on temporal discrimination performance was 
not shared by the selective 5-HT3 receptor agonist m-CPBG (Kilpatrick et al. 
1990). It is unlikely that the lack of effect of m-CPBG reflects the use of an 
inadequate dose of this drug, since the dose range used in this experiment has 
been found to be active in other behavioural paradigms (Higgins et al. 1993). 
The lack of effect of m-CPBG stands in contrast to the robust effect of 
quipazine. Quipazine has a very high affinity for 5-HT3 receptors (Kd = 2 nM: 
Glennon et al. 1989; Sharif et al. 1991), and somewhat lower affinity 
(micromolar range) for several other subtypes of 5-HT receptor, including 5-
HTIB, 5-HT2A and 5-HT2C receptors (Hoyer 1988). Quipazine's effect on 
temporal discrimination was not altered by co-administration of MDL-72222, 
but was completely abolished by co-administration of ketanserin. MDL-72222 
is a selective 5-HT3 receptor antagonist (Fozard 1984); the doses used in this 
experiment have been shown to be behaviourally active in a variety of tests that 
are thought to reflect 5-HT3 receptor function (Costall and Naylor 1992; 
Higgins et al. 1992; Mazzola-Pomietto et aL 1995). Taken together, these 
findings suggest that central 5-HT3 receptor stimulation does not influence 
temporal discrimination. Furthermore, the complete reversal of quipazine's 
effect by ketanserin strongly implicates 5-HT2 receptors in this effect. A 
contribution of 5-HT IB receptors is rendered unlikely by the fact that ketanserin 
has a rather low affinity for 5-HTI receptors compared to its very high affinity 
for 5-HT2 receptors (Leysen et al. 1981; Zgombick et al. 1995). No firm 
statement can be made about the nature of ketanserin's interaction with 
quipazine in the present experiments, since only a single dose of the agonist 
and antagonist were tested. However, there is good evidence that ketanserin is 
a competitive antagonist at 5-HT2 receptors both in the periphery (van Nueten 
et al. 1981) and in the central nervous system (Branchek et al. 1990). Since 
ketanserin has an 80-100 times higher affinity for the 5-HT 2A receptor than for 
the 5-HT2c receptor (Baxter et al. 1995; Barnes and Sharp 1999), it is likely 
that the effect of quipazine is mediated by 5-HT2A receptors (see Body et al. 
2003). Confirmation of this suggestion will require further experiments using 
more selective 5-HT2A and 5-HT2C receptor antagonists. 
In a previous experiment, Body et al. (2002) found that the 5-HT1A 
receptor agonist 8-0H-DPAT also impaired temporal discrimination in the 
discrete-trials psychophysical procedure (Body et al. 2002a). This effect of 8-
OH-DPAT was evidently mediated by a postsynaptic receptor population, since 
the effect survived destruction of the ascending 5-HTergic pathways by intra-
raphe injection of the selective neurotoxin 5,7-dihydroxytryptamine. The 
present findings suggest that 5-HT2A and 5-HTIA receptors mediate 
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qualitatively similar effects on temporal discrimination. Whether or not the two 
receptor subtypes reside on the same population of neurones is a question for 
future research. 
The present results implicate 5-HT2A receptors in quipazine's effect on 
temporal discrimination. 5-HT2A receptors are widely distributed in the brain 
(see Hoyer et al. 2002), including areas, such as the basal ganglia, that are 
thought to playa significant role in the control of timing behaviour (Gibbon et 
al. 1997a; MateH and Meck 2000, 2004). Future experiments employing 
intracerebral injection of agonists may help to elucidate the location of the 
receptor population underlying quipazine's effects on temporal discrimination. 
The increase in T50 produced by quipazine was somewhat greater in the 
first phase of the experiment (from 24.0 to 30.2) than in the tinal phase (from 
23.4 to 25.9). The reason for this difference is not clear. However, the fact that 
significant increases were seen in both phases suggests that it is a qualitatively 
reliable effect. The rightward displacement of the psychometric function seen 
in this experiment stands in contrast to the leftward displacement of the curve 
(reduction of T50) produced by the 5-HT2A12c receptor agonist 001 in a 
previous experiment using the free-operant psychophysical procedure (Body et 
al. 2003). Assuming that quipazine was acting via 5-HT2 receptors in this 
experiment, as argued above, this is a surprising observation that may have 
implications not only for the role of 5-HT in interval timing behaviour but also 
for theoretical models of interval timing. Most current models of interval 
timing assume, either tacitly or explicitly, that a single central timekeeper or 
internal clock is engaged in all forms of timing performance, including both 
temporal discrimination and temporal differentiation (see Zeiler 1998; 
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Grondin 2001; Ho et al. 2002). The notion of a unitary internal clock has 
recently been questioned on psychophysical grounds, in the light of evidence 
for systematic quantitative differences in the precision of timing revealed by 
different types of timing task (Grondin 2001), and some authors have doubted 
the necessity for positing any kind of clock-like mechanism underlying 
animals' timing performance (e.g. Zeiler 1998). Pharmacological evidence may 
also be pertinent to this debate (Ho et al. 2002). The finding of systematic 
qualitative differences between the effects of some psychoactive drugs on 
temporal discrimination and temporal differentiation suggests either that these 
drugs interact with distinct timekeepers that may underlie the two types of 
interval timing behaviour, or that the drugs influence some "non-timing" 
processes that are invoked to differing degrees by the different types of timing 
task. For example, one obvious difference between the free-operant and 
discrete-trials psychophysical procedures is the occurrence of repetitive 
responding in the former schedule but not in the latter. Other differences 
include the possibility of switching from one operandum to the other in the 
free-operant, but not the discrete-trials schedule, and possible differences 
between the rates or probabilities of reinforcement provided by the two types 
of schedules (see Ho et al. 2002). Whatever factors are ultimately found to be 
responsible for the diverse effects of drugs on temporal discrimination and 
temporal differentiation, it is apparent that general conclusions about the 
neurobiological substrate of interval timing cannot be derived from 
examination of the effects of drugs on anyone timing task (see Ho et al. 2002). 
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CHAPTER 3 
Experiment 2: 
EFFECTS OF QUIP AZINE AND 
m-CHLOROPHENYLBIGUANIDE (m-CPBG) 
ON TEMPORAL DIFFERENTIATION 
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3.1. INTRODUCTION 
Experiment 1, described in Chapter 2, examined the effects of quipazine and m-
CPBG on temporal discrimination in the discrete-trials psychophysical procedure 
(Body et al. 2002a). The experiment described in this chapter examined the effects 
of the same drugs on temporal differentiation in the free-operant psychophysical 
procedure (Stubbs 1976; Chiang et al. 1998). 
Temporal differentiation, one of the principal classes of interval timing 
behaviour (see section 1.3), entails the temporal regulation of behaviour during an 
ongoing time interval. It is revealed by immediate timing schedules (Killeen and 
Fetterman 1988; Killeen et al. 1997), such as the free-operant psychophysical 
procedure (Stubbs 1976). In this schedule the subject is presented with two levers, 
one of which (A) provides reinforcement during the first half of a trial, while the 
other (B) provides reinforcement during the second half of a trial. Typical 
performance on this schedule consists of a declining response rate on lever A and 
a concomitantly increasing response rate on lever B as the trial progresses. 
Temporal differentiation is measured quantitatively from the sigmoid 
psychometric curve, which is derived from the proportion of responding directed 
towards lever B (%B) over the course of the trial. This curve is well described by 
the same two parameter logistic function that is used to describe temporal 
discrimination performance (Killeen et al. 1997; Ho et aI2002). 
As reviewed in section 1.5, temporal differentiation in the free-operant 
psychophysical procedure is sensitive to 5-HT1A and 5-HT2Areceptor stimulation. 
The 5-HT lA receptor agonist 8-hydroxy-2-( di-n-propylamino )tetralin (8-0H-
DPAT) disrupts performance on this schedule, displacing the psychometric curve 
to the left and reducing T50, an effect that can be blocked by the selective 5-HTIA 
98 
receptor antagonist N-[2-( 4-[2-methoxyphenyl]-I-piperazinyl)ethyl]-N-2-
pyridinyl-cyclohexanecarboxamide (WAY-I 00635) (Chiang et al. 2000b; Body et 
al. 2002a, 2004). 
Recently Body et al. (2003, 2004) found that the 5-HT2A12C receptor 
agonist, 2,5-dimethoxy-4-iodoamphetamine (DOl), and the 5-HT releasing agent, 
fenfluramine, also reduced T50, effects that could be blocked by the selective 5-
HT 2A receptor antagonist ketanserin but not by WAY -100635 (Body et al. 2003, 
2004). These findings indicate that stimulation of either 5-HT1A or 5-HT2A 
receptors can influence temporal differentiation. 
The aim of the present experiments was to examine whether temporal 
differentiation is sensitive to stimulation of 5-HT 3 receptors. The effects oftwo 5-
HT 3 receptor agonists were examined on temporal differentiation performance; it 
was also examined whether the effects ofthese agonists could be reversed by a 5-
HT3 and/or a 5-HT2A receptor antagonist. The agonists and antagonists used in this 
experiment were the same as those used in Experiment 1. 
3.2. METHOD 
3.2.1. Subjects 
Twenty-four female Wistar rats aged approximately 4 months and weighing 250-
290 g at the start of the experiment, were housed under the same conditions as 
those used in Experiment 1. 
3.2.2. Apparatus 
The rats were trained in standard operant conditioning chambers (Campden 
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Instruments Limited, Sileby, UK) (see Section 2.2.2, for description). 
3.2.3. Behavioural training 
Two weeks before starting the experiment, the food deprivation regimen was 
introduced and the rats were gradually reduced to 80% of their free-feeding body 
weights. Then they were trained to press the lever for the sucrose reinforcer, and 
were exposed a discrete-trials continuous reinforcement schedule, in which the 
two levers were presented in random sequence, for three sessions. The rats then 
underwent 50-minute training sessions in the free-operant psychophysical 
procedure, 7 days a week, at the same time each day during the light phase of the 
daily cycle (between 0800 and 1300 hours), for the remainder of the experiment. 
The reinforcer, a 0.6 M solution of sucrose in distilled water, was prepared daily 
before each session. 
The free-operant psychophysical procedure used was identical to that llsed 
by Chiang et al. (1998, 2000a, 2000b). Each session consisted of fifty 50-s trials, 
successive trials being separated by lO-s intertrial intervals. In 40 ofthe 50 trials, 
reinforcement was provided on a constant-probability variable-interval 30-s 
schedule (Catania and Reynolds 1968). The levers were inserted into the chamber 
at the start of each trial, and were withdrawn during the intertrial interval. During 
the first 25 s of the trial, reinforcers were delivered only for responses on lever A, 
whereas during the last 25 s, reinforcers were delivered only for responses on 
lever B. The positions of lever A and lever B (left versus right) were 
counterbalanced across subjects. Four of the 50 trials in each session were probe 
trials, in which no reinforcers were delivered. The remaining six trials were 
forced-choice trials, in which only one lever was present in the chamber (lever A, 
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three trials; lever B, three trials). The probe and forced-choice trials were 
interspersed randomly among the standard trials, with the constraint that at least 
one standard trial occurred between successive probe or forced-choice trials. In 
the standard and probe trials, switching between the two levers was restricted to 
one switch per trial: in each trial, the first response on lever B resulted 111 
withdrawal of lever A until the start of the next trial (Chiang et al. 1998). 
3.2.4. Drug treatment 
The drug treatment regimen started after 90 sessions of preliminary training under 
the free-operant psychophysical procedure. The drug treatment regimens were the 
same as in Experiment 1 (see Chapter 2). 
Agonists: quipazine dimaleate, 0.5, 1,2 mg kg"; m-chlorophenylbiguanide 
hydrochloride (m-CPBG), 2.5,5, 10 mg kg-I. Both drugs were dissolved in 0.9% 
sodium chloride solution; quipazine was administered subcutaneously 15 min 
before the start of the experimental session, and m-CPBG intraperitoneally 30 min 
before the start of the session. 
Antagonists: topanyI3,5-dichlorobenzoate (MDL-72222), 0.25, 0.5, 1 mg 
kg-' was dissolved in glacial acetic acid, buffered to pH 5.5, and diluted with 0.9% 
sodium chloride to give the desired concentration; it was injected intraperitoneally 
30 min before the start ofthe session. Ketanserin tartrate, 0.5, 1,2 mg kg-' was 
dissolved in 0.9% sodium chloride; it was injected subcutaneously 15 min before 
the start of the session. 
Agonist/antagonist interaction. Quipazine 2 mg kg-' was administered 
alone and in combination with either MDL-72222 1 mg kg-' or ketanserin 2 mg 
kg-I. The same vehicles and times of administration were used as in the agonist-
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alone and antagonist-alone series (see above). 
3.2.5. Data analysis 
Only the data collected from the probe trials were used in the analysis. Separate 
analyses were carried out on the effects of quipazine, m-CPBG, MDL-72222 and 
ketanserin, and the interaction between quipazine, MDL-72222 and ketanserin. 
Relative response rates. The mean response rate on each lever in 
successive time-bins was calculated for each rat under each treatment condition. 
Relative response rate on lever B (%B), defined as the response rate on lever B 
divided by the combined response rate on both levers, was analyzed by a two-
factor analysis of variance (treatment x time-bin) with repeated measures on both 
factors. 
Psychometric/unctions. A two-parameter logistic function was fitted to the 
relative response rate data: %B = 1001(1 +[tIT5o]"), where t is time from trial onset, 
T50 (the indifference point) is a parameter expressing the time at which %B = 
50%, and E is the slope of the function (AI-Zahrani et al. 1996; £ has a negative 
value in the case of ascending sigmoid functions). The curve-fitting procedure 
yields estimates (± SE est) of the values of T50 and the slope, from which the 
Weber fraction was determined as follows. The limen was defined as half the 
difference between T75 and T 25 (T75 and T 25 are the values of t corresponding to 
%B = 75% and %B = 25%), and the Weber fraction was calculated as the ratio of 
the limen to T50. Goodness of fit of the logistic functions was expressed as the 
index of determination, p2. The values of T50, E, and the Weber fraction were 
analyzed by one-factor analyses of variance (treatments) with repeated measures. 
In the case of a significant effect of treatment, comparisons were made between 
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each active treatment and the control (vehicle alone) condition using Dunnett's 
test (significance criterion, P<0.05). In the case of data from the quipazine-
ketanserinlMDL-72222 interaction, multiple comparisons were made between 
treatment with quipazine alone and the combined quipazine + antagonist 
treatments, using Neuman-Keul's test (significance criterion, P<0.05). 
Overall response rates. Overall response rate was calculated for each rat 
under each treatment condition. For each series of treatments, the data were 
analyzed using a one-factor analysis of variance (treatment), with repeated 
measures, followed by post-hoc analyses as described above. 
Switching. The probability of a switch occurring in each S-s epoch of the 
probe trials was calculated for each rat. Logistic functions (see above) were fitted 
to the cumulative probability distributions, and the inflection point, S50, was used 
as a measure of mean switching time (Body et al. 2003). The values of S50 were 
subjected to one-factor analyses of variance, as described above. 
3.3. RESULTS 
Under each treatment condition, response rate on lever A declined and response 
rate on lever B increased as a function of time from trial onset, the proportion of 
responding allocated to lever B (%B) increasing progressively as a function of 
time from trial onset. 
3.3.1. Effects of the agonists 
Quipazine. The effect of quipazine on relative response rate is shown in 
Fig. 3 .1.A. Analysis of variance of these data revealed significant main effects of 
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Figure 3.1 A. Effect of quipazine on relative response rate on lever B in the free-
operant psychophysical procedure. Ordinate: percent responding on lever B (%8); 
abscissa: time from trial onset (s). Points indicate group mean data under each 
treatment condition (see inset). B. Effect of quipazine on probability of switching 
from lever A to lever B. Ordinate: cumulative probability of switching; abscissa: 
time from trial onset (s). 
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treatment [F(3,69) = 7.4, P<O.OOI] and time-bin [F(9,207) = 727.5, P<O.OO 1], and 
a significant treatment x time-bin interaction [F(27,62 I) = 6.8, P<O.OOI]. 
Logistic functions were fitted to the data from each rat under each 
treatment condition; the group mean values of parameters of these functions (± 
SEM) are shown in Table 3.1. Quipazine dose-dependently displaced the 
psychometric function to the left, reducing the value of T50; analysis of variance 
showed a significant effect of treatment [F(3,69) = 9.9, P<O.OOI], and multiple 
comparisons with the vehicle-alone condition indicated that quipazine 1 and 2 mg 
kg-1 significantly reduced T50. Quipazine also produced some flattening of the 
psychometric function, this being reflected in a significant effect on the slope of 
the function, E [F(3,69) = 5.0, P<O.OI], the effect of2 mg kg-I being statistically 
significant. The Weber fraction was increased by quipazine [F(3,69) = 6.9, 
P<O.OOI], the effect of2 mg kg-1 being significant. 
The effect of quipazine on the cumulative probability of switching is 
shown in Fig.3.1 B. Logistic functions were fitted to the data from each rat; group 
mean values of the inflection point, S50 (± SEM) are shown in Table 3.1. 
Quipazine reduced S50 [F(3,69) = 7.7, P<O.OOI], indicating a reduction of the 
mean time of switching from lever A to lever B; the effects of 1 and 2 mg kg-1 
were statistically significant. 
Quipazine significantly reduced overall response rate (see Table 3.1) 
[F(3,69) = 50.0, P<O.OOI], the effects of all three doses being statistically 
significant. 
m-CPBG. The relative response rate data are shown in Fig. 3.2A. Analysis 
of variance showed a significant main effect of time-bin F(9,207) = 670.8, 
P<O.OOI], but no significant main effect of treatment [F(3,69) = 2.6, P>0.05] and 
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Table 3.1. Effects ofthe agonists on measures of performance on the free-operant psychophysical procedure: group mean values (± SEM) 
Relative response rate function Cumulative switching function Overall response 
p2 p2 
rate, 
Treatment T50, s slope, c Weber fraction S50, s 
responses min"! 
Vehicle 17.8 ±0.8 -4.7 ±OJ 0.99 ±O.OO 0.26 ±0.01 14.9 ±0.6 0.98 ±O.OO 69.8 ± 9.0 
quipazine 0.5 mg kg"! 17.6±0.7 -4.8 ±0.3 0.99 ±O.OO 0.25 ±0.01 14.7 ±0.7 0.98 ±O.OO 61.3 ± 9.7 * 
quipazine 1 mg kg"! 15.8 ± 0.7 * -4.3 ±0.3 0.99 ±O.OO 0.29 ±0.02 12.7 ±0.8 * 0.97 ±0.01 49.8 ± 10.2 * 
....... 
0 quipazine 2 mg kg"! 14.8 ± 0.8 * -3.7 ±0.3 * 0.98 ±O.OO 0.35 ±0.03 * 12.1 ±0.6* 0.97 ±O.OO 41.0 ± 8.2 * 0\ 
Vehicle 21.3 ±0.7 -5.5 ±0.3 0.99 ±O.OO 0.22 ±0.02 17.9 ±0.8 0.98 ±0.01 61.5 ±2.1 
m-CPBG 2.5 mg kg"' 21.4 ±0.8 -6.6 ±0.5 0.99 ±O.OO 0.19 ±0.01 18J ±0.9 0.98 ±O.OO 62.5 ± 1.8 
m-CPBG 5 mg kg"! 22.6 ± 0.8 -6.2 ±0.4 0.98 ±O.OO 0.20 ±0.01 19.5 ±0.8 0.98 ±O.OO 63.1 ±2.7 
m-CPBG 10 mg kg"' 21.8±1.0 -6.4 ±0.6 0.98 ±0.01 0.21 ±0.02 18.2 ±0.9 0.96 ±O.Ol 59.4 ± 2.1 * 
Significant difference from vehicle condition, * P < 0.05 (see text for details) 
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Figure 3.2 A. Effect ofm-CPBG on relative response rate on lever B. B. E1fect of 
m-CPBG on probability of switching. Conventions as in Fig. 3.1. 
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no significant interaction [F(27,621) = 1.2, P>O.OS]. 
Parameters ofthe logistic functions are shown in Table 3.1. m-CPBC; lJad 
no significant effect on the values ofT50 [F(3,69) = 2.2, P>O.OS], £ [F(3,69) = 2.5, 
P>O.OS] or the Weber fraction [F(3,69) = 2.2, P>O.OS]. 
Cumulative probability of switching is shown in Fig. 3.2B. The value of 
S50 was not significantly affected by m-CPBG [F(3,69) = 2.1, P>O.OS] Cfable 1). 
Overall response rate was reduced by m-CPBG [F(3,69) = 3.0, P (J.051. 
the effect of 10 mg kg-1 being statistically significant (Table 3.1). 
3.3.2. Effects of the antagonists 
MDL-72222. The relative response rate data are shown in Fig.3.3!\. 
Analysis of variance showed a significant main effect of time-bin [F(9,207) ."-
678.1, P<O.OO 1], but no significant main effect of treatment [F< 1], and no 
significant interaction [F(27,621) =1.0, P>O.OS]. 
Parameters of the logistic functions are shown in Table 3.2. MDL-72222 
had no significant effect on the values of T50 [F<I], £ [F(3,69) = 1.4, P>O.OS] or 
the Weber fraction [F(3,69) = 1.3, P>O.OS]. 
Cumulative probability of switching is shown in Fig. 3.3B. The value of 
S50 was not significantly affected by MDL-72222 [F<I] (Table 3.2). 
Overall response rate was increased by MDL-72222 [F(3,69) = 6.5, 
P<O.OS], the effect of 0.5 mg kg-1 being statistically significant (see Table 3.2). 
Ketanserin. The relative response rate data are shown in Fig. 3.4A. 
Analysis of variance showed a significant main effect of time-bin [F(9,207) = 
524.5, P<O.OOI]. The main effect of treatment was significant [F(3,69) = 6.S, 
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Table 3.2. Effects of the antagonists on measures of performance on free-operant psychophysical procedure: group means (± SEM) 
Relative response rate function Cumulative switching function 
Treatment T50, s slope, I:: p2 Weber S50, s p2 Overall response 
fraction rate, reseonses min-I 
Vehicle 20.8 ±0.8 -5.5 ±0.3 0.99 ±O.OO 0.22 ± 0.01 18.0 ± 0.7 0.99 ± 0.00 66.2 ± 3.1 
MDL-72222 0.25 mg kg-I 21.0 ±0.8 -6.3 ±0.6 0.99 ±O.OO 0.20 ± 0.02 18.1 ± 0.6 0.98 ± 0.00 68.1 ± 2.9 
MDL-72222 0.5 mg ki l 20.6 ±0.7 -6.0 ±OA 0.99 ±O.OO 0.20 ± 0.01 17.8 ± 0.7 0.98 ± 0.01 72.8 ± 3.3 * 
...... 
...... 
...... 
MDL-72222 1 mgkg-I 20.7 ±0.8 -6.3 ±0.4 0.99 ± 0.00 0.20 ± 0.01 17.9 ± 0.9 0.98 ± 0.00 67.1 ± 3.0 
Vehicle 21.5 ±0.9 -5.3 ±0.3 0.99 ±O.OO 0.23 ± 0.02 18.1 ± 0.9 0.98 ± 0.00 57.9 ± 1.8 
ketanserin 0.5 mg kg-I 22.1 ± 1.0 -5.4 ±0.5 0.97 ± 0.00 0.24 ± 0.02 18.6 ±0.9 0.97 ± 0.00 60.0 ± 1.5 
ketanserin 1 mg kg-I 23.6 ± 1.0 * -5.5 ±0.6 0.98 ± 0.00 0.26 ± 0.03 19.5 ± 0.9 0.97 ± 0.00 62.4 ± 1.9 
ketanserin 2 mg kg-I 21.9 ±0.9 -5.1 ±0.4 0.98 ± 0.01 0.26 ± 0.02 19.0 ± 0.7 0.97 ± 0.01 65.7 ± 1.7 * 
Significant difference from vehicle condition, * P < 0.05 (see text for details) 
P<O.OI], but not the interaction [F(27,62 I) =1.4, P>0.05]. 
Parameters of the logistic functions are shown in Table 3.2. Ketanserin 
produced a small rightward displacement of the psychometric function, reflected in 
an increase in T5o. Analysis of variance showed a significant effect of treatment on 
T50 [F(3,69) = 4.8, P<O.Ol], the 1 mg kg-! dose producing a significant increase. 
Ketanserin did not significantly affect the value of £ [F(3,69) = 1.4, P>0.05] or the 
Weber fraction [F<l]. 
Cumulative probability of switching is shown in Fig. 3.4B. The value of S50 
was not significantly affected by ketanserin [F(3,69) = 1.7, P>0.05] (Table 3.2). 
Overall response rate was increased by ketanserin [F(3,69) = 3.3, P<0.05], the effect 
of2 mg kg-! being statistically significant (see Table 3.2). 
3.3.3. Agonist antagonist interaction 
The relative response rate data are shown in Fig. 3 .5A. Analysis of variance revealed 
significant main effects of time-bin [F(9 ,207) = 765.1, P<O. 00 I] and treatment 
[F(3,69) = 32.2, P<O.OOI], and a significant treatment x time-bin interaction 
[F(27,621) = 18.9, P<O.OOI]. Quipazine displaced the psychometric function to the 
left compared to the function derived for the vehicle treatment. MDL-72222 did not 
appear to reverse this effect of quipazine, as the locus of the curve derived for the 
quipazine + MDL-72222 treatment was clo.se to the curve derived for quipazine 
alone. However, ketanserin reversed the effect of quipazine, the curve derived for 
quipazine + ketanserin resulted lying to the right of that derived for the vehicle alone 
condition. 
The parameters of the logistic functions are shown in Table 3.3. There was a 
significant effect of treatment on T50 [F(3,69) = 43.3, P<O.OOI]. Multiple 
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Figure 3.5. Interaction between quipazine (QUIP), MDL-7222 (MDL) and 
ketanserin (KET) on performance on the free-operant psychophysical procedure. A. 
Relative response rate; B. Probability of switching. Conventions as in Fig. 1. In hoth 
graphs, the psychometric function is displaced to the left by quipazine; this efkct is 
reversed by co-administration ofketanserin, but not by co-administration or MDL-
72222. 
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Table 3.3 Interaction between quipazine and the antagonists on performance on free-operant psychophysical procedure: group mean values (± SEM) 
Treatment 
Vehicle 
quipazine 2 mg kg-I 
quipazine 2 mg kg- l + 
MDL-72222 1 mg kg- l 
quipazine 2 mg kg-I + 
ketanserin 2 mg kg- l 
T50, s 
20.8 ±0.7 
17.0 ±0.8 * 
15.6 ±0.8 * 
24.2 ±1.1 *# 
Relative response rate function 
slope, € p2 
-5.7 ± 0.3 0.99 ± 0.00 
-4.3 ± 0.3 * 0.98 ± 0.01 
-4.0 ± 0.3 * 0.98 ± 0.00 
-6.4 ± 0.3 # 0.99 ± 0.00 
Cumulative switching function 
Overall response rate, 
Weber fraction S50, s p2 (responses min-I) 
0.21 ± 0.01 17.6 ± 0.6 0.98 ± 0.00 62.9 ± 2.6 
0.29 ± 0.02 * 13.4 ± 0.8 * 0.98 ± 0.00 40.1 ± 3.4 * 
0.33 ± 0.03 * 13.1 ± 0.8 * 0.97 ± 0.01 37.8 ± 3.1 * 
0.19 ± 0.01 # 20.7 ± 0.9 # 0.98 ± 0.01 68.6 ± 3.0 # 
Significant difference from vehicle condition, * P < 0.05; significant difference from quipazine 2 mg kg-! condition, # P < 0.05 (see text for details) 
comparisons with the vehicle condition (Dunnett's test) showed that T50 was 
significantly reduced by quipazine and by quipazine + MDL-72222 (reflecting 
leftward displacement of the curve), and significantly increased by quipazine + 
ketanserin (reflecting rightward displacement of the curve). Multiple comparisons 
with the quipazine condition (Newman-Keuls test) showed that the reduction in 
T50 produced by quipazine was significantly reversed by combined treatment with 
ketanserin but not by combined treatment with MDL-72222. 
There was a significant effect oftreatment on £ [F(3,69) = 17.7, P<O.OOlj. 
Multiple comparisons with the vehicle alone condition showed that the value ort 
was increased both by quipazine and by quipazine + MDL-72222 (reflecting 
flattening of the psychometric curve). 
There was a significant effect of treatment on the Weber fraction [F(3,69) 
= 16.2, P<O.OO I]. Multiple comparisons with the vehicle alone condition showed 
that quipazine and quipazine + MDL-72222 increased the Weber fraction. 
Multiple comparisons with the quipazine condition showed that the increase in the 
Weber fraction produced by quipazine was significantly reversed by ketanserin 
but not by MDL-72222. 
There was a significant effect of treatment on overall response rate 
[F(3,69) = 46.3, P<O.OOI]. Quipazine and quipazine + MDL-72222 significantly 
reduced overall response rate compared to the vehicle alone condition. Ketanserin, 
but not MDL-72222, significantly attenuated the reduction in response rate 
produced by quipazine. 
The effect of quipazine on the cumulative probability of switching is 
shown in Fig. 3 .5B. Logistic functions were fitted to the data from each rat; group 
mean values of S 50 (± SEM) are shown in Table 3.3. There was a significant effect 
of treatment on S50 [F(3,69) = 47.7, P<O.OOI]. Both quipazine and quipazine + 
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MDL-72222 significantly reduced S50, indicating a reduction of the mean time of 
switching from lever A to lever B, whereas quipazine + ketanserin increased S 50, 
compared to the vehicle alone condition. The effect of quipazine was significantly 
reversed by ketanserin but not by MDL-72222. 
3.4. DISCUSSION 
In accordance with previous findings with the free-operant psychophysical 
procedure (Stubbs 1976; Bizo and White 1994, Chiang et al. 1998, 2000a, 2000b; 
Machado and Guilhardi 2000, Body et aI, 2002, 2003, 2004), response rate on 
lever A declined, and response rate on lever B increased, during the course of the 
trial, this being reflected in an increasing percentage of total responding devoted 
to lever B (%B) as the trial progressed. The values of T50 and the Weber fraction 
derived from the relative response rate function (%B vs t), and the mean switching 
time, S50, estimated using the cumulative probability of switching in successive 
epochs of the probe trials, were similar to those reported previously for rats 
responding under this schedule (Chiang et al. 1999, 2000a, 2000b; Body et al. 
2002,2003,2004). Comparison of the control (vehicle-alone treatment) values of 
T50 obtained in the different phases of the experiment indicates that the value 
obtained during the initial assessment of quipazine was somewhat lower than the 
values seen in subsequent phases. This suggests that performance may not have 
fully stabilized when the first treatment series was initiated, despite the extensive 
preliminary training that the rats had received (90 daily training sessions). This 
does not seem to have had a major impact on the results of the experiment, as 
indicated by the comparable effects of quipazine in the first and last phase of the 
experiment (see below). Nevertheless, a longer period of preliminary training 
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would be desirable in future experiments. 
Quipazine (0.5-2.0 mg kg-I) produced a dose-dependent leftward 
displacement of the psychometric functions, reflected in significant reductions of 
the values of T50 and S50. This effect indicates a facilitation of 'premature' 
switching from the lever associated with reinforcement during the first half ofthe 
trial to the lever associated with reinforcement during the latter half of the trial. 
The behavioural processes underlying this effect remain uncertain. One possible 
theoretical interpretation is that quipazine may have altered the functioning ofthe 
hypothetical internal clock that is purported to underlie interval timing behaviour 
(Gibbon et al. 1997; Hinton and Meck 1997). However it is important to note that 
this effect was not seen in the case of another timing schedule, the discrete-trials 
psychophysical procedure (Experiment 1: see Chapter 2). Therefore the results are 
not consistent with an interaction with a 'unitary' internal clock that, according to 
SET, underlies all types of interval timing performance (see Section 1.4). 
Although the most conspicuous effect of quipazine was on the locus of the 
psychometric function, the highest dose of quipazine used in these experiments 
also produced some flattening of the function, and a consequent increase of the 
Weber fraction, suggesting that this dose of quipazine had a deleterious effect on 
the precision of temporal differentiation (see Gibbon et al. 1997; Killeen et al. 
1997). 
The selective 5-HT3 receptor agonist m-CPBG (Kilpatrick et al. 1990; 
Dukat et al. 1996) had no significant effect on temporal differentiation. As 
discussed in Chapter 2 (section 2.4), it is unlikely that this reflects the use of an 
inadequate dose of m-CPBG, since the dose range used in this experiment has 
been found to be active in other behavioural paradigms. In doses similar to those 
used here, m-CPBG has been found to be active in behavioural tests of anxiety, 
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showing an 'anxiogenic' profile in the elevated plus maze test (Andrews and File 
1992), and reversing the effect of the 5-HT3 receptor antagonists ICS 205-930 
(Nakagawa et al. 1998) and ondansetron (Eguchi et al. 2001) in other anxiety 
models. In the same dose range, m-CPBG fully substitutes for other 5-HT3 
receptor agonists in drug discrimination tests (Dukat et al. 2000). m-CPBG (1 and 
10 mg kg-I) has been found to disrupt the acquisition of conditioned responses in 
an autoshaping paradigm, an effect that was completely reversed by co-
administration of the 5-HT3 receptor antagonists ondansetron and tropisetron 
(Hong and Meneses 1996). Finally, m-CPBG also produces conditioned place and 
taste aversion; however, this effect may be mediated, at least in part, by peripheral 
(gastrointestinal) effects of the drug (Higgins et al. 1993). 
The lack of effect of m-CPBG stands in contrast to the robust effect or 
quipazine. Quipazine has a very high affinity for 5-HT3 receptors (Kd = 2 nM: 
Glennon et al. 1989; Sharif et al. 1991), and somewhat lower affinity (micromolar 
range) for several other subtypes of 5-HT receptor, including 5-HT 1B, 5-HTzA and 
5-HTzc receptors (Hoyer 1988). The effect of quipazine on temporal 
differentiation was not altered by co-administration of MDL-72222, but was 
completely abolished by co-administration of ketanserin. MDL-72222 is a 
selective 5-HT3 receptor antagonist (Fozard 1984); the doses used in this 
experiment have been shown to be behaviourally active in a variety of tests that 
are thought to reflect 5-HT3 receptor function (Costall and Naylor 1992; Higgins 
et al. 1992; Mazzola-Pomietto et al. 1995). Taken together, these findings suggest 
that central5-HT 3 receptor stimulation does not influence temporal differentiation 
in the rat. Furthermore, the complete reversal of quipazine's effect on T50 and S50 
by ketanserin strongly implicates 5-HTz receptors in this effect. Since ketanserin 
has an 80-100 times higher affinity for the 5-HTzA receptor than for the 5-HT2C 
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receptor (Baxter et al. 1995; Barnes and Sharp 1999), it is likely that this effects of 
quipazine is mediated by 5-HT2A receptors (see Body et al. 2003). In this context 
it may be noted that the dose ofketanserin that antagonized quipazine's effect in 
this experiment has previously been shown to antagonize the reduction of T50 and 
S50 induced by the 5-HT2N2C receptor agonist DOl (Body et al. 2003, 2004) and 
the 5-HT releasing agent fenfluramine (Body et al. 2004). 
The effect of quipazine on temporal differentiation thus appears to be 
mediated not by 5-HT3 receptors but by 5-HT2A receptors. In this respect, the 
P!esent results (like the results of Experiment 1) are consistent with findings with 
other behavioural paradigms. Although quipazine has been found to behave like 
other 5-HT3 receptor agonists, including m-CPBG, in some tests (Dukat et al. 
2000), many of its behavioural effects, including the induction of head twitching 
(Sanchez and Amt 2000) and lordosis (Wolf et al. 1998), and the enhancement of 
progressive ratio schedule performance (Wolff and Leander 2000), are believed to 
be mediated by 5-HT 2 receptors. In drug discrimination studies, quipazine can 
substitute for both 5-HT3 (Dukat et al. 2000) and 5-HT2A (Wolff and Leander 
2000; Smith et al. 2002) receptor agonists. 
Quipazine produced a significant reduction of the overall rate of 
responding, which was reversed by co-administration of ketanserin, suggesting 
that this effect, like the reduction of T50, was mediated by 5-HT 2A receptors. It is 
very unlikely, however, that the change in T50 was a direct consequence of the 
change in response rate. Since T50 is derived from relative response rate data (the 
percentage of overall responding devoted to lever B), it should be impervious to 
changes in absolute response rate (Chiang et aI, 2000a; Odum et aI, 2002). 
Moreover, the other index ofthe indifference point, the mean switching time S5(), 
which is not calculated from response rates, was affected by quipazine in the same 
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manner as T5o. It may also be noted that previous experiments have riiled to 
identify consistent correlations between changes in T50 and changcs'l; '0rall 
response rate, either within or between drug conditions (Body et ql\W4). 
Whether the effects ofDOr and quipazine on temporal differentiation and ',,, erall 
response rate are mediated by different populations of 5-HT2A recepiJ: r ; is a 
question for future experiments. 
Taken together, the present findings that a selective 5-HC " ' ~ p t o r r
agonist, m-CPBG, was without effect, and that the effect of a mix(:(' ' IT 2IJ 
receptor agonist, quipazine, was fully attributable to its action at 5-HT 21\ n' lors, 
suggest that while 5-HT 2A receptor stimulation has a robust influence OIJ :, oral 
differentiation, 5-HT3 receptor stimulation does not. This conclusion m. 'ave 
implications for current conceptions ofthe role of5-HT/dopamine inter:):; ill 
interval timing behaviour. It is widely believed that dopaminergic transm; " 1 ill 
the basal ganglia plays a pivotal role in the regulation of interval timit! ,'ck 
1986, 1996; Gibbon et al. 1997; Matell and Meck 2000; see Section 1.5.1 're 
is good evidence that 5-HT3 receptors contribute to the regulation of ,\tr, :lC 
release (Blandina et al. 1989; Carboni et al. 1989; Zazpe et al. 1994; Cel d. 
1996). It might therefore be expected that 5-HT 3 receptor stimulation W'" ,-T 
timing performance, an expectation that found no support in the 'It 
experiments. The explanation for the apparent discrepancy may lie in l d 
differences in the nature of 5-HT/dopamine interactions. There is evidence .1, 
influence of 5-HT 3 receptors on dopamine release is mainly confined to sin .i 
innervated by the mesolimbic/mesocorticaI dopaminergic projection (incl Ut l; I '. 
ventral striatum/nucleus accumbens), rather than the dorsal striatum 
receives its input from the nigrostriatal pathway (Wang et al. 
DeDeurwaerdere et al. 1998; Porras et aI. 2003). The failure of 5-HT3 · 
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stimulation to affect temporal differentiation may therefore reflect a primary 
involvement of the dorsal rather than the ventral striatal dopaminergic 
mechanisms in this behaviour (Hinton and Meck 1997; Matell and Meck 2000). 
The location of the 5-HT2 receptors that apparently mediate not only 
quipazine's effects on temporal differentiation, but also those of DOl (Body et al. 
2003, 2004) and fenfluramine (Body et al. 2004) remains uncertain. There is 
evidence for a facilitatory role of striatal 5-HT2A and 5-HT2C receptors on 
dopamine release in this structure (DiGiovanni et al. 1999; Lucas and Spampinato 
2000). Further experiments using intra-striatal injection of selective 5-HT 2A and 5-
HT2c receptor agonists may help to establish whether these receptor populations 
are responsible for the disruption of temporal differentiation induced by 5- HT2 
receptor agonists. 
Finally, it should be noted that, while pharmacological stimulation of 5-
HT 2A receptors has been found to exert consistent effects on temporal 
differentiation (Body et al. 2003, 2004; present results), it is unlikely that 
endogenous stimulation of this receptor population makes a major contribution to 
temporal differentiation under normal conditions. If this were the case, blockade 
of 5-HT2A receptors would be expected to produce a rightward displacement of 
the psychometric function (i.e. the opposite effect to that produced by 5-HT2A 
receptor agonists: Body et al. 2003, 2004). Although there is some indication that 
this occurred in the present experiment (see, especially, Figure 3.5), the results of 
previous experiments indicate that this is not a reliable effect of ketanserin (see 
Body et al. 2003, 2004). It should also be emphasized that even after complete 
destruction of the ascending 5-HTergic pathways, rats are still able to execute 
accurate temporal differentiation performance on the free-operant psychophysical 
procedure (Chiang et al. 1999; Body et al. 2002, 2004). 
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CHAPTER 4 
Experiment 3: 
EFFECTS OF 2,5-DIMETHOXY-4-
IODOAMPHETAMINE (DOl) ON TEMPORAL 
DISCRIMINATION 
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4.1. INTRODUCTION 
As reviewed in Chapter 2, two major types oftiming schedule are immediate and 
retrospective timing schedules (Killeen and Fetterman, 1988; Killeen et al. 1997). 
Immediate timing schedules require the organism to regulate its own behaviour in 
time (temporal differentiation), whereas retrospective timing tasks entail 
discrimination of the durations of exteroceptive stimuli (temporal discrimination). 
Examples of the two types of timing are free-operant and discrete-trials 
psychophysical procedures (Stubbs 1976; Body et al. 2002) (for a full description 
see Section 1.2.1.). 
In a recent series of experiments, Body et al. (3003, 2004) obtained 
evidence that 5-HT2 receptor stimulation disrupts temporal differentiation in the 
free-operant psychophysical procedure. The 5-HT2N2C receptor agonist 2,5-
dimethoxy-4-iodoamphetamine (DOl) dose-dependently reduced T50 in this 
schedule (Body et al. 2003,2004). This effect of DOl was mimicked by the 5-HT 
releasing agent fenfluramine, the effects of both drugs being abolished by the 5-
HT2A receptor antagonist ketanserin (Body et al. 2004). 
The experiment described in Chapter 3 of this thesis (Experiment 2) 
extended these observations. It was found that quipazine, a non-selective 5-HT 
receptor agonist with high affinity for both 5-HT3 and 5-HT2A receptors, also 
reduced T50 in the free-operant psychophysical procedure, an effect that was 
antagonized by ketanserin, but not by the selective 5-HT3 receptor antagonist 
topanyl 3,5-dichlorobenzoate (MDL-72222), implicating 5-HT2A rather than 5-
HT 3 receptors in this effect. 
Experiment 1, described in Chapter 2, showed that quipazine also affected 
temporal discrimination in the discrete-trial psychophysical procedure. However, 
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instead of reducing T50 , as it did in the free-operant psychophysical procedure, 
quipazine flattened the psychometric function in the discrete-trials psychophysical 
schedule, increasing the Weber fraction; it also displaced the function to the right, 
increasing T5o. These effects of quipazine were reversed by ketanserin, suggest 
that they were mediated by 5-HT2A receptors. The experiment described in this 
chapter was carried out in order to obtain further information on the effect of 5-
HT2A receptor stimulation on temporal discrimination. The aims of the experiment 
were firstly to examine the effect of DOl on performance on the discrete-trials 
psychophysical procedure, and secondly to examine the sensitivity of DOl' s effect 
to ketanserin and the highly selective 5-HT2A receptor antagonist (±)2J-
dimethoxyphenyl-l-(2-( 4-piperidine )-methanol) (MDL-l 00907) (see Barnes and 
Sharp 1999; Hoyer et al. 2002; Leysen 2004). 
4.2. METHODS 
4.2.1. Subjects 
Twenty female Wistar rats, aged approximately 4 months and weighing 250-290 g 
at the start of the experiment, where housed under the same conditions as those 
used in Experiment 1. 
4.2.2. Apparatus 
The rats were trained in operant conditioning chambers (Campden Instruments 
Limited, Sileby, UK), similar to those used in Experiment 1 (see Section 2.2.2., 
for description). The only difference between the chambers used in Experiment 1 
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and those used in the present experiment was that in the present ex periment the 
reinforcer delivering device consisted of a motor-operated pellet dispenser which 
delivered 4S-mg food pellets. 
4.2.3. Behavioural training 
At the start of the experiment, the food-deprivation regimen was started and the 
rats were gradually reduced to 80% of their free-feeding body weights. They were 
then trained to press the levers, and were exposed to a discrete-trials continuous 
reinforcement schedule, in which the two levers were presented in random 
sequence, for three sessions. Thereafter, the rats underwent SO-minute training 
sessions under the discrete-trials psychophysical procedure identical to that 
described earlier (see Section 2.2.3.). 
4.2.4. Drug treatment 
The drug treatment regimen started after 90 sessions of preliminary training under 
the discrete-trials psychophysical procedure. Injections of drugs were given on 
Tuesdays and Fridays, and injections of the vehicle alone (0.9% sodium chloride 
solution) on Mondays and Thursdays; no injections were given on Wednesdays, 
Saturdays or Sundays. Each dose of each drug was administered five times, in 
order to accrue a sufficient number of trials for function fitting (see below). The 
order of treatments within each series was balanced within and between animals 
according to a Latin square. Subcutaneous injections were given using a 26-gauge 
needle at a volume of 1.0 ml kg-I; intraperitoneal injections were given using a 2S-
gauge needle at a volume of 2.S ml kg-I. The doses of the drugs tested were as 
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follows: 2,5,-dimethoxy-4-iodoamphetamine (DOl), 0.0625, 0.125, 0.25 mg kg-1 
(s.c.); ketanserin 2 mg kg-1 (s.c.); (±)2,3-dimethoxyphenyl-l-(2-(4-piperidine)-
methanol) (MDL-100907), 0.5, 1 mg kg-1 (i.p.). 001 and ketanserin were 
dissolved in 0.9% sodium chloride solution. MDL 100907 was dissolved in glacial 
acetic acid and sterile water, buffered to pH 5.5 and diluted to volume with 0.9% 
sodium chloride solution. DO I and ketanserin were administered 15 minutes, and 
MDL-I00907 25 minutes before the experimental session. 
4.2.5. Data analysis 
Separate analyses were carried out on the each treatment series (see below). 
For each treatment, the percentages of responses emitted on lever B (%B) 
at each time-point were analysed by two-factor analyses of variance (treatment x 
time) with repeated measures on both factors. In the event of a significant main 
effect of treatment or a significant treatment x time interaction, analyses of the 
simple main effect at each time-point were carried out, followed by comparisons 
between each active treatment with the control (vehicle-alone) condition using 
Dunnett's test. In the case of data from the drug interaction studies, mUltiple 
comparisons were made between treatment with DOl alone and the combined 001 
+ antagonist treatments, using Neuman-Keul's test. 
Quantitative analysis of the psychometric functions was identical to that 
carried out in Experiment 1 (see Section 2.2.5.) 
4.3. RESULTS 
Under each treatment condition, the proportion of responding allocated to lever B 
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(%B) increased progressively as a function of stimulus duration, t. Under the 
vehicle-alone condition and all active treatment conditions, the number of 
'missed' trials (i.e. trials in which no response was emitted on either lever A or 
lever B) was <0.5%. 
4.3.1. Effect of DOl 
The effect of DOl (0.0625,0.125,0.25 mg kg-I) on proportional choice oflever B 
(%B) is shown in Figure 4.1. Analysis of variance revealed that the main effect of 
treatment was not statistically significant [F(3,57) = 2.6, P=0.06]. The main effect 
of time was significant [F(9,171) = 551.0, P<O.OOI], and there was a significant 
treatment x time interaction [F(27,513) = 2.9, P<O.OOI]. Analysis of the simple 
main effects revealed significant treatment effects 12.5 s after trial onset, and at all 
time points >25 s after trial onset. Multiple comparisons with vehicle showed that 
DOl 0.25 mg kg-1 produced a significant increase in %B 12.5 s after trial onset and 
significant decreases 32.5, 37.5,42.5 and 47.5 s after trial onset. 
Logistic functions were fitted to the data from each rat under each 
treatment condition; the group mean values of parameters of these functions (1-
SEM) are shown in Table 4.1. DOl flattened the psychometric function and tended 
to displace it rightwards; these effects are reflected in the parameter values. There 
was an apparent dose-dependent increase in the value of T50; however, analysis of 
variance did not reveal a significant effect of treatment [F(3,57) = 1.7, N.S.]. 
There was a significant effect on the slope, E [F(3,57) = 12.4, P<O.OOI], the 
increase in E produced by DOl 0.125 and 0.25 mg kg-1 being statistically 
significant. The Weber fraction was increased by DOl [F(3,57) = 10.4, P<O.OOI], 
the effect of 0.25 mg kg-1 being significant. 
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Figure 4.1. Effect of DOl (0.0625, 0.125, 0.25 mg kg-I) on relationship between 
proportional choice of lever B (%B) and stimulus duration (t, seconds) in the 
discrete-trials psychophysical procedure. Points indicate group mean data under 
each treatment condition (see inset). Significance of difference from vehicle-alone 
treatment: * P < 0.05. 
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Table 4.1. Effects of the DOl on measures of performance on the discrete-trials psychophysical 
procedure: group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment Tso, s slope, c p2 Weber fraction 
Vehicle 25.2 ± 0.6 -3.4 ± 0.1 0.98 ± 0.01 0.34 ± 0.02 
DOl 0.0625 mg kg- l 25.4 ± 0.7 -3.3 ± 0.2 0.93 ± 0.01 0.37 ± 0.03 
DOl 0.125 mgkt l 27.0 ± 1.3 -3.0 ± 0.2 * 0.93 ± 0.02 0.40 ± 0.02 
DOl 0.25 mg kg- l 28.1 ± 2.0 -2.5 ± 0.2 * 0.89 ± 0.02 0.53 ± 0.05 * 
* Significantly different from vehicle condition, P < 0.05 (see text for details) 
4.3.2. Interaction between DOl and ketanserin 
The %B data are shown in Figure 4.2. Analysis of variance revealed significant 
main effects of treatment [F(3,57) = 5.1, P<O.OI] and time [F(9,171) = 579.8, 
P<O.OOI], and a significant treatment x time interaction [F(27,513) = 4.03, 
P<O.OOI]. Analysis of the simple main effects revealed significant treatment 
effects 7.5 s after trial onset, and at all time points 2:32.5 s after trial onset. 
Multiple comparisons with the vehicle-alone condition showed that DOl produced 
a significant increase in %B 7.5 s after trial onset and significant decreases in %B 
32.5,37.5,42.5 and 47.5 s after trial onset. In no case did 001 + ketanserin differ 
significantly from vehicle-alone treatment, and in every case 001 + ketanserin 
differed significantly from the DOl-alone treatment conditions. 
The parameters ofthe logistic functions are shown in Table 4.2. There was 
a significant effect of treatment on T50 [F(3,57) = 3.8, P<0.02]. Multiple 
comparisons with the vehicle condition showed that T50 was significantly 
increased by DOl, but not significantly changed by ketanserin or 001 + 
ketanserin. Multiple comparisons with the DOl condition showed that the increase 
in T50 produced by DOl was significantly reversed by combined treatment with 
ketanserin. 
There was a significant effect of treatment on £ [F(3,57) = 11.5,P<0.001]. 
Multiple comparisons with the vehicle alone condition showed that the value of t: 
was increased by DOl, but not by ketanserin or by DOl + ketanserin. Multiple 
comparisons with the DOl condition showed that DOl's effect on the parameter 
was reversed by ketanserin. 
There was a significant effect of treatment on the Weber fraction [F(3,57) 
= 9.6, P<O.OOI]. Multiple comparisons with the vehicle alone condition showed 
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Figure 4.2. Interaction between ketanserin (2 mg kg-I) and DOl (0.25 mg kg-I) on 
relationship between proportional choice of lever B and stimulus duration in the 
discrete-trials psychophysical procedure. Conventions as in Fig. 4.1. 
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Table 4.2. Interaction between DOl and ketanserin on measures of performance on the discrete-trials 
psychophysical procedure: group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment T50, s slope, c p2 Weber fraction 
Vehicle 24.5 ± 0.6 -3.7 ± 0.3 0.98 ± 0.00 0.34 ± 0.03 
DOl 0.25 mg kg-1 28.2 ± 1.5* -2.5 ± 0.2* 0.89 ± 0.02 0.53 ± 0.05* 
ketanserin 2 mg kg-1 24.6 ± 0.7 -3.7 ± 0.2 0.95 ± 0.01 0.33 ± 0.03 
DOl 0.25 mg kg-1 + 25.0 ± 0.8# -3.6 ± 0.3# 0.94 ± 0.01 0.36 ± 0.04# 
ketanserin 2 mg kg-1 
that the Weber fraction was increased by DOl, but not by ketanserin or by DOl + 
ketanserin. Multiple comparisons with the DOl condition showed that the increase 
in the Weber fraction produced by DOl was significantly reversed by ketanserin. 
4.3.3. Interaction between DOl and MDL-I00907 
Two treatment series were carried out, examining the effects ofMDL-l 009070.5 
and 1.0 mg kg-I, respectively. The %B data from the two series are shown in Figs. 
4.3A and 4.3B. Analysis of variance of these data showed that in the first series 
(MDL-100907 0.5 mg kg-I), there were significant main effects of treatment 
[F(3,57) = 4.8, P<O.Ol] and time [F(9,171) = 500.6, P<O.OOI], and a significant 
treatment x time interaction [F(27,621) = 4.4, P<O.OOI]. Analysis of the simple 
main effects revealed significant treatment effects 27.5, 37.5,42.5 and 47.5 s after 
trial onset. Multiple comparisons with the vehicle-alone condition showed that 
DOl produced significant decreases in %B at all these time points. Multiple 
comparisons between the DOl and DOl + MDL-1 00907 (0.5 mg kg-I) conditions 
indicated that MDL-1 00907 significantly attenuated the effect of DOl only at the 
47.5-s time point. In the second series (MDL-I00907 1.0 mg kg-I), there were 
significant main effects oftreatment [F(3,57) = 10.9, P<O.OOI] and time [F(9, 171) 
= 553.2, P<O.OOl], and a significant treatment x time interaction [F(27,62 1) = 5.1, 
P<O.OOl]. Analysis of the simple main effects revealed significant treatment 
effects at all time points ~ 2 2 . 5 5 s after trial onset. Multiple comparisons with the 
vehicle-alone condition showed that DOl produced significant decreases in %B at 
all these time points. Multiple comparisons between the DOl and DOl + MDL-
100907 (1.0 mg kg-i) conditions indicated that MDL-100907 significantly 
attenuated the effect of DOl at all these time points except 37.5 s after trial onset. 
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Figure 4.3. Interaction between MDL-I00907 (0.5 mg kg-I: A; 1.0 mg kg-I: B) 
and DOl (0.25 mg kg-I) on relationship between proportional choice of lever B 
and stimulus duration in the discrete.;..trials psychophysical procedure_ Conventions 
as in Fig. 4.1. 
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The parameters of the logistic functions are shown in Table 3. In the first series, 
there was a significant effect of treatment on Tso [F(3,57) = 3.5, P<0.02]. Multiple 
comparisons with the vehicle condition (Dunnett's test) showed that Tso was 
significantly increased by DOl, but not significantly changed by the other 
treatments. Multiple comparisons with the DOl condition showed that the increase 
in Tso produced by DOl was significantly reversed by combined treatment with 
MDL-100907 0.5 mg kg-I. In the second series, there was also a significant effect 
of treatment on Tso [F(3,57) = 10.8, P<O.OOl]. Again, DOl significantly increased 
Tso, compared to the vehicle condition, the other treatment conditions having no 
significant effect. There was a significant difference between the DOl and DOl + 
MDL-I00907 1.0 mg kg- I conditions, indicating that MDL-1 00907 significantly 
reversed the effect of DOl on Tso. 
There were significant effects of treatment on € in both treatment series 
[first series: F(3,57) = 11.1; second series: F(3,57) = 13.1; P<O.OOl in both cases]. 
Multiple comparisons indicated that, in both cases, DOl significantly increased 
this parameter, compared to the vehicle alone condition, whereas neither dose of 
MDL-100907 had a significant effect. The effect of DOl on € was reversed by 
MDL-100907 1.0 mg kil but not by MDL-100907 0.5 mg kg-I. 
There were significant effects of treatment on the Weber fraction [first 
series: F(3,57) = 5.9; second series: F(3,57) = 10.8; P<0.05 in both cases]. 
Multiple comparisons indicated that, in both cases, DOl significantly increased the 
Weber fraction, compared to the vehicle alone condition, whereas neither dose of 
MDL-100907 had a significant effect. The effect of DOl on the Weber fraction 
was reversed by MDL-100907 1.0 mg kg-I but not by MDL-100907 0.5 mg kg-I. 
135 
...... 
w 
0\ 
Table 4.3. Interaction between DOl and MDL-I00907 on measures of performance on the discrete-trials 
psychophysical procedure: group mean values (± SEM) 
Treatment 
Vehicle 
DOl 0.25 mg ki! 
MDL-100907 0.5 mg kg-! 
DOl 0.25 mg kg-! + 
MDL-100907 0.5 mg kg-! 
Vehicle 
DOl 0.25 mg kg-! 
MDL-I00907 J.O mg kg-! 
DOl 0.25 mg kg-' + 
MDL-I00907 J.O mg kg-! 
Tso, s 
24.1 ± 0.7 
28.8 ± 1.7* 
24.8 ± 1.3 
25.3 ± 1.1# 
24.3 ± 0.6 
31.7 ± 2.0* 
24.0 ± 0.9 
25.0 ± 0.9# 
Parameters of logistic psychometric function 
slope, c p2 Weber fraction 
-4.1 ± 0.3 0.97 ± 0.01 0.31 ± 0.03 
-2.5 ± 0.2* 0.86 ± 0.05 0.63 ± 0.11* 
-4.1 ± 0.4 0.95 ± 0.01 0.33 ± 0.03 
-2.8 ± 0.2* 0.93 ± 0.01 0.47 ± 0.05 
-3.9 ± 0.3 0.95 ± 0.01 0.32 ± 0.03 
-2.6 ± 0.2* 0.85 ± 0.05 0.63 ± 0.16* 
-3.8 ± 0.3 0.94 ± 0.02 0.37 ± 0.06 
-3.2 ± 0.2# 0.94 ± 0.01 0.40 ± 0.04# 
* Significanly different from vehicle condition, P < 0.05; # significantly different from DOl 0.25 mg kg-I, P < 0.05 
4.4. DISCUSSION 
Temporal discrimination performance in the discrete-trials psychophysical 
procedure used in this experiment was similar to that reported previously: 
proportional choice of lever B increased as a sigmoid function of stimulus 
duration, this being well described by a two-parameter logistic equation (Body et 
a1. 2002; Also see chapter2). 
DOl produced a dose-dependent disruption of temporal discrimination, 
which was most readily apparent in the case of longer stimulus durations. This 
resulted in rightward displacement and flattening of the psychometric function, 
reflected in a trend for the value of T50 to be increased (statistically significant in 
three of the four treatment series), combined with increases in the slope parameter, 
c, and the Weber fraction. 
The increase in £ and the Weber fraction are indicative of an impairment 
of the precision with which the rats discriminated the durations of the light 
stimulus (see Killeen et a1. 1997). It is not possible to say with certainty, on the 
basis of these results, whether the deleterious effect of DOL on discriminative 
accuracy is specific for the temporal dimension, or whether it may reflect a more 
general breakdown of stimulus control. Further experiments, examining the effect 
of DOl on discrimination along other stimulus dimensions will be needed to 
address this question. 
The increase III T50 induced by DOl is open to more than one 
interpretation. One possibility is that DOl may have had a direct effect on the 
neural mechanisms of timing. For example, according to pacemaker-based models 
of timing, an acute rightward shift of the psychometric function may reflect an 
increase in the period of the hypothetical pacemaker (see Gibbon 1991; Gibbon et 
a1. 1997a; Hinton and Meck 1997). However, another possibility, discussed in 
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Chapter 2, in the contextofquipazine's effect on T50, is that the rightward shit! oj' 
the psychometric function, like the increase in the Weber fraction, may renect a 
breakdown of stimulus control. Inspection ofthe psychometric functions shown in 
Figures 4.1-4.3 indicates that DOl had relatively little effect on discriminative 
accuracy in the case of shorter stimulus durations, but markedly reduced the 
accuracy of discrimination of longer intervals. It is possible that stimulus control 
is relatively weak, and therefore more vulnerable to disruption, in the case of 
longer durations (see Section 2.4.). 
The pattern of effect of DOl seen in this experiment is quite unlike that 
seen in experiments that have employed other types of timing schedule. In contrast 
to increase of T50 seen in the retrospective timing schedule used in this 
experiment, DOl has been found to produce leftward displacement of the timing 
function in immediate timing tasks. Thus, Body et al. (2003, 2004a) found that 
DOl dose-dependently reduced T50 in the free-operant psychophysical procedure 
(Stubbs 1976), and as will be discussed in another chapter of this thesis, it was 
found that DOl displaced the response rate function to the left, reducing the peak 
time, in the fixed-interval peak procedure (Catania 1970; Roberts 1981). It is 
difficult to see how these very different effects of DOl on temporal discrimination 
and temporal differentiation can both be accounted for in terms of an interaction 
with a unitary pacemaker that is purported to underlie both types of timing 
behaviour (Gibbon 1977, 1991), since the increase and decrease of T50 would 
seem to imply both a lengthening and a shortening of the period of the pacemaker. 
A possible solution to this problem is suggested by recent interpretations of the 
effects of amphetamine-like drugs on interval timing. Meck and Benson (2002) 
and Buhusi (2003) have proposed that these drugs may alter timing performance 
by two separate mechanisms: a direct interaction with the hypothetical pacemaker, 
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and disruption of 'attention-sharing'. It remains to be seen whether the effects of 
001 on timing are amenable to a similar interpretation. However it may be noted 
that any such attempt to account for DOl's effects on timing on the basis of two 
distinct processes must be predicated on an explanation of why these processes 
make different relative contributions to temporal discrimination and temporal 
differentiation performance. 
The effect of 001 on temporal discrimination seen in this experiment is 
similar to the effect of quipazine seen in Experiment 1 (see Sction 2.3). 
Quipazine has nanomolar affinity for 5-HT3 receptors, and somewhat lower 
affinity for 5-HT2 receptors (Hoyer 1988; Glennon et aI., 1989; Sharif et aI., 
1991). 5-HT3 receptors appeared not to be involved in quipazine's effect on 
temporal discrimination, since the effect could not be reversed by the selective 5-
HT3 receptor antagonist MDL-72222 (see Section 2.3). However, quipazine's 
effect was completely reversed by the 5-HT2 receptor antagonist ketanserin. Since 
ketanserin has approximately 80-100-fold higher affinity for 5-HT2A than for 5-
HT 2C receptors (Baxter et al. 1995; Barnes and Sharp 1999), it was suggested that 
quipazine's effect on temporal discrimination was probably mediated by 5-HT2A 
receptors (see Section 2.4). 
001 is a full agonist at both 5-HT2A and 5-HT2C receptors (see Hoyer et al. 
2002). In view ofketanserin's preference for 5-HT2A receptor over the 5-HT2C 
receptor, the ability of this antagonist to reverse DOl's effect on temporal 
discrimination in the present experiment suggests a predominant involvement of 
5-HT2A receptors. However, more persuasive evidence for this suggestion is 
provided by the ability ofMDL-100907 to reverse DOl's effect, because MOL-
100907 is a highly selective 5-HT 2A receptor antagonist with minimal affinity for 
5-HT2C receptors (see Barnes and Sharp 1999; Hoyer et al. 2002; Leysen 2004). 
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In conclusion, the present results, taken together with those of experiment 
1, indicate that 5-HT2A receptor stimulation disrupts temporal discrimination in 
the rat. However, the behavioural mechanisms that underlie this effect remain to 
be clarified. 
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CHAPTER 5 
Experiment 4: 
EFFECTS OF STIMULATION OF 5-HT2 
RECEPTORS IN THE DORSAL STRIATUM ON 
TEMPORAL DISCRIMINATION 
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5.1 INTRODUCTION 
The experiments presented in Chapters 2 and 4 (Experiments 1 and 3) provide 
evidence for a disruptive effect of 5-HT2A receptor stimulation on temporal 
discrimination. Experiment 1 showed that quipazine, a non-selective 5-HT 
receptor agonist with high affinity for 5-HT3 receptors and somewhat lower 
affinity for 5-HT2A receptors, flattened the psychometric timing function in the 
discrete-trials psychophysical procedure, increasing the Weber fraction. This 
effect was evidently not mediated by 5-HT3 receptors, because it was resistant to 
the selective 5-HT 3 receptor anatagonist MDL-72222. The ability ofketanserin, a 
5-HT2 receptor antagonist with higher affinity for 5-HT 2A receptors than for other 
subtypes of 5-HT 2 receptor, to reverse this effect of quipazine, strongly implicated 
5-HT2A receptors in the effect. Experiment 3 extended these observations by 
showing that the 5-HT 2A12C receptor agonist DOl had a similar disruptive effect on 
temporal discrimination to quipazine, and that DOl's effect was reversed both by 
ketanserin and by the highly selective 5-HT2A receptor antagonist MDL-l 00907. 
The anatomical location ofthe 5-HT2A receptors that mediate these effects 
on temporal discrimination remains unknown. 5-HT2A receptors are widely 
distributed in the brain, the densest populations being found in the basal ganglia 
and cerebral cortex (Barnes and Sharp 1999; Hoyer et al. 2002; Leysen 2004). The 
experiments described in this chapter examined the possibility that the 5-HT 2A 
receptor population relevant to temporal discrimination may be located in the 
dorsal striatum. There is a great deal of evidence that the dorsal striatum plays a 
major role in voluntary timing behaviour (Gibbon et al. 1997; Hinton and Meek 
1997,2004; Harrington et al. 1998; Meck and Benson 2001; Ferrandez et al. 2003; 
Matell et al. 2003; Nenadie et al. 2003; Pastor et al. 2004; Meck 2005; see also 
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Section 1.4.5), and the presence of a dense population of5-HT2A receptors in this 
structure suggests that this may be an appropriate starting point for a search for the 
location ofthe 5-HT2A receptors that mediate effects on temporal discrimination. 
The main objectives of the present experiments were firstly to examine the 
effect of intra-striatal injection of DOl and MDLl 00907 on temporal 
discrimination, and secondly to examine whether the effect of systemically 
administered DOl on temporal discrimination would be blocked either by the 
highly selective 5-HT 2A receptor antagonist MDL-l 00907 (see Barnes and Sharp 
1999; Hoyer et al. 2002), or by the highly selective 5-HT2c receptor antagonist 
RS-I02221 (Bonhaus et al. 1997), administered directly into the dorsal striatum. 
5.2. METHODS 
5.2.1. SUbjects 
Twenty nine female Wi star rats aged approximately 4 months and weighing 250-
290 g at the start of the experiment were housed under the same condition as in 
Experiment 1 (see Section 2.2.1) 
5.2.2. Apparatus 
The rats were trained in operant conditioning chambers (CeNeS Ltd, Cambridge, 
UK) of internal dimensions 25 cm x 25 cm x 22 cm. One wall of chamber 
contained a recess fitted with a hinged Perspex flap, into which a peristaltic pump 
could dispense the liquid reinforcer (0.6 M sucrose solution). In other respects, the 
chambers were similar to those used in the previous experiments (see Section 
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2.2.2.). 
5.2.3. Behavioural training 
At the start of the experiment, the food deprivation regimen commenced and the 
rats were gradually reduced to 80% oftheir free-feeding body weights. They were 
then trained to press the levers, and were exposed to a discrete-trials continuous 
reinforcement schedule, in which the two levers were presented in a random 
sequence, for three sessions. Thereafter, the rats underwent 50-minute training 
sessions under the discrete-trials psychophysical procedure, as described in 
Experiment 1 (see Section 2.2.3). 
5.2.4. Surgery 
Surgical preparation took place after >90 sessions of preliminary training under 
the discrete-trials psychophysical procedure. The rats were anaesthetized with 4% 
halothane in oxygen, and placed in a stereotaxic apparatus, with the incisor bar 
fixed 3.3 mm below the inter-aural line; anaesthesia was maintained with 2% 
halothane in oxygen during the surgery. Bilateral 22-gauge guide cannulae 
(Plastics One Inc., Roanoke, VA, USA) were introduced into the brain via l-mm 
holes drilled in the skull, and their tips were positioned at the dorsal margin of the 
corpus striatum, according to the following stereotaxic coordinates: AP + 1.0 mm, 
L ±2.5 mm, DV -4.0 mm, measured from bregma (Paxinos and Watson 1998). 
Three stainless steel anchor screws were placed in the skull, the cannula assembly 
was fixed to the skull with dental cement, and the wound was closed around the 
cannula assembly. Stylets were introduced into the guide cannulae, and the 
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assembly was covered by a plastic screw cap. The rats were returned to the daily 
training routine on the day following surgery. 
5.2.5. Drug treatment 
Two weeks after surgery, the rats were acclimatized to manual restraint and the 
intracerebral injection procedure over a number of sessions before starting the 
drug treatment regimen. Intracerebral injections were given via bilateral 28-gauge 
injection canulae which protruded 1 mm below the tips of the guide cannulae. 
Sterile drugs solutions or vehicle (see below) were infused at a rate of 0.2 III min-I 
via polythene tubes connected to 100-111 Hamilton syringes driven by a dual 
syringe pump (Linton Instrumentation, Diss, UK). The volume injected was 
always 0.5 III (total injection time, 2.5 minutes). The injection cannulae remained 
in place for one minute after the completion of the injection to allow for diffusion 
within the tissue. The cannulae were then removed and the stylets replaced, and 
the rats were returned to their home cages for 2-3 minutes before being placed in 
the operant conditioning chambers. The experimental session began six minutes 
after completion ofthe injection. Intracerebral injections were given twice a week, 
with at least 72 hours between successive injections. A maximum of 12 injections 
were given to each rat. 
The rats were divided into three groups. Group I (n=IO) received the 
following three treatments, each treatment being given four times: (i) vehicle 
(intracerebral [i.c.]), (ii) DOl (lllg, i.c.), (iii) DOl (3 Ilg, i.c.). Group 2 (n=10) 
received the following three treatments, each treatment being given four times: (i) 
vehicle (i.c.), (ii) MDL-100907 (0.1 Ilg, i.c.), (iii) MDL-100907 (0.3 Ilg, i.c.). 
Group 3 (n=9) received the following four treatments, each treatment being given 
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three times: (i) vehicle (s.c.) + vehicle (i.c.), (ii) 001 (0.25 mg kg-', s.c.) + vehicle 
(i.c.), (iii) 001 (0.25 mg kg-I, s.c.) + MDL-100907 (0.3 /-lg, i.c.), (iv) DOl (0.25 
mg kg-I, s.c.) + RS-I02221 (0.15 /-lg, i.c.). 
The doses for intracerebral injection were chosen on the basis of previous 
studies in which these compounds were injected intracerebrally (for references, 
see Discussion). The protocol for subcutaneous injections was the same as in 
Experiment I, (see Section 2.2.4.). 
DOl was dissolved in sterile water, MDL-I 00907 was dissolved in glacial 
acetic acid, and RS-102221 [8-(5-(2,4-dimethoxy-5-(trifluoromethylphenyl-
sulphonamido )phenyl-5-oxopentyl) 1 ,3,8-triazaspiro( 4.5)decane-2,4-dione HCI] 
was dissolved in 0.9% sodium chloride solution. Each drug solution was diluted to 
volume with phosphate buffered saline (pH 7.0). Doses of the drug refer to the 
weights of the salts. 
5.2.6. Histology 
At the end of the experiment, the rats were killed by CO2 and their brains were 
removed and fixed in 10% formol saline for one week. The brains were sectioned 
using a freezing microtome. Coronal sections (60 /-lm) taken through the striatum 
were mounted on gelatine-coated slides. The selected sections were dried in 
formaldehyde vapour and placed through the following series of solutions: 95% 
ethanol (15 min), 70% ethanol (I min), 50% ethanol (1 min), distilled water (2 
min), 0.25% cresyl violet (2 min), distilled water (1 min), 50% ethanol (1 min), 
70% ethanol (2 min), 95% ethanol (2 min), 100% ethanol (1 min), xylene (5 min). 
Slides were mounted with DPX and coverslipped. An investigator who was blind 
to the behavioural results performed the microscopic examination. Drawings of 
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the locations of the cannula tips were superimposed on the appropriate pages of 
the stereotaxic atlas of Paxinos and Watson (1998). 
5.2.7. Data analysis 
The data from the three groups (Group 1: intra-striatally administered DOl; 
Group 2: intra-striatally administered MDL-100907; Group 3: systemically 
administered DOl combined with intra-striatally administered MDL-l 00907 and 
RS102221) were analysed separately. The methods of analysis were similar to 
those used in Experiments 1 and 3 (see Section 2.2.5). 
For each treatment, the percentages of responses emitted on lever B (%B) 
at each time-point were analysed by two-factor analyses of variance (treatment x 
time) with repeated measures on both factors. In the event of a significant main 
effect of treatment or a significant treatment x time interaction, analyses of the 
simple main effect at each time-point were carried out, followed by comparisons 
between each active treatment with the control (vehicle-alone) condition using 
Dunnett's test. In the case of data from the drug interaction study (Group 3), 
multiple comparisons were made between treatment with DOl + vehicle and the 
combined DOl + antagonist treatments, using Neuman-Keul's test. Quantitative 
analysis of the psychometric functions was identical to experiment 1 (see Section 
2.2.5.) 
5.3. RESULTS 
Under each treatment condition, proportional choice of lever B (%B) increased 
progressively as a function of stimulus duration, t. Under the vehicle-alone 
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condition and all active treatment conditions, the number of 'missed' trials (i.e. 
trials in which no response was emitted on either lever A or lever B) was <OSlo. 
5.3.1. Intra-striatal administration of DOl (Group 1) 
The effect of DOl (1, 3 Jlg) on proportional choice of lever B (%B) is shown in 
Fig. 5.1. Analysis of variance of these data revealed that the main effect of the 
treatment was not statistically significant [F(2,16) = 1.0, P>O.I]. The main effect 
of time was statistically significant [F(9,n) = 267.7, P<O.OOI]. There was no 
significant treatment x time interaction [F(18,144) = 1.0, P>O.I]. 
Logistic functions were fitted to the data from each rat under each 
treatment condition; the group mean values ofthe parameters of these functions (:1:: 
SEM) are shown in Table 5.1. There was no significant effect of treatment on Ij(), 
E or the Weber fraction [F<I in each case]. 
5.3.2. Intra-striatal administration ofMDL-lO0907 (Group 2) 
The effect ofMDL-100907 (I, 3 Jlg) on proportional choice oflever B (%B) is 
shown in Fig. 5.2. Analysis of variance of these data revealed that the main effect 
of the treatment was not statistically significant [F< 1]. The main effect of time 
was statistically significant [F(9,8I) = 207.6, P <0.001]. There was no significant 
treatment x time interaction [F(I8,I62) = 1.5, P>0.05]. 
Logistic functions were fitted to the data from each rat under each 
treatment condition; the group mean values of the parameters of these functions (± 
SEM) are shown in Table 5.2. There was no significant effect of treatment on T50, 
E [F<I in each case], or the Weber fraction [F(2,28) = 1.7, P>0.05]. 
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Figure 5.1. Effect of intra-striatally administered DOl (1, 3 ~ g ) ) on the relationship 
between proportional choice oflever B (%B) and stimulus duration (t, seconds) in 
the discrete-trials psychophysical procedure. Points indicate group mean data 
under each treatment condition (see inset). 
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Table 5.1. Effects of the intra-striatally administered DOl on measures of performance on the 
discrete-trials psychophysical procedure: group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment T50, s slope, E p2 Weber fraction 
Vehicle 26.1 ± 1.1 -4.6 ± 1.3 0.93 ± 0.01 0.32 ± 0.04 
........ DOl 1 ~ g g 24.4 ± 0.9 -4.4 ± 0.6 0.95 ± 0.01 0.29 ± 0.04 VI 
0 
DOl 3 ~ g g 24.5 ± 1.1 -3.6 ± 0.6 0.92 ± 0.02 0.37 ± 0.06 
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Figure 5.2. Effect of intra-stria tally administered MDL-100907 (0.1, OJ /-lg) on 
the relationship between proportional choice of lever B (%B) and stimulus 
duration (t, seconds) in the discrete-trials psychophysical procedure. Points 
indicate group mean data under each treatment condition (see inset). 
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Table 5.2. Effects of intra-stria tally administered MDLI00907 on measures of performance on the 
discrete-trials psychophysical procedure: group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment T50, s slope, £ p2 Weber fraction 
Vehicle 24.8 ± 0.9 -3.30 ± 0.20 0.74 ± 0.01 0.35 ± 0.02 
MDL 100907 Illg 24.1 ± 1.2 -3.41 ± 0.33 0.92 ± 0.10 0.36 ± 0.40 
MDL 100907 31lg 23.7 ± 1.1 -3.18 ± 0.32 0.92 ± 0.00 0.43 ± 0.04 
5.3.3. Interaction between systemically administered DOl with intra-
striatally administered MDL-I00907 and RS-I02221 (Group J) 
The %B data are shown in Fig. 5.3. Analysis of variance of these data revealed a 
significant main effect of time [F(9,81) = 64.9, P<O.OOI]. There was no 
significant main effect of treatment [F<l]. However, there was a significant 
treatment x time interaction [F(27, 243) = 2.7, P<O.OOI]. Analysis of the simple 
main effects revealed significant treatment effects 37.5 s [F(3,27) = 5.8, p." 
0.005] and 47.5 s [F(3,27) = 4.3, P< 0.05] after trial onset. Multiple comparisons 
showed that DOL produced a significant decrease in %B at both these time points; 
in neither case was this effect significantly reversed by either MDL-I00907 or 
RS-102221. 
Logistic functions were fitted to the data from each rat under each 
treatment condition; the group mean values ofthe parameters ofthese functions (± 
SEM) are shown in Table 5.3. There was no significant effect of treatment on T50 
[F(3,21) = 1.3, P>O.l]. The effect of treatment on c was statistically significant 
[F(3,21) = 5.6, P<0.005]. Post hoc tests showed that the value of this parameter 
was increased by systemically administered DOL; however DOL's effect was not 
significantly reversed by either MDL-100907 or RS-102221. The effect of 
treatment on the Weber fraction fell short of statistical significance [F(3,21) = 2.6, 
0.1>P>0.05]. 
5.3.4. Histology 
Figure 5.4 shows the cannula placements for all the rats. In each rat, the tracks of 
the internal cannulae terminated in the dorsal striatum in both hemispheres. 
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Figure 5.3. Interaction between systemically admisistered Doi and intrastriatally 
administered MDL-100907 and RS-102221 on the relationship between 
proportional choice of lever B (%B) and stimulus duration in the discrete-trials 
psychophysical procedure. DOl significantly reduced %B at the 37.5 and 47.5 s 
time points (* P<0.05). In neither case was this effect significantly altered by 
either MDL-100907 or RS-102221 (see text for details). 
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Table 5.3. Interaction between systemically administered DOl and intra-striatally administered 
MDL-100907 and RS 1 02221 on measures of performance on the discrete-trials 
psychophysical procedure: group mean values (± SEM) 
Parameters of logistic psychometric function 
Treatment T50, s slope, c p2 Weber fraction 
Vehicle + Vehicle 23.0 ± 1.7 -3.3 ± 0.5 0.88 ± 0.03 0.42 ± 0.08 
DOl + Vehicle 26.8 ± 2.1 -1.9 ± 0.2* 0.83 ± 0.04 0.69 ± 0.10 
DOl + MDL-l 00907 27.6 ± 4.8 -2.2 ± 0.3* 0.78 ± 0.04 0.59 ± 0.08 
DOl + RS-l 02221 31.0 ± 4.0 -1.6 ± 0.4* 0.64 ± 0.10 0.99 ± 0.33 
* significantly different from control (Vehicle + Vehicle) condition (P<0.05); see text for details 
AP +1.5 
AP +1.0 
AP +0.5 
Figure 5.4. Diagram of cannula placements within the dorsal striatum. Points 
indicate the approximate positions of the tips of the injection cannulae derived 
from the histological slides (see text for details). The three sections are taken from 
Paxinos and Watson's atlas at the AP locations indicated. Circles: brains of rats 
from Group 1; triangles: brains of rats from Group 2; inverted triangles: brains or 
rats from Group 3. 
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5.4. DISCUSSION 
Temporal discrimination performance in the discrete-trials psychophysical 
procedure used in this experiment was similar to that reported previously: 
proportional choice of lever B increased as a sigmoid function of stimulus 
duration, this being well described by a two-parameter logistic equation (Body ct 
al. 2002a; see also Chapters 2 and 4). The fits of the logistic functions were 
somewhat poorer in this experiment than in the previous experiments employing 
the discrete-trials psychophysical procedure (Experiments I and 3). This probably 
reflects the fact that in the present experiment the data were derived from only 
three or four sessions under each treatment condition, as opposed to five sessions 
in the other experiments. The smaller number of treatment sessions in the present 
experiment was due to the limited number of intracerebral injections that it was 
considered appropriate to give to each rat. The giving of twelve injections seems 
to be justified, in that the histological examination of the brains did not indicate 
any significant structural damage to the striatum. Further experiments may be 
needed to ascertain whether this number could be increased without incurring 
unacceptable tissue damage. 
Systemically administered DOl (Group 3) produced some disruption of 
temporal discrimination, although the effect was less marked than in Experiment 
3. In the present experiment, the slope of the psychometric function was 
significantly flattened by DOl; however, in contrast to Experiment 3, T50 and the 
Weber fraction were not significantly altered. It is possible that this reflects the 
smaller number of animals and the smaller number of injections given to each 
animal in the present experiment (see above). 
There is a substantial body of evidence indicating that the dorsal striatum 
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plays a pivotal role in the regulation of interval timing behaviour (Harrington et al. 
1998; Meck and Benson 2001; Matell et al. 2003; Nenadic et al. 2003; Hinton and 
Meck 2004; Matell and Meck 2004; Pastor et al. 2004; Lustig .et al. 2005; Meck 
2005). 5-HT 2A receptors exist in considerable numbers in the striatum (see Barnes 
and Sharp 1999; Hoyer et al. 2002), where they may contribute to the regulation 
of the activity ofthe direct striatal output pathway (Bishop et al. 2004). Therefore 
it was decided, in the present experiment, to examine whether the 5-HT 2A receptor 
popUlation responsible for DOl's effect on temporal discrimination might be 
located in the dorsal striatum. However, DOl had no significant effect on temporal 
discrimination when it was injected directly into the dorsal striatum (Group 1). 
Furthermore, MDL-I00907, administered directly into the dorsal striatum, had 
not effect on temporal discrimination (Group 2), and was not able to attenuate the 
effects of systemically administered DOl on the slope of the psychometric 
function (Group 3). Thus the present results suggest that the population of5-HT2A 
receptors that mediates DOl's effects on temporal discrimination probably does 
not reside in the dorsal striatum. 
The failure of intra-striatally injected RS-I02221 to block the effect of 
DOl argues against a significant role of striatal5-HT2c receptors in DOl's eflect, 
because RS-I02221 has a considerably higher affinity for 5-HT2c receptors than 
for other 5 -HT 2 receptor subtypes (Bonhaus et al. 1997). It has yet to be 
established whether systemic administration of5-HT2c receptor antagonists can 
alter the effect of DOl on timing behaviour. 
The possibility cannot be totally excluded that the lack of effect of the 
intracerebrally administered drugs in these experiments was due to the use of 
inadequate doses. However, intracerebral injection of DOl in doses comparable to 
those used in the present experiments has been found to be effective in other 
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behavioural tests (Sipes and Geyer 1997; Bishop et al. 2004). Moreover, doses of 
MD L-l 00907 and RS-l 02221 similar to those used in the present experiment have 
been found to attenuate cocaine-induced behaviour when injected into the ventral 
tegmental area and nucleus accumbens, respectively (McMahon et al. 2001; Filip 
and Cunningham 2002). Therefore, it seems reasonable to interpret the inability of 
DOl and the two antagonists to affect temporal discrimination following direct 
injection into the dorsal striatum as indicating that the relevant receptor population 
is not located in this structure. 
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CHAPTER 6 
Experiments 5 and 6: 
EFFECTS OF SYSTEMICALLY AND INTRA-
STRIATALLY ADMINISTERED DOl ON 
TEMPORAL DIFFERENTIATION 
Experiment 5: Effects of systemically administered DOl and 
MDL-I00907 
Experiment 6: Effects of intra-striatally administered DOl, 
MDL-I00907 and RS-I02221 
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6.1. INTRODUCTION 
The experiments described in the previous chapter investigated the hypothesis that 
the disruptive effects of 5-HT2 receptor agonists on temporal discrimination might 
be mediated by a 5-HT2A receptor population located in the dorsal striatum, an 
area that has been implicated in the control of interval timing behaviour. The 
results did not support the hypothesis. 
The experiments described in this chapter examined the same hypothesis 
in the case of temporal differentiation. There is good evidence that 5-HT2A 
receptor stimulation can alter temporal differentiation in the free-operant 
psychophysical procedure. The results of Experiment 2 (see Chapter 3) showed 
that the non-selective 5-HT receptor agonist quipazine produced a leftward 
displacement ofthe psychometric function derived from this schedule, reflected in 
a reduction of the indifference point T50 . The reversal ofthis effect by ketanserin 
strongly suggests that the quipazine's effect was mediated by 5-HT2A receptors. 
This result is consistent with previous findings by Body et al. (2003, 2004), 
showing that DOl reduced T50 in the free-operant psychophysical procedure, and 
that this effect could be reduced by ketanserin. 
One aim ofthe experiments described in this chapter was to extend these 
observations with ketanserin to the highly selective 5-HT2A receptor antagonist 
MDL-100907. The other aim was to examine whether the effect of systemically 
administered DOl would be reproduced when the agonist was injected directly 
into the striatum. In addition it was examined whether intra-striatal injection of 
MDL-100907 and the highly selective 5-HT2c receptor antagonist RS-I02221 
(Bonhaus et al. 1997) could block the effect of DOl on temporal differentiation. 
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6.2. Experiment 5: EFFECTS OF SYSTEMICALLY 
ADMINISTERED DOl AND MDL-I00907 
6.2.1. Methods 
6.2.1.1. Subjects 
Twenty female Wistar rats aged approximately 4 months and weighing 250-290 g 
at the start of the experiment were housed individually under the same conditions 
as in Experiment 1. 
6.2.1.2. Apparatus 
The rats were trained in operant conditioning chambers (CeNeS Ltd, Cambridge, 
UK) identical to those used in Experiment 4 (see Section 5.2.1). 
6.2.1.3. Behavioural training 
At the start of the experiment, the food deprivation regimen commenced and the 
rats were gradually reduced to 80% of their free-feeding body weights. They were 
then trained to press the levers, and were exposed to a discrete-trials continuous 
reinforcement schedule, in which the two levers were presented in a random 
sequence, for three sessions. Thereafter, the rats underwent 50-minute training 
sessions under the free-operant psychophysical procedure as described in 
Experiment 2 (see Chapter 3 for details). 
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6.2.1.4. Drug treatment 
The drug treatment regimen started after 80 sessions of preliminary training under 
the free-operant psychophysical procedure. DOl was injected subcutaneously 
using a 26-gauge needle, at a volume of 1.0 ml kg-I, 15 minutes before the start of 
the experimental session. MDL-1 00907 was injected intraperitoneally using a 25-
gauge needle, at a volume of 2.5 ml kg-', 25 minutes before the start of the 
session. Drugs were administered on Tuesdays and Fridays, vehicle injection:) 
were given on Mondays and Thursdays, and no injections were given on 
Wednesdays, Saturdays or Sundays. The order of treatments was balanced within 
artd between animals according to a Latin square. Control injections used the 
vehicle appropriate for that drug (see below). Each treatment was administered 
five times in order to accrue a sufficient number of probe trials to obtain reliable 
estimates ofthe timing indices for individual rats (Chiang et al. 2000 a, b). Each 
rat received DOl 0.25 mg kg-I, MDL-100907 0.5 mg ki', artd a combined 
treatment with DOl 0.25 mg kg-I + MDL-100907 0.5 mg kg-I. Doses ofthe drugs 
refer to the weights of the salts. 
DOl was dissolved in 0.9% sodium chloride solution. MDL-I 00907 
was dissolved in glacial acetic acid artd sterile water, buffered to pH 5.5 and 
diluted to volume with 0.9% sodium chloride solution. 
6.2.1.5. Data analysis 
Only the data collected from the probe trials were used in the analysis. The 
methods for data artalysis were similar to those used in Experiment 2 (see Section 
3.2.5.). 
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Relative response rates. Relative response rate on lever B (%B), defined 
as the response rate on lever B d i v ~ d e d d by the combined response rate on both 
levers, was analysed by a two-factor analysis of variance (treatment x time-bin) 
with repeated measures on both factors. 
Psychometric functions. A two-parameter logistic function was fitted to the 
relative response rate data from each rat under each treatment condition: 
%B= 1001(1 +[tIT50]E), where t is time from trial onset, T50 (the indifference point) 
is a parameter expressing the time at which %B=50%, and £ is the slope of the 
function; these parameters were used to derive the Weber fraction, as described 
previously (see Section 3.2.5). The values ofT50, £, and the Weber fraction were 
analysed by one-factor analyses of variance (treatments) with repeated measures. 
In the case of a significant effect of treatment, comparisons were made between 
each active treatment and the control (vehicle alone) condition using Dunnett's 
test. In the case of data from agonist-antagonist interaction, multiple comparisons 
were made between treatment with DOl alone and the combined DOl + MDL-
100907 treatment, using the Newman-Keuls test (significance criterion, P<0.05). 
Overall response rates. Overall response rate was analysed using a one-
factor analysis of variance (treatment), with repeated measures, followed by post-
hoc analyses as described above.· 
Switching. The probability of a switch occurring in each 5-s epoch of the 
probe trials was calculated for each rat. Logistic functions (see above) were fitted 
to the cumulative probability distributions, and the inflection point, S50, was 
derived (see Section 3.2.5.) The values of S50 were subjected to one-factor 
analyses of variance, as described above. 
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6.2.2. Results 
Psychometric functions 
In each treatment condition, response rate on lever A declined and 
response rate on lever B increased as a function of time from trial onset, the 
proportion of responding allocated to lever B (%B) increasing progressively 
during the course of the trial (Figure 6.1). Analysis of variance revealed 
significant main effects of time-bin [F(9,171)=453.6, P<O.OOI] and treatment 
[F(3,57)=5.3, P<O.OI], and a significant treatment x time-bin interaction 
[F(27,513)=5.2, P<O.OOI]. 
Logistic functions were fitted to the %B data from each treatment 
condition; the group mean values of the parameters of these functions (±SEM) are 
shown in Table 6.1. 
Indifference point, Tso. Analysis of variance showed a significant effect of 
treatment [F(3,57)=7.6, P<O.OOI]. Multiple comparisons showed that 001 
significantly reduced Tso. The effect of 001 was significantly reversed by co-
administration ofMDL-100907; there was no significant difference between the 
values of Tso derived from the vehicle and DOl + MDL-l 00907 conditions. 
Slope. There was no significant effect of treatment (F<l). 
Goodness of fit, p2. The mean values of p2 were >0.97 under each 
treatment condition. 
Weber fraction. There was no significant effect of treatment [F(3,57)=1.3, 
P>0.1]. 
Overall response rates. The group mean overall response rates (±SEM) 
under each treatment condition are shown in Table 6.1. There was a significant 
effect of treatment [F(3,57)=30A, P<O.OOI]. Multiple comparisons showed that 
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Figure 6.1. A. Effect of systemic treatment with DOl, MDL-I00907 and 
combined treatment with DOl + MDL-l 00907 on performance on the free-operant 
psychophysical procedure. Ordinate: percent responding on lever B (%B); 
abscissa: time from trial onset (s). Points indicate group mean data under each 
treatment condition (see inset). B. Effect on the treatments on probability of 
switching from lever A to lever B. Ordinate: cumulative probability of switching; 
abscissa: time from trial onset (s). 
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Table 6.1. Experiment 5: Effects of the treatments timing performance on the free-operant psychophysical procedure 
Mean± SEM 
Treatment T50(S) t Weber fraction Response rate 
(responses min-1) 
S50 (s) 
-- -- -- -- -----
Vehicle 13.77 ± 0.20 -3.79 ± 0.20 0.31 ± 0.02 55.97 ± 1.20 12.05 ± 0.74 
DOl 0.25 mg kg-1 11.75 ± 0.84* -4.53 ± 0.59 0.31 ± 0.03 36.66 ± 2.13* 9.62 ± 0.74* 
....... 
0\ 
MDL-100907 0.5 mg kg- 1 -..,J 14.62 ± 0.73 -4.48 ± 0.25 0.26 ± 0.01 61.29 ± 1.34 12.82 ± 0.76 
DOl 0.25 mg kg-1 + 13.97 ± 0.83# -4.18 ± 0.30 0.29 ± 0.02 53.01 ± 1.19# 11.25 ± 0.82# 
MDL-100907 0.5 mg kg-1 
DOl significantly reduced the overall response rate, and that this effect was 
significantly attenuated by MDL-I00907. 
Switching. DOl displaced the switching probability function to the left, and 
this effect was reversed by MDL-100907 (Figure 6.1). There was a significant 
effect of treatment on S50 [F(3,57)=6.7, P<O.Ol]. Multiple comparisons showed 
that DOl reduced S50 and that this effect was attenuated by co-administeation of 
MDL-I00907; there was no significant difference between the values of 5'5(} 
derived from the vehicle and DOl + MDL-I00907 conditions (Table 6.1). 
6.3. Experiment 6: EFFECTS OF INTRA-STRIATALLY 
ADMINISTERED DOl, MDL-I00907 AND RS-I0222 1 
6.3.1. Methods 
6.3.1.1. Subjects 
Eighteen female Wi star rats aged approximately 4 months and weighing 250-290 
g at the start of the experiment were housed individually under the same 
conditions as in the previous experiment. 
6.3.1.2. Apparatus 
The same apparatus was used as in the previous experiment. 
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6.3.1.3. Behavioural training 
The rats were trained under the same schedule as that used in the previous 
experiment. 
6.3.1.4. Surgery 
Surgical preparation was identical to that used in Experiment 4 (see Section 
5.2.4). 
6.3.1.5. Drug treatment 
Two weeks after surgery the rats were divided into two, groups. Group 1 (n-'-"9) 
received the following three treatments, each treatment being given four times: (i) 
vehicle (intracerebral [i.c.]), (ii) DOr (1 jlg, i.c.), (iii) DOr (3 jlg, i.c.). Group 2 
(n=9) received the following four treatments, each treatment being given three 
times: (i) vehicle (s.c.) + vehicle (i.c.), (ii) DOL (0.25 mg kg-I, s.c.) + vehicle 
(i. c.), (iii) DOl (0.25 mg kg-I, s.c.) + MDL-100907 (0.3 /lg, i.c.), (iv) DOL (0.25 
mg kg-I, s.c.) + RS-I02221 (0.15 /lg, i.c.). The doses for intracerebral injection 
were chosen on the basis of previous studies in which these compounds were 
injected intracerebrally (for references, see Discussion). The protocol for 
subcutaneous injections was the same as in Experiment 5, and for intra-cerebral 
injections was the same as in Experiment 4. 
DOr was dissolved in sterile water, MDL-l 00907 was dissolved in glacial 
acetic acid, and RS-102221 [8-(5-(2,4-dimethoxy-5-(trifluoromethylphenyl-
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sulphonamido )phenyl-5-oxopentyl) 1 ,3,8-triazaspiro( 4.5)decane-2,4-dione Hell 
was dissolved in 0.9% sodium chloride solution. Each drug solution was diluted to 
volume with phosphate buffered saline (pH 7.0). Doses of the drug refer to the 
weights of the salts. 
6.3.1.6. Histology 
Histological analysis was the same as experiment 4 (see Section 5.2.6). 
6.3.1.7. Data analysis 
The data from the two groups (Group I: DOl, i.c.; Group 2: DOl, s.c. + MDL-
100907, i.c. and RS-I 02221, i.c.) were analysed separately. The same methods of 
analysis were used as in Experiment 5 (see Section 6.2.l. 7). 
6.3.2. Results 
6.3.2.1. Intra-striatal administration of DOl (Group 1) 
Psychometric functions. Under all treatment conditions, response rate on 
lever A declined and response rate on lever B increased as a function of time from 
trial onset, the proportion of responding devoted to lever B (%B) increasing 
progressively during the course of the trial (Figure 6.2). Analysis of variance 
(treatment x time-bin) revealed significant main effects of time-bin 
[F(9,72)=41O.8, P<O.OOI] and treatment [F(2, 1 6)=4.9, P<0.05], and a significant 
treatment x time-bin interaction [F(18,144)=3.2, P<O.OOl]. The parameters of the 
fitted curves are shown in Table 6.2. 
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Figure 6.2. Effects of intra-striatal administration of DOl (l and 3 ~ g ) ) on 
performance on the free-operant psychophysical procedure. Conventions as in 
Figure 6.1. . 
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Table 6.2. Experiment 6: effects of the treatments on timing performance on the free-operant psychophysical procedure 
Mean± SEM 
Treatment T50(S) 
E Weber fraction Response rate (responses min-I) 
S50 (s) 
Vehicle (i.c.) 16.31 ± 1.03 -4.03 ± 0.22 0.28 ± 0.02 50.55 ± 3.02 14.92 ± 0.87 
DOr 1 Ilg (i.c.) 17.56 ± 1.00 -4.17 ± 0.31 0.28 ± 0.02 50.43 ± 3.03 15.93 ± 0.94 
DOr 3 Ilg (i.c.) 15.91 ± 0.78 -4.09 ± 0.27 0.28 ± 0.02 51.65 ± 3.49 14.02 ± 0.58 
...... 
-l 
N 
Vehicle (s.c.) + vehicle (i.c.) 17.52 ± 1.42 -4.13 ± 0.24 0.28 ± 0.02 44.04 ± 3.63 13.61 ± 1.37 
DOr 0.25 mg kg-I (s.c.) + 14.82 ± 1.54* -3.17 ± 0.32* 0.38 ± 0.03* 30.44 ± 2.81 * 10.43 ± 1.12* 
vehicle (i.c.) 
DOr 0.25 mg kg-I (s.c.) + 
15.50 ± 1.69* -3.29 ± 0.31 * 0.37 ± 0.04* 34.38 ± 3.23* 10.64 ± 1.49* 
MDL-100907 0.3 Ilg (i.c.) 
DOl 0.25 mg kg-I (s.c.) + 
14.97 ± 1.28* -3.30 ± 0.26* 0.36 ± 0.03* 32.96 ± 2.06* 10.93 ± 1.29* 
RS-102221 0.15 Ilg (i.c.) 
* Significantly different from vehicle (P<0.05) 
Indifference point, T50. There was a significant effect of treatment 
[F(2,16)=4.4, P<0.05]. However, multiple comparisons with the vehicle alone-
condition revealed that neither dose of 001 produced a significant effect on T50. 
Slope. There was no significant effect of treatment (F<l). 
Goodness of fit, p2. The mean values of l were >0.99 under each 
treatment condition. 
Weber fraction. There was no significant effect of treatment (F< I). 
Overall response rate. There was no significant effect oftreatment (F< I). 
Switching, S50. Analysis of variance revealed a significant main effect of 
treatment [F(2,16)=5.l, P<0.05]. However, multiple comparisons with the 
vehicle-alone treatment revealed that neither dose of 001 produced a significant 
effect on S50. 
6.3.2.2. Intra-striatal administration of MDL-I00907 and RS-I02221: 
interaction with systemically administered DOl (Group 2) 
Psychometric functions. Under all treatment conditions, response rate on 
lever A declined and response rate on lever B increased as a function of time from 
trial onset, %B increasing progressively during the course of the trial (Figure 6.3). 
Analysis of variance of the relative response rate data (treatment x time-bin) 
revealed a significant effect of time-bin [F(9,72)=207.8, P<O.OOI]. The main 
effect of treatment was not significant [F(3,24)=1.9, P>0.05], but there was a 
significant treatment x time-bin interaction [F(27,216)=51.1, P<O.OOI]. DOl 
displaced the psychometric function to the left compared to the function derived 
for the vehicle-alone treatment condition. Neither MDL-I 00907 nor RS-I 02221 
reversed this effect of DOL This was confirmed by statistical analysis of the 
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parameters of the logistic functions derived from the four treatment conditions, 
shown in Table 6.2. 
Indifference point, T50. There was a significant effect of treatment 
[F(3,24)=3.5, P<0.05]. Multiple comparisons showed that 001 reduced T50 and 
that the value of T50 obtained in the 001 + vehicle condition did not differ 
significantly from that obtained in the 001 + MDL-l 00907 and 001 + RS-l 02221 
conditions, indicating that neither antagonist attenuated DOl's effect on T50 . 
Slope. There was a significant effect of treatment [F(3 ,24 )=8.7, P<O. 00 I J. 
001 produced an increase of the value of G, and hence a flattening of the 
psychometric curve. Multiple comparisons showed that neither MDL-l 00907 nor 
RS-I02221 attenuated this effect of 001. 
Goodness of fit, l. The mean values of p2 were >0.97 under each 
treatment condition. 
Weber fraction. There was a significant effect of treatment [F(3,24)=6.6, 
P<O.Ol]. Multiple comparisons showed that 001 increased the Weber fraction and 
that neither MDL-I00907 nor RS-I02221 reversed this effect of 001. 
Overall response rate. There was a significant effect of treatment 
[F(3,24)=15.4, P<O.OOI]. Multiple comparisons showed that 001 reduced overall 
response rate and that neither MD L-l 00907 nor RS-l 02221 reversed this effect of 
001. 
Switching, S50. 001 reduced the value of S50 (Figure 6.3). There was a 
significant effect of treatment [F(3,24)=5.8, P<O.OI]. MUltiple comparisons 
revealed a significant effect of 001; the effect of 001 was not attenuated by either 
MDL-l 00907 or RS-I02221. 
174 
100 c> 100 
w Z 
l- I 
« 0 0:: 80 I- 80 
w ~ ~C/) C/) I 
Z l- I 0 60 z 60 I a.. w p 
C/) 0 VEHICLE s.c. + 0 I W 0:: I 
0:: VEHICLE i.c. w I 
~ ~ 40 • 001 s.c. + a.. 40 p W / 
I- VEHICLE i.c. > / 
Z A 001 s.c. + ~ ~ p W 0 20 MDL-100907 i.c. 20 I I 
0:: ,. 001 s.c. + ::::l 
W RS-102221 i.c. :2 a.. ::::l 
0 
0 0 
0 10 20 30 40 50 0 10 20 30 40 50 
TIME FROM TRIAL ONSET TIME FROM TRIAL ONSET 
Figure 6.3. Effects of systemic treatment with Dor (0.25 mg kg-I) alone and in 
combination with intra-striatal administration of MDL-100907 (0.3 flg) and RS-
102221 (0. 15flg) on performance on the free-operant psychophysical procedure. 
Conventions as in Figure 6.1. 
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6.3.2.3. f { i s t o l o ~ ~
Figure 6.4 shows the cannula placements for all the rats. In each rat, the 
tracks of the internal canulae terminated in the dorsal striatum in both 
hemispheres. 
6.4. DISCUSSION 
In accordance with prevIOUS experiments usmg Stubbs' free-operant 
psychophysical procedure (Stubbs 1976; Bizo and White 1994a,b; Killeen et al. 
1997; Chiang et al. 1998; Machado and Guilhardi 2000; see also Experiment 2), 
response rate on lever A declined, while response rate on lever B increased, as a 
function oftime from trial onset. This was reflected in an increasing percentage of 
total responding on lever B (%B) as the trial progressed, that was well described 
by a two-parameter logistic function. 
As has been observed in previous experiments (Body et al. 2003, 2004), 
systemically administered DOl (0.25 mg/kg) reduced the value of T50. The effect 
of DOl was completely abolished by systemic co-administration ofMDL-l 00907 
(0.5 mg/kg). DOl is a 5-HT2 receptor agonist with approximately equal affinity for 
the 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes (see Barnes and Sharp 1999; 
Hoyer et al. 2002). Body et al. (2003, 2004) previously found that the effect of 
DOl on T50 could be antagonized by ketanserin, an antagonist with considerably 
higher affinity for the 5-HT2A receptor than for the 5-HT2C receptor (see Hoyer et 
al. 2002), and concluded that the effect of DOl was probably mediated by 5-HT2A 
receptors. This conclusion is greatly strengthened by the present results obtained 
with MDL-100907, a 5-HT2A receptor antagonist with minimal affinity for the 
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Figure 6.4. Diagram of cannula placements within the dorsal striatum. Points 
indicate the approximate positions of the tips of the injection cannulae derived 
from the histological slides (see text for details). The three sections are taken from 
Paxinos and Watson's atlas at the AP locations indicated. Open circles: brains of 
rats from Group 1 ;jilled circles: brains of rats from Group 2. 
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other 5-HT2 receptor subtypes (Sorensen et al. 1993; Kehne et al. 1996; Schmidt 
et al. 1997). 
Systemically administered DOr reduced the overall rate of responding on 
the free operant psychophysical procedure. This effect has been noted before with 
DOr (Body et al. 2003). The suppression of responding by DOl also appears to be 
mediated by 5-HT2Areceptors, as it was completely reversed by MDL-100907.1t 
is important to note that T50 is estimated from relative response rate, and should 
therefore be impervious to a change in absolute response rates (Chiang et al. 
2000a; Odum et al. 2002). It is therefore unlikely that the change in T50 was 
secondary to the change in absolute response rate. Moreover, DOr also produced a 
decrease in the mean switching time, S50, a measure that is comparable to T 50, but 
which is calculated independently of response rate. The reduction inS50 produced 
by DOr was also reversed by MDL-I00907. 
As discussed in the previous chapter, there is a substantial body of 
evidence indicating that the dorsal striatum plays a pivotal role in the regulation of 
interval timing behaviour (Harrington et al. 1998; Meck and Benson 2001; MateH 
et al. 2003; Nenadic et al. 2003; Hinton and Meck 2004; MateH and Meck 2004; 
Pastor et al. 2004; Lustig et al. 2005; Meck 2005). Since 5-HT2A receptors exist in 
considerable numbers in the striatum (see Barnes and Sharp 1999; Hoyer et al. 
2002), it seemed appropriate to examine whether the 5-HT2A receptor population 
responsible for DOl's effect on temporal differentiation might be located in the 
dorsal striatum. However, in contrast to its robust effect when administered 
systemically, DOr had no significant effect on temporal differentiation when it 
was injected directly into the dorsal striatum. Furthermore, MDL-I00907, 
administered directly into the dorsal striatum, was not able to attenuate the effects 
of systemically administered DOr on T 50, S50 or response rate. Thus the present 
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results suggest that the population of5-HT2A receptors that mediates DOl's effects 
on temporal differentiation probably does not reside in the dorsal striatum. 
The failure of intra-striatally injected RS-I02221 to block the effect of 
DOl argues against a significant role of striatal5-HT2c receptors in DOl's effect, 
because RS-l 02221 has a considerably higher affinity for 5-HT 2C receptors than 
for other 5-HT2 receptor subtypes (Bonhaus et al. 1997). As in the case of 
temporal discrimination (see previous chapter), it remains to be established 
whether systemic administration of 5-HT2c receptor antagonists can alter the 
effect of DOl on temporal differentiation. 
As discussed in the previous chapter, the possibility cannot be totally 
excluded that the lack of effect of the intracerebrally administered drugs in these 
experiments was due to the use of inadequate doses. However, as noted above 
intracerebral injection of DOl in doses comparable to those used in the present 
experiments has been found to be effective in other behavioural tests (Sipes and 
Geyer 1997; Bishop et al. 2004), and doses of MDL-100907 and RS-I02221 
similar to those used in the present experiments have been found to be 
behaviourally active when injected into the ventral tegmental area and nucleus 
accumbens (McMahon et al. 2001; Filip and Cunningham 2002). Therefore, it 
seems reasonable to interpret the inability of DO! and the two antagonists to affect 
temporal differentiation following direct injection into the dorsal striatum as 
indicating that the relevant receptor population is not located in this structure. 
Current models of the neural substrate of interval timing generally 
emphasize the role of the striatum as a component of a cortico-striato-thalamo-
cortical loop (Meek and Benson 2001; F errandez et al. 2003; Matell et al. 2003; 
Hinton and Meek 2004; Matell and Meck 2004; Lustig et al. 2005; Meck 2005). 
5-HT2A receptors are expressed in more than one component of these loops. 
179 
Although they are especially well represented in the dorsal striatum, there are also 
dense populations in other parts of the basal ganglia and in the cerebral cortex 
(Pompeiano et al. 1994; Wright et al. 1995; Hamada et al. 1998; Cornea-Hebert et 
al. 1999; Bubser et al. 2001; Hoyer et al. 2002). In the cortex, in situ hybridization 
(Burnet et al. 1995; Wright et al. 1995) and single cell recording studies (Marek 
and Aghajanian 1999) have localized 5-HT2A receptors to glutamatergic 
corticostriatal projection neurones. In addition, there is evidence that 5-HT2A 
receptors are present on dopaminergic neurones of the ventral tegmental area and 
substantia nigra, the nuclei of origin of the forebrain dopaminergic projection 
(Ikemoto et al. 2000; Nocjar et al. 2002). Whether either or both of these receptor 
popUlations is responsible for the effects of 5-HT 2A receptor agonists on temporal 
differentiation is an open question that awaits further investigation. 
180 
CHAPTER 7 
Experiment 7: 
EFFECTS OF 5-HT1A AND 5-HT2A RECEPTOR 
STIMULATION ON TEMPORAL 
DIFFERENTIATION PERFORMANCE IN THE 
FIXED-INTERVAL PEAK PROCEDURE 
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7.1 INTRODUCTION 
As reviewed in Chapter 1, performance on several types of interval timing 
schedule is sensitive to acute treatment with drugs acting at 5-HT 1A and 5-
HT 2A receptors. 
The 5-HT lA receptor agonist 8-hydroxy-2-( di-n-propylamino )tetralin 
(8-0H-DPAT) has been tested in several types of timing task, including the 
free-operant psychophysical procedure (Stubbs 1976) and the interval bisection 
task (Catania 1970) (for details of these timing schedules see Chapter 1). In the 
free-operant psychophysical procedure, 8-0H-DPAT displaced the 
psychometric function to the left, this being reflected in a reduction of the 
indifference point, Tso; however, the slope of the function was only minimally 
affected by 8-0H-DPAT (Chiang et al. 2000b; Body et al. 2001, 2002b, 2004). 
Confirmation of the involvement of 5-HT1A receptors in 8-0H-DPAT's effect 
was provided by the reversal of the effect by co-administration of the highly 
selective 5-HT lA receptor antagonist N-[2-( 4-[2-methoxyphenyl]-I-
piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY -100635) 
(Body et al. 2003, 2004). 
8-0H-DPAT produced a very different pattern of effect in the interval 
bisection task. In this schedule, 8-0H-DPAT reduced the slope of the 
psychometric function, but did not alter Tso (Chiang et al. 2000b). In the 
discrete-trials psychophysical procedure (Body et al. 2002a), 8-0H-DPAT's 
effect on the function resembled that seen with the interval bisection task: the 
slope was reduced, but Tso was not altered (Body et aI., 2002a). 
The effects of the 5-HT2A12C receptor agonist 2,5,-dimethoxy-4-
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iodoamphetamine (DOl) on timing performance are similar to those of 8-0H-
DP AT. DOl reduced Tso in the free-operant psychophysical procedure, an 
effect that was reversed by the 5-HT2A receptor antagonist ketanserin (Body et 
al. 2003, 2004), but reduced the slope of the function in the discrete-trials 
psychophysical procedure (see Section 4.3). Quipazine, an agonist with high 
affinity for both 5-HT3 and 5-HT2A receptors, also reduced Tso in the free-
operant psychophysical procedure (see Section 3.3), and reduced the slope of 
the function in the discrete-trials psychophysical procedure (see Section 2.3). 
In both cases, quipazine's effect was reversed by ketanserin, implicating 
5-HT2A receptors in the effects of quipazine in both types of timing schedule. 
Drug-induced displacement of the psychometric timing function is 
often interpreted in terms of a change in the period of the hypothetical 
pacemaker that is widely believed to underlie interval timing performance 
(Meck 1986, 1996; Gibbon et al. 1997). However, the divergent effects of the 
5-HTIA and 5-HT2A receptor agonists on performance in different types of 
timing task defy a straightforward explanation in these terms, because 
according to classical pacemaker-based theories of timing, such as Scalar 
Expectancy Theory (Gibbon 1977) and the Behavioural Theory of Timing 
(Killeen and Fetterman 1988), the same pacemaker regulates timing 
performance on all voluntary timing tasks, and therefore it would be expected 
that a drug that affects pacemaker function would have at least qualitatively 
similar effects on performance on different types of timing schedule (see Zeiler 
1998; Grondin 2001). 
In searching for an alternative explanation for the effects of 5-HTIA and 
5-HT2A receptor agonists on timing performance, it is appropriate to consider 
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procedural differences that might distinguish those tasks that reveal T50-
reducing effects of these agonists from those that do not (Ho et al. 2002). One 
possible distinguishing feature is suggested by Killeen et aI.' s (1997) proposal 
that timing schedules can be classified according to the relation between the 
organism's behaviour and the interval being timed. According to Killeen et 
al.'s (1997) taxonomy, two major classes of timing schedule are immediate and 
retrospective timing schedules (Killeen and Fetterman 1988; Killeen et al. 
1997). In immediate timing schedules the organism's behaviour comes under 
the control of time during an elapsing interval (temporal differentiation), 
whereas retrospective timing tasks require the organism to discriminate the 
durations of exteroceptive stimuli that have elapsed before the discriminative 
response is made (temporal discrimination) (see Section 1.3). The free-operant 
psychophysical procedure fulfils the criteria for an immediate timing schedule, 
whereas the interval bisection and discrete-trials psychophysical schedules 
belong to the category of retrospective timing tasks. Viewed in these terms, it 
is possible that acute 5-HTIA and 5-HT2A receptor stimulation results in a 
reduction of T50 only in immediate timing tasks. If this is the case, one might 
expect that agonists of these receptors would displace T50 in other immediate 
timing tasks. 
The experiments reported here tested this prediction by examining the 
effects of 8-0H-DPAT and DOl on performance on the fixed-interval peak 
procedure. This schedule (Catania 1970; Roberts 1981) is one of the most 
widely used schedules in studies of interval timing in animals (see Hinton and 
Meck 1 9 9 7 ~ ~ Matell and Meck 2004). In standard fixed-interval trials, 
reinforcement follows the first response after a fixed interval has elapsed; in 
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probe trials, reinforcement is omitted and responding is allowed to continue for 
a period several times longer than the fixed interval. Interval timing is revealed 
by the evolution of response rate during the course of the probe trials. Rising 
from a low level at the start of the trial, response rate attains a peak close to the 
designated time of reinforcer availability in the standard trials, and 
subsequently declines. The time of maximum response rate (peak time, {peak) is 
the primary index of temporal differentiation, and has a theoretical status 
equivalent to that of T50 in the schedules described above (see Hinton and 
Meck 1997; Killeen et al. 1997). Like the free-operant psychophysical 
procedure, the fixed-interval peak procedure belongs to the category of 
immediate timing schedules (Killeen et al. 1997). However the two schedules 
differ in one important respect. In the former schedule, timing is measured 
from proportional choice between two concurrently available operanda, 
whereas the latter is a single-operandum schedule. Thus, while effects of drugs 
on T50 might be influenced by alterations of the propensity to switch from one 
operandum to the other (see Chiang et al. 1998), effects of drugs on {peak cannot 
readily be accounted for by such a mechanism. 
7.2. METHODS 
7.2.1. Subjects 
Thirty female Wistar rats aged approximately 4 months and weighing 250-290 
g at the start of the experiment were used. Twelve rats were used for the first 
treatment series and eighteen for the second series (see below, Drug 
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treatment). The rats were housed individually under the same conditions as in 
Experiment 1 (see Section 2.2.1) 
7.2.2. Apparatus 
The rats were trained in operant conditioning chambers (Campden Instruments, 
Sileby, UK). Eighteen chambers were used; each rat was always tested in the 
same chamber. Twelve chambers were used for the first series of treatments 
(see below); these were equipped with motor-operated dippers which delivered 
a liquid reinforcer (50 jll of a 0.6 M sucrose solution) (for description, see 
Section 2.2.2). The remaining six chambers were used for the second treatment 
series (see below); these were equipped with dispensers which delivered 45-mg 
food-pellet reinforcers (for description, see Section 4.2.2). Only one retractable 
lever was used in these experiments; this was the left-hand lever for nine rats 
and the right-hand lever for the other nine. The same computer as that used in 
Experiment 1 was used to control the schedule and record the behavioural data 
(see Section 2.2.2). 
7.2.3 Behavioural training 
At the start of the experiment, the food-deprivation regimen was started and the 
rats were gradually reduced to 80% of their free-feeding body weights. They 
were then trained to press the levers, and were exposed to a continuous 
reinforcement schedule for three daily sessions. Thereafter, the rats underwent 
50-minute training sessions under the fixed-interval 30-s peak procedure as 
186 
described below, seven days a week, at the same time each day during the light 
phase of the daily cycle (between 8:00 and 13:00 hours). Each session 
consisted of 32 trials separated by 10-s intertrial intervals. Trials started with 
insertion of the lever into the chamber, and terminated with lever withdrawal. 
In fixed-interval trials (16 per session), reinforcement was delivered following 
the first response emitted after 30 s had elapsed since the onset of the trial. Tn 
probe trials (16 per session), reinforcement was omitted, and the lever 
remained in the chamber for 120 s. The fixed-interval and probe trials occurred 
in a pseudo-random sequence with the constraint that no more than three trials 
of either type occurred in succession. Timing behaviour was assessed from 
performance in the probe trials. 
7.2.4. Drug treatment 
The drug treatment regimen started after 90 sessions of preliminary training 
under the fixed-interval peak procedure. Treatments were given by 
subcutaneous injection (1.0 ml kg-I body weight). The protocol for 
subcutaneous injections was the same as experiment 1 (see Section 2.2.4.). In 
the first series (n=12) the treatments were 8-0H-DPAT HBr (0.05 mg kg-I), 
WAY-100635 (0.1 mg kg-I), and 8-0H-DPAT HBr (0.05 mg kg-I) + WA Y-
100635 (0.1 mg kg-I). In the second series (n=18) the treatments were (-)-DOI 
HCI (0.25 mg kg-I), ketanserin tartrate (2 mg kg-I), and (-)-DOI HCI (0.25 mg 
kg-I) + ketanserin tartrate (2 mg kg-I). Doses refer to weights of the salt. 
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7.2.5. Data analysis 
Response rate was recorded in successive two-second epochs of the probe 
trials. For each rat, mean response rate R, for each treatment condition, derived 
from all the sessions in which that treatment was administered (see above), was 
plotted against time measured from the onset of the trial, t. The following 
modified Gaussian function was fitted to each rat's data (Buhusi 2005): 
[1] 
where (a+c) is the estimated peak response rate, tpeak is the peak time (location 
of the peak of the Gaussian component of the function), b represents the spread 
of the function (standard deviation of the Gaussian component); the right-hand 
term is a linear ramp of slope d and an ordinate value c at time t=tpeak. This 
function has been found to provide an acceptable description of performance in 
the peak procedure (Buhusi et al. 2005; MacDonald and Meek 2005). The 
following measures were derived for each rat under each treatment condition: 
the peak time (tpeak), the peak response rate (a+c), and the Weber fraction 
(coefficient of variation of the Gaussian component of the function: bltpeak). 
Goodness of fit of the f i t t e ~ ~ functions was expressed as /.' These measures 
were compared across treatments by repeated-measures analysis of variance. In 
the case of a significant effect of treatment, comparisons were made between 
each active treatment and the vehicle-alone condition using Dunnett's test, and 
between the agonist-alone and agonist+antagonist treatments, using Neuman-
Keul's test (significance criterion, P<0.05). 
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7.3. RESULTS 
7.3.1. 8-0H-DPAT 
The group mean data obtained in the probe trials are shown in Figure 7.1. The 
left-hand panel shows the absolute response rates, and the right-hand panel the 
response rates expressed as a percentage of the maximum rate. Table 7.1 shows 
the group mean (± SEM) values of the timing parameters derived from fitting 
the modified Gaussian function to the data from the individual rats. 
Peak time, tpeak. Under the vehicle-alone treatment condition, tpeak (32.5 
± 1.4 s) was close to the scheduled reinforcement time (30 s). Analysis of 
variance of the tpeak data revealed a significant effect of treatment [F(3,33)=4.0, 
p<0.02]. Multiple comparisons indicated that 8-0H-DPAT (0.05 mg kg·') 
significantly reduced tpeak. WA Y-I00635 (0.1 mg kg-I), administered alone, 
had no significant effect on tpeak; however it significantly antagonized the 
reduction of tpeak induced by 8-0H-DPAT. The value of tpeak seen following 
combined treatment with 8-0H-DPAT + WA Y-100635 did not differ 
significantly from that seen following vehicle-alone treatment. 
Weber fraction. There was no significant overall effect of treatment on 
the Weber fraction [F(3,33)=2.1, p>O. 1]. 
Peak response rate. There was a significant overall effect of treatment 
on peak response rate [F(3,33)=2.9, p<O.05]. Multiple comparisons showed 
that all three active treatments (8-0H-DPAT, WAY-I00635 and 8-0H-DPAT 
+ WAY-I00635) produced a significant reduction of peak response rate 
compared to the vehicle-alone treatment. 
189 
.-
I 
W 
3 0 r - - - - - - - ~ = = = = = = = = = = ~ ~
25 
o VEHICLE 
• 8-0H-DPAT 0.05 mg kg-' 
... WAY-100635 0.1 mg kg" 
• 8-0H-DPAT 0.05 mg kg" + 
WAY-100635 0.1 mg kg" 
1 0 0 ~ - - ~ ~ - - - - - - - - - - - - - - - - - -
w 
~ ~
~ ~ 80 
Z 
o 
I- 20 
::J 
CL 
(J) 
w Z 
~ ~
0:::: 60 
~ ~
CJ) 15 W 
::J 
~ ~CJ) 
Z 
o 
CL 10 CJ) 
~ ~ 40 
u.. 
w 
0:::: 
5 
o 20 40 60 80 100 120 
TIME FROM TRIAL ONSET,s 
o 
I-
Z 20 
w 
o 
0:::: 
w 
CL 
o 20 40 60 80 100 120 
TIME FROM TRIAL ONSET,s 
Figure 7.1. Effects of8-0H-DPAT (O.OS mg kg-i), WAY-10063S (0.1 mg kg-
i), and combined treatment with 8-0H-DPAT (O.OS mg kg-I) + WAY-100635 
(0.1 mg kg-I) on performance on peak fixed-interval 30-s schedule. Left-hand 
panel. Ordinate: absolute response rate (responses minute-I); abscissa: time 
from trial onset (s). Points are group mean data from successive 2-s time bins: 
open circles, vehicle treatment; filled circles, 8-0H-DPAT; filled triagies, 
WAY-10063S;filled squares, 8-0H-DPAT + WAY-0063S. Right-hand panel. 
Ordinate: response rate expressed as percent of maximum response rate (other 
conventions as in left hand panel). Note the leftward displacement of the peak 
function (reduction of peak time) induced by 8-0H-DP AT, and reversal of this 
effect by WAY-10063S. 
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Table 1. Effects of 8-0H-DPAT, WAY-I00635 and combined treatment with 8-0H-DPAT + WAY-I00635 on performance on the 
fixed-interval peak procedure 
Treatment 
Vehicle 
8-0H-DPAT 0.5 mg kil 
WAY-l 00635 0.1 mgkg-I 
8-0H-DPAT 0.5 mg kg-I + 
WAY-I00635 0.1 mg kil 
Parameters derived from fit of modified Gaussian function (mean ± SEM) 
Peak response rate 
tpeak> s Weber fraction ,; (responses min-I) 
32.5 ± 1.4 0.43 ± 0.04 0.932 ± 0.016 28.6 ± 4.6 
26.5 ± 1.7 * 0.61 ± 0.07 0.800 ± 0.051 23.7 ± 6.2 * 
30.6 ± 1.6 0.74 ± 0.18 0.789 ± 0.057 23.5 ± 5.3 * 
32.4 ± 1.4 # 0.40 ± 0.06 0.794 ± 0.094 23.2 ± 4.5 * 
Significance of difference from vehicle condition, * p<O.05; significance of difference from 8-0H-DPAT 0.5 mg kg-I, # p<0.05 
7.3.2. J)()I 
The group mean data obtained in the probe trials are shown in Figure 7.2. The 
left-hand panel shows the absolute response rates, and the right-hand panel the 
response rates expressed as a percentage of the maximum rate. Table 7.2 shows 
the group mean (± SEM) values of the timing parameters derived from fitting 
the modified Gaussian function to the data from the individual rats. 
Peak time, tpeak. Under the vehicle-alone treatment condition, tpeak (33.2 
± 1.3 s) was close to the scheduled reinforcement time (30 s). Analysis of 
variance of the tpeak data revealed a significant effect oftreatment [F(3,51 )=6.0, 
p<O.01]. Multiple comparisons indicated that DOl (0.25 mg kg-I) significantly 
reduced tpeak. Ketanserin (2 mg kg-I), administered alone, had no significant 
effect on tpeak; however it antagonized the reduction of tpeak induced by DOL 
The value of tpeak seen following combined treatment with 001 + ketanserin 
did not differ significantly from that seen following vehicle-alone treatment. 
Weber fraction. The overall effect of treatment on the Weber fraction 
fell just short of statistical significance [F(3,51)=2.7, p=0.055]. The values 
obtained following treatment with DOl and ketanserin were somewhat higher 
than that seen following vehicle-alone treatment. 
Peak response rate. There was a significant overall effect of treatment 
on peak response rate [F(3,51)=2.9, p<O.05]. Multiple comparisons showed 
that DOl produced a significant reduction of peak response rate compared to 
the vehicle-alone treatment. 
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Figure 7.2. Effects of DOl (0.25 mg kg-II' ketanserin (2 mg kg-I), and 
combined treatment with DOl (0.25 mg kg- ) + ketanserin (2 mg kg-I) on 
performance on the peak fixed-interval 30-s schedule. Open circles, vehicle; 
filled circles DOl; filled triangles, ketanserin;filled squares, DOl + ketanserin. 
Other conventions as in Figure 1. Note the leftward displacement of peak 
function (reduction of peak time) induced by DOl, and reversal of this effect by 
ketanserin. 
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Table 2. Effects of the DOl, ketanserin and combined treatment with DOl + ketanserin on performance on the fixed-interval peak 
procedure 
Parameters derived from fit of modified Gaussian function (mean ± SEM) 
Peak response rate 
Treatment tpeal" s Weber fraction r2 (responses min"l) 
Vehicle 33.2 ± 1.3 0.45 ± 0.04 0.801 ± 0.032 36.0 ± 6.2 
DOl 0.25 mg kg"! 29.7 ± 1.1 * 0.60 ± 0.04 0.797 ± 0.040 29.7 ± 5.0 * 
ketanserin 2 mg kg"! 33.6 ± 1.2 0.61 ± 0.09 0.797 ± 0.040 32.5 ± 5.6 
DOl 0.25 mg kg"! + 
34.5 ± 1.3 # 0.45 ± 0.04 0.804 ± 0.036 30.9 ± 5.3 
ketanserin 2 mg kg"! 
Significance of difference from vehicle condition, * p<0.05; significance of difference from DOl 0.25 mg kg"J. # p<0.05 
7.4. DISCUSSION 
Performance in the fixed-interval peak procedure seen in these 
experiments conformed to the characteristic bell-shaped response-rate function 
reported in many previous experiments (see Hinton and Meck 1997). 
Performance could be described by a modified Gaussian curve ('Gaussian plus 
ramp' function: Buhusi et al. 2005), enabling estimates of tpeak and the Weber 
fraction to be derived from each rat under each treatment condition. 
The 5-HT1A receptor agonist 8-0H-DPAT displaced the response-rate 
function to the left. This was reflected in a significant reduction of tpeak. The 5-
HTIA receptor antagonist WA Y-l 00635 had no significant effect on tpeak; 
however, it completely abolished the reduction of tpeak produced by 8-0H-
DPAT. 8-0H-DPAT is a potent agonist of 5-HT1A receptors; however, it also 
has some partial agonist activity at 5-HT7 receptors (see Thomas and Hagan 
2004). The ability of WAY-100635 completely to antagonize 8-0H-DPAT's 
effect on tpeak strongly implicates 5-HTIA receptors in this effect of 8-0H-
DPAT, since WAY-100635 is highly selective for the 5-HTIA site (see Hoyer 
et al. 2002; Lanfumey and Hamon 2004). 
8-0H-DPAT's ability to reduce tpeak is consistent with its ability to 
reduce the indifference time, T50, in another immediate timing schedule, the 
free-operant psychophysical procedure (Chiang et al. 2000; Body et al. 2001, 
2002b, 2004). 8-0H-DPAT's effect on T50 is also sensitive to antagonism by 
WA Y-I00635, suggesting that the same receptor population may be 
responsible for both effects. 5-HT IA receptors occur both on cell bodies and 
dendrites of 5-HTergic neurones in the raphe nuclei (somatodendritic 
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autoreceptors) and on postsynaptic membranes in the forebrain target regions 
of the 5-HTergic projection (see Lanfumey and Hamon 2004). It remains 
uncertain whether the effects of 8-0H-DPAT seen here were mediated by 
presynaptic or by postsynaptic 5-HT1A receptors. However, circumstantial 
evidence favours postsynaptic receptors, because 8-0H-DPAT's effect on 
performance on the free-operant psychophysical procedure is impervious to 
destruction of the ascending 5-HTergic pathways (Body et al. 2001, 2002b, 
2004). 
The 5-HT2N2C receptor agonist DOl also reduced tpeak. Ketanserin, 
when administered alone, had no significant effect on tpeak; however, it 
completely antagonized the effect of DOl on this parameter. It is likely that the 
5-HT2A receptor subtype is likely to have been responsible for mediating DOl's 
effect on tpeak in this experiment. Although DOl has approximately equivalent 
affinity for 5-HT2A, 5-HT2B and 5-HT2C receptors, ketanserin has an 80-100 
times higher affinity for the 5-HT2A receptor than for the other two 5-HT2 
receptor subtypes (Baxter et al. 1995; Barnes and Sharp 1999); moreover, 5-
HT2B receptors are very sparsely expressed in the central nervous system 
(Barnes and Sharp 1999). Confirmation of this suggestion will require further 
experiments using more selective 5-HT2A and 5-HT2C receptor antagonists. 
As with 8-0H-DPAT, so also with DOl, the present finding with the 
fixed-interval peak procedure has its counterpart in the free-operant 
psychophysical procedure. DOl produced a dose-dependent reduction of Tso in 
this schedule, which could be completely reversed by ketanserin, suggesting 
mediation of the effect by 5-HT2A receptors (Body et al. 2002b, 2004; see also 
Experiment 5). Thus the present results, taken together with previous findings 
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with the free-operant psychophysical procedure, suggest that 5-HTIA and 5-
HT2A receptors mediate qualitatively similar effects on temporal 
differentiation. 
As well as reducing {peak, both 8-0H-DPAT and 001 also induced some 
broadening of the peak function, this being reflected in an increase of the 
Weber fraction (marginally statistically significant only in the case of DOl), 
and ~ ~ modest reduction of the peak response rate. However, the effects of 8-
OH-DPAT and DOl on the peak response rate were not reversed by thl:ir 
respective antagonists, WAY-100635 and ketanserin, suggesting that they may 
constitute non-specific effects on performance. 
The reduction of the indices of central tendency of timing in the 
immediate timing tasks (tpeak in the fixed-interval peak procedure and T50 in the 
free-operant psychophysical procedure) produced by 8-0H-DPAT and 001 
stands in contrast to the effects of these drugs on the analogous measures 
derived from performance on retrospective timing tasks. As discussed above, 
5-HTIA and 5-HT2A receptor agonists either have no effect on T50 in these 
tasks, or in some cases may even increase this parameter (see Chapter 2). This 
dissociation of effects on temporal differentiation and temporal discrimination 
is not easy to reconcile with an interaction of the drugs in question with the 
ubiquitous internal clock that is purported to underlie interval timing in all its 
guises (Gibbon 1977; Killeen and Fetterman 1988). The impasse could be 
breached by postulating two timekeepers, subserved by different 
neuropharmacological mechanisms, with separate responsibilities for temporal 
differentiation and temporal discrimination (see Ho et al. 2002). However, such 
an unparsimonious approach may be unwarranted at this stage, in the light of 
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evidence that a number of other neurobiological interventions do produce 
coherent effects on the two forms of interval timing (Gibbon et al. 1997; 
Hinton and Meck 1997; MateH and Meck 2004). 
An alternative tactic may be to search for other ('non-timing') 
behavioural processes that are differentially represented in immediate and 
retrospective timing schedules, and which may differ in their sensitivities to 5·· 
HTIA and 5-HT2A receptor stimulation. One candidate process discussed above, 
the propensity for switching between concurrently available operanda, which is 
known to be sensitive to manipulation of 5-HTergic function (AI-Ruwaitea et 
al. 1997, 1999; Chiang et al. 1999), is rendered somewhat unlikely by the 
present findings, since the fixed-interval peak procedure used in this 
experiment employed only a single operandum (however, see Ho et al. 1998, 
for discussion of the possible involvement of' switching' in performance on the 
fixed-interval peak procedure). Another candidate process may be 'attention-
sharing' (Meck and Benson 2002; Buhusi and Meck 2002; Buhusi 2003). It has 
been suggested that dopaminergic manipulations may influence timing by 
interacting both with the hypothetical pacemaker and with attentional 
processes, and that inconsistencies between effects of dopamine receptor 
agonists and antagonists on different types of timing task may reflect 
differential interaction with these two processes (Buhusi 2003). Further work 
will be needed to establish whether such an explanation can help to account for 
the divergent effects of 5-HT1A and 5-HT2A receptor stimulation on 
performance on immediate and retrospective timing tasks. One approach to 
addressing this question could be to examine the effects of the agonists on 
timing performance in the two types of timing task using different time ranges. 
198 
For example, it has been proposed that effects on the function of the 
hypothetical clock should be reflected in a shift of the psychometric function 
whose magnitude is proportional to the criterion duration, whereas effects on 
attentional processes should be reflected in a shift of the function which is 
uniform across different criterion durations (Hinton and Meck 1997; Buhusi 
2003). 
The neuronal mechanisms whereby 8-0H-DPAT and DOl exert their 
similar effects on temporal differentiation in the fixed-interval peak procedure 
remain to be elucidated. 5-HT1A receptors are expressed both on post-synaptic 
cells and on the cell bodies and dendrites of 5-HTergic neurones; as discussed 
above, it is likely that the effect of 8-0H-DPAT seen here were mediated by 
post-synaptic receptors. 5-HT2A receptors are located almost exclusively on 
postsynaptic membranes (Barnes and Sharp 1999; Hoyer et al. 2002). 
However, it is unlikely that the 5-HT1A and 5-HT2A receptors responsible for 
the similar effects of 8-0H-DPAT and DOl on temporal differentiation arc 
located on the same group of neurones, because these two receptor subtypes 
generally mediate opposite effects on neuronal excitability (hyperpolarization 
and depolarization, respectively: Barnes and Sharp 1999; Hoyer et al. 2002; 
Lanfumey and Hamon 2004; Leysen 2004). Further experiments employing 
direct injection of the agonists into discrete brain regions may help to reveal 
the neuroanatomicallocation of the two receptor populations. 
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CHAPTER 8 
GENERAL DISCUSSION 
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8.1. The role of 5-HT receptors in timing 
The results of this project confirm and extend the previous findings on the 
effects of 5-HT receptor stimulation on temporal discrimination and temporal 
differentiation. 
In experiment 1 it was found that the non-selective 5-HT2/5-HT3 
receptor agonist quipazine disrupted temporal discrimination in the discrete-
trials psychophysical procedure. This effect of quipazine was probably 
mediated by 5-HT2 rather than 5-HT3 receptors, because it was not blocked by 
the selective 5-HT3 receptor antagonist MDL-72222, whereas it was 
completely reversed by the 5-HT2 (,5-HT2A-preferring') antagonist ketanserin. 
Experiment 3 extended these findings by showing that the 5-HT2N2C receptor 
agonist DOl disrupted temporal discrimination in a similar manner to 
quipazine, and that DOl's effect could be antagonized by the highly selective 
5-HT2A receptor antagonist MDL-I00907. 
In a previous experiment, Body et al. (2002a) found that 5-HTIA 
receptor agonist 8-0H-DPAT also impaired temporal discrimination in the 
discrete-trials psychophysical procedure. The findings in experiments 1 and 3, 
taken together with Body et aI.' s (2002a) results, suggest that 5-HT lA and 5-
HT2A receptors mediate qualitatively similar effects on temporal 
discrimination, The effect of 8-0H-DPAT described by Body et al. (2002a) 
was evidently mediated by a postsynaptic receptor population, since the effect 
survived destruction of ascending 5-HTergic pathways by intra-raphe injection 
of 5,7-DHT. It is likely that the 5-HT2A-mediated effect seen here was also 
mediated by a postsynaptic receptor population, because 5-HT2A receptors have 
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been found mainly on postsynaptic membranes (see section 1.2.3.3.). Whether 
or not the two receptor subtypes reside on the same population of neurones is a 
question which will need to be addressed in future experiments. 
The disruptive effect of 5-HT2A receptor stimulation (and 5-HTIA 
receptor stimulation: Body et al. 2002a) consisted of a marked degradation of 
stimulus control, as revealed by an increase in the Weber fraction. There was 
also a tendency for the indifference point, T 50, to be increased. Increases in T50 
can be interpreted in more than one way. One of the possible explanations is 
that DOl and quipazine might have increased the period of the hypothetical 
pacemaker (Gibbon 1991; Hinton and Meck 1997; see section 8.3 for further 
discussion). 
Quipazine (experiment 2) and DOl (experiment 5) also affected 
temporal differentiation in the free-operant psychophysical procedure. These 
effects appear to be mediated by 5-HT2A receptors, since they were reversed by 
ketanserin and MDL-I00907, respectively. These effects resembled the effects 
of DOl on performance on this schedule previously reported by Body et al. 
(2003, 2004). Body et al. (2004) confirmed the postsynaptic location of the 
receptors responsible for DOl's effect on temporal differentiation, by 
demonstrating that the effect of DOl was not reduced after destruction of the 
ascending 5-HTergic pathways. 
Although 5-HT2A receptors mediate effects on both temporal 
discrimination and temporal differentiation, the effects on the two types of 
timing performance are strikingly different. In contrast to the increase in the 
Weber fraction and T50 seen in the former case, T50 was consistently reduced by 
5-HT2 receptor stimulation in the case of temporal differentiation (experiments 
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2 and 5). This is in agreement with earlier findings (Body et al. 2002b, 2003, 
2004). The theoretical implications of this discrepancy is discussed in section 
8.3. 
The anatomical location of the 5-HT2A receptors responsible for the 
effects on temporal discrimination and differentiation remains unknown. 
Evidence from experiments 4 and 6 suggests that they are unlikely to reside in 
the dorsal striatum. 5-HT2A receptors have been found in many parts of the 
central nervous system, and a considerable amount of work may be needed to 
track down the relevant receptor population. In view of the theoretical 
importance of the qualitative discrepancy between effects on temporal 
discrimination and temporal differentiation (see below), it will be of 
considerable interest to discover whether the same or different populations of 
5-HT 2A receptors mediate these effects. 
Experiment 7 examined the effects of DOL and 8-0H-DPAT on 
temporal differentiation on a different type of immediate timing schedule, the 
fixed-interval peak procedure. Both drugs displaced the peak time, (peak, to the 
left, an effect that is qualitatively similar to the reduction of T50 seen in the 
free-operant psychophysical procedure. These results thus extend Body et aI.' s 
(2004) findings that 5-HTIA and 5-HT2A receptor stimulation have similar 
effects on temporal differentiation. 
8.2. 5-HT and Dopamine 
The interaction between 5-HT and dopamine in the brain is not a simple one, as 
reviewed in Chapter 1. 5-HT plays a complicated set of roles in the brain that 
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are difficult to encompassed with a single theory. In some cases, dopaminergic 
function has been found to be antagonized by 5-HT receptor stimulation; 
however, in other cases the two monoamines appear to have synergistic effects. 
The situation is further complicated by the fact that different 5-HT receptor 
subtypes have been found to mediate opposing effects on dopaminergic 
function in some cases (see Daw et al. 2002). In the striatum, endogenous 5-HT 
has no influence on dopamine release under basal conditions, but positively 
modulates dopamine outflow when nigro-striatal dopaminergic transmission is 
activated (Lucas et al. 2000). In the nucleus accumbens selective blockade of 
5-HT2C128 receptor subtypes increases dopamine release (Di Matteo et al. 
1998). 
According to some pacemaker-based theories of interval timing, it has 
been suggested that the facilitatory effect of striatal dopaminergic mechanisms 
is opposed by an inhibitory effect of 5-HT on the hypothetical pacemaker 
(Hinton and Meck 1997). The results of this project, taken in conjunction with 
earlier findings, suggest that this proposal may not be correct. Thus, numerous 
studies have reported that tpeak in the peak procedure is reduced by the 
dopamine-releasing agent amphetamine, and increased by dopamine D2 
receptor antagonists (see Meck 1986, 1996; Gibbon et al. 1997; MateH and 
Meck 2000). The results of experiment 7 indicate that both 5-HTIA and 5-HT2A 
receptor stimulation can also reduce tpeak. Moreover, the indifference point, T50, 
in another temporal differentiation schedule, the free-operant psychophysical 
procedure, is consistently reduced by amphetamine (Chiang et al. 2000a) and 
by 5-HTIA (Body et aI., 2001, 2002b, 2004) and 5-HT2A (Body et al. 2003, 
2004; present project, experiments 2 and 5) receptor agonists. 
-
204 
There is good evidence that 5-HT3 receptors contribute to the regulation 
of dopamine release (Blandina et al.1989; Carboni et al. 1989; Zazpe et al. 
1994; Cervo et al. 1996). It might therefore be expected that 5-HT 3 receptor 
stimulation would alter timing performance, an expectation that found no 
support in experiment 2. The explanation for this discrepancy may lie in the 
regional differences in the nature of 5-HT/dopamine interactions. There is 
evidence that dopamine releasing effects of 5-HT3 receptors is mainly 
restricted to the structures innervated by mesocortical and meso limbic 
dopaminergic projections, rather than the dorsal striatum, which receives its 
input from the nigrostriatal pathway (Wang et al. 1996; De Deurwaerdere et al. 
1998; Porras et al. 2003). The failure of 5-HT3 receptor stimulation to affect 
temporal differentiation in experiment 2 may therefore reflect a primary 
involvement of dorsal rather than the ventral striatal dopaminergic mechanisms 
in this behaviour (Hinton and Meck 1997; Matell and Meck 2000). 
8.3. Theoretical Implications 
One of the most consistent findings that can be extracted from these 
experiments is that temporal discrimination and temporal differentiation can be 
affected in qualitatively different ways by the same 5-HT receptor agonists. 
This finding cannot easily be reconciled with the concept of a single time-
keeper mechanism that is believed to underlie all types of interval timing 
behaviour (see Hinton and Meck 1997; MateH and Meck 2000; Meck 2005). 
As succinctly stated by Zeiler, "any model that posits a unitary internal clock, 
would seem to imply that an intervention that alters its speed, should produce 
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qualitatively similar disruptions of temporal differentiation and temporal 
discrimination" (Zeiler 1998). 
The present project has provided evidence that 5-HT 2A receptor 
stimulation reduces T50 in a temporal differentiation schedule and increases it 
in a temporal discrimination schedule. According to pacemaker-based theories 
of timing, this would seem to imply that the pacemaker was speeded up in the 
former case and slowed down in the latter. The present results join an 
increasing body of findings suggesting that stimulation of the same type of 
receptor in different timing tasks can produce different results. For example, 
Chiang et al. (2000b) found that the 5-HT1A receptor agonist 8-0H-DPAT 
increased the Weber fraction in the interval bisection task, without affecting the 
bisection point; and Body et al. (200Ia) found a similar effect of 8-0H-DPAT 
in another retrospective timing schedule, the discrete-trials psychophysical 
procedure. In contrast, 8-0H-DPAT selectively reduced T50 in the free-operant 
psychophysical procedure (Chiang et ai. 2000b; Body et ai. 2003, 2004). Thus 
8-0H-DPAT has qualitatively different effects in immediate and retrospective 
timing schedules. 
The difficulty posed for pacemaker-based theories of timing by results 
such as these has been discussed by Chiang et al. (2000a). One of two courses 
of action seems to be unavoidable. Either the notion of a single pacemaker 
underying both temporal discrimination and temporal differentiation has to be 
abandoned, or the effects of drugs on one type (or even both types) of timing 
task must be attributed to some 'non-pacemaker-based' action. A difficulty 
with the latter alternative is that drug-induced changes in pacemaker function 
have traditionally been inferred from changes in the locus of T50 derived from 
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psychometric functions. If a change in the locus of T50 can no longer be relied 
upon as evidence for a change in pacemaker function, the testability of 
pacemaker-based theories is considerably compromised. It may be noted that 
the pacemaker concept is still essentially a 'hypothetical construct', and 
attempts to link it to any particular neural structures remain highly speculative. 
It is to be hoped that improved understanding of the neural mechanisms of 
timing will eventually help to resolve this controvery (see Buhusi 2003; Matell 
and Meck 2000, 2004). 
8.4. Future research 
The results of the present project have identified 5-HT1A and 5-HT2A receptors 
as mediators of substantive effects on interval timing behaviour. An obvious 
area for continued research is the exploration of the roles of other 5-HT 
receptor subtypes. This is especially relevant in the case of those receptors that 
are known to contribute to the regulation of dopamine release in the component 
structures of cortico-striato-thalamo-cortical loops, which are the current focus 
of theorizing about the neural basis of timing behaviour (Buhusi 2003; Matell 
and Meck 2004; Meek 2005) .. 
It will also be important to explore the anatomical location of the 5-HT 
receptor populations that are involved in timing. Experiments 4, 5 and 6 
constitute an initial move in this direction; it seems that the 5-HT 2A receptors 
responsible for effects on temporal discrimination and temporal differentiation 
are probably not located in the dorsal striatum. However, as discussed in 
chapter 6, 5-HT2A receptors are expressed in more than one component of the 
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cortico-striato-thalamo-cortical loops (Pompeiano et al. 1994; Wright et al. 
1995; Hamada et al. 1998; Cornea-Herbert et al. 1999; Bubser et al. 2001; 
Hoyer et al. 2002); additionally there is evidence that 5-HT2A receptors are 
present on dopaminergic neurones of the ventral tegmental area and substantia 
nigra. Whether or not these receptor populations are responsible for the effects 
of 5-HT 2A receptor agonists on interval timing behaviour is an open question 
that awaits further investigation. 
Finally, future experiments should address the possibility that sex 
differences may exist in the quantitative features of interval timing behaviour, 
and in the sensitivty of timing behaviour to drugs acting at 5-HT receptors. All 
the experiments described in this thesis were carried out on female Wistar rats. 
This facilitates comparison of the present results with previous results obtained 
in this laboratory, which also employed female rats. It is unlikely that 
behavioural rhythms associated with the oestrus cycle would have had any 
systematic effect on the perfonnances seen in the present experiments, because 
each treatment was administered to each rat five times at 3- or 4-day intervals, 
the order of treatments being counterbalanced across rats. Thus confounding of 
the treatment conditions with oestrus status is unlikely to have occurred. 
Nevertheless, the possibility that male rats might have responded differently 
from female rats to the treatments used in these experiments deserves serious 
consideration in view of recent evidence for oestrogen-induced changes in 
neurotransmitter metabolism and synaptic plasticity in the rat (Bi et al. 2001; 
McEwen et al. 2001). 
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APPENDIX 
Chemical names of the drugs identified in the text by pharmaceutical 
company code numbers 
8-0H-DPAT 8-hydroxy-2-(di-n-propilamino)tetraline 
BW-723-C86 1-[5(2-thienylmethoxy)-lH-3-indolyl]propan-2-amine 
hydrochloride 
CP-93129 5H-Pyrrolo[3,2-b ]pyridine-5-one, 1 ,4-dihydro-3-(1 ,2,3,6-
tetrahydro-4-pyridinyl) 
CP-94253 (5-propoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-H-p[3,2-
b ]pyridine hydrochloride 
DOl 2,5-Dimethoxy-4-iodoamphetamine hydrochloride 
DR-4004 2a-( 4-( 4-phenyl-l ,2,3,6-tetrahydropyridyl)butyl)-2a,3 ,4,5-
tetrahydrobenzo[ cd]indol-2-( 1 H)-one 
GR-466 1 1 2-propenamide, 3-[3-[2-(dimethylamino)ethyl]-lH-indol-5-yl]-
N-[( 4-methoxyphenyl)methyl] 
GR-55562 3-[3-(dimethylamino)propyl]-4-hydroxy-N-[4-(4-
pyridinyl)phenyl]benzamide 
GR-113808 [1-2[(methylsulfonyl)amino )ethyl]-4-piperidinyl]methyl-l-
methyl-lH-indole-3-carboxilate 
GR-125487 [1-[2-(methylsulfonyl)amino ]ethyl]-4-piperidinyl]-methyl 5-
fluoro-2-methoxy-lH-indole-3-carboxilate 
GR-127935 N-[ 4-methoxy-3-( 4-methyl-l-piperazinyl)phenyl]-2C-methyl-
4C-(5-methyl)-1 ,2,4-oxadiazol-3-yl)-1, 1 C-biphenyl-4-
carboxamide hydrochloride 
L Y -334370 5-( 4-flurobenzoyl)-amino-3-(1-methylpiperidin-4-yl)-lH-indoIe 
fumarate 
LY-344864 N-[(3R)-3-(dimethylamino)-2,3,4,9-tetrahydro-lH-carbazol-6-
yl]-4-fluoro-benzamide 
m-CPBG l-(m-chlorophenyl)biguanide 
m-CPP 1-(3-chlorophenyl)piperazine 
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MDL-72222 3-Tropanyl-3,5-dichlorobenzoate 
MDL-I00907 (±)2,3-dimethoxyphenyl-l-[2-( 4-piperidine)-methanol] 
PNU-I09291 (S)-3,4-dihydro-l-[2-[4-( 4-methoxyphenyl)-I-
piperazinyl]ethyl]-N-methyl-1H-2-benzopyran-6-carboxamide. 
Ro-04-6790 4-amino-N-[2,6-bis(methylamino-4-pyrimidinyl]-
benzensulfonamide 
Ro-60-0175 (S)-2-(6-chloro-5-fluroindol-l-yl)-I-methyethylamineRS-
67333: (1-(4-amino-5-chloro-2-methoxyphenyl)-3-( I-n-buty 1-4-
piperidinyl)-I-propanone 
RS-67506 (1-( 4-amino-5-chloro-2-methoxyphenyl)-3-[ 1-[2-
[(methylsulfonyl)amino ]ethyl]-4-piperidinyl]-I-propanone) 
RS-67532 [1-( 4-amino-5-chloro-2-(3,5-dimethoxy benzyloxyphenyl)-5-( 1-
piperidinyl)-I-pentanone] 
RS-I02221 8-[5-(5-amino 2,4-dimethoxyphenyl) 5-oxo-pentyl]-1 ,3,8-
triazaspiro[ 4,5]decane-2,4-dione 
RU-24969 IH-Indol,5-methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-
butanedioate 
SB-200464 N-(1-methyl-5-indonyl)-N'-(3-pyridyl) urea hydrochloride 
SB-216641 [1, 1'-Biphenyl]-4-carboxamide, N-[3-[2-
(dimethylamino)ethoxy]-4-methoxyphenyl]-2'-m(5-methyl-
1,2,4-oxadiazol-3yl) 
SB-224289 1'-methyl-5[[2'-methyl-4'-)5-methyl-l ,2,4-oxadiazol-3-
yl)biphenyl-4-yl]carbonyl-2,3,6, 7 -tetrahydrospiro[ furo[2,3-
f]indol-3 ,4'-piperidine ] oxalate 
SB-242084 6-chloro-5-methyl-l-[2-(2-methylpyridyl-3-oxy)-pyrid-5-yl 
carbamoyl]indoline 
SB-258719 (R)-3,N-dimethyl-N-[I-methyl-3-( 4-methylpiperidin-l-
yl)propyl]benzene sulphonamide 
SB-271046 5-chloro-N-( 4-methoxy-3-piperazin-l-yl-phenyl)-3-methyl-2-
benzothiophenesulphonamide 
WAY -100635 N-(2-( 4-(2-methoxyphenyl)-I-piperazinyl)ethyl)-N-(2-pyridyl)-
cyclohexanecarboxamide trichloride 
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